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Abstract  
Positron Emission Tomography (PET) is emerging as a powerful method for imaging cancer 
through the design and development of new radiotracers. Antibodies have promising 
properties as ligands for targeting cancer, as they have the advantage of displaying high 
affinity for their respective receptors. However, the use of antibodies as radiotracers is 
limited to the use of long-lived isotopes, as these large biomolecules additionally display 
slow blood circulation and clearance. The use of short-lived isotopes such as 18F or 68Ga, in 
combination with antibodies, would provide the ideal balance between targetability and 
clearance. This may be achieved by use of a two-step pretargeting strategy, whereby a 
reactive tag is conjugated to the antibody and allowed to localise in the tissue to be imaged, 
before systemic administration of a chemical reporter (e.g. a labelled reactive partner) which 
allows the ‘pretargeted’ tissue to be imaged.  
The Strain-Promoted Azide/Alkyne Cycloaddition (SPAAC) reaction between cyclooctynes 
and azides was evaluated as an appropriate bioorthogonal reaction for application to a 
pretargeting strategy using short-lived isotopes. The synthesis of a library of cyclooctyne 
precursors was carried out, which were evaluated in terms of their reactivity with azides, and 
their suitability for in vivo applications. An 18F-labelled version of the SPAAC reaction was 
developed, demonstrating the ability of the reaction to be carried out under different 
conditions. This model reaction was translated to in vivo pretargeting using a cyclooctyne 
modified Herceptin monoclonal antibody and an 18F-labelled azide. These initial experiments 
indicated that the SPAAC reaction may not be fast enough to occur at the low concentrations 
which are found in vivo. The reaction was thoroughly examined in terms of kinetics at 
different concentrations, and a high concentration-dependence upon rate of reaction was 
confirmed. This was supported by a 68Ga-labelled SPAAC reaction, which was carried out 
using reportedly more reactive cyclooctynes than those used in the initial experiments. In 
general, the reaction showed a greater preference to be carried out in organic solvents such 
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as acetonitrile, and under closer to physiological conditions the reactions were less likely to 
proceed.  
The Inverse-electron-Demand Diels-Alder (IeDDA) reaction between tetrazines and strained 
alkenes was evaluated as an alternative bioorthogonal reaction for demonstrating in vivo 
pretargeting. A series of 68Ga-labelled IeDDA reactions between a 68Ga-labelled tetrazine 
and a series of norbornene analogues demonstrated the superior reaction kinetics and 
biocompatibility of the IeDDA reaction. The initial translation of the IeDDA reaction to a 
proof-of-concept for pretargeting using cyclic RGD pentapeptides was initially unsuccessful, 
attributed to the surprisingly poor reactivity of norbornene-modified cyclic RGD 
pentapeptides towards a 68Ga-labelled tetrazine. The reaction between a 68Ga-labelled 
tetrazine and a Cetuximab antibody, which had been modified with the more reactive trans-
cyclooctene (TCO) moeity, was successfully demonstrated. The hypothesised pretargeting 
strategy using this model reaction was achieved on high EGFR expressing cells, validating 
the IeDDA reaction in this context. These results suggested tantalising opportunities for 
application of the IeDDA reaction to in vivo pretargeting for PET imaging using short-lived 
isotopes such as 18F and 68Ga.  
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Glossary of Terms 
Ac     Acetate anion 
ADME     Absorption, Distribution, Metabolism and Excretion 
BARAC    Biarylazacyclooctyne 
BCN     Bicyclo[6.1.0]nonyne 
Boc     Di-tert-butyl dicarbonate 
BPDS     n-(m-trifluoromethylphenyl)phenoxazine-4,6- 
     dicarboxylic acid 
n-BuLi     n-Butyllithium 
CCD     Charge-Coupled Device 
Cps     Counts per second 
CT     X-ray computed tomography 
CuAAC    Copper-catalysed Azide/Alkyne Cycloaddition 
Cyclen     1,4,7,10-tetraazacyclododecane 
C225     Cetuximab monoclonal antibody 
DBU     1,8-Diazabicyclo[5.4.0]undec-7-ene 
DDQ     2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DMP 1,1,1-Triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-
one 
DFO     Desferrioxamine-B 
DIBAC     Aza-dibenzocyclooctyne 
DIBAL-H    Diisobutylaluminum hydride 
DIBO     Dibenzocyclooctynol 
DIBOD     sym-Dibenzo-1,5-cyclooctadinene-3,7-diyne 
DIFO     Difluorinated cyclooctyne  
DIMAC    Aza-dimethoxycyclooctyne 
DIPEA     N,N-Diisopropylethylamine  
DMA     N,N-Dimethylacetamide 
DMAP     4-Dimethylaminopyridine 
DMF     N,N-Dimethylformamide 
DMSO     Dimethylsulfoxide 
DOTA     1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic 
     acid 
DOTA-Az 2,2′,2″-(11-Azido-3,6,9-trioxaundecan-1-amino)-2-
oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic acid   
DOTA-GA-NH2   2,2',2''-(10-(1-Carboxy-4-((2-(2,5-dioxo-2,5-dihydro-1H-
     pyrrol-1-yl)ethyl)amino)-4-oxobutyl)-1,4,7,10- 
     tetraazacyclododecane-1,4,7-triyl)triacetic acid 
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DOTA-GA-Tz 2,2',2''-(10-(1-Carboxy-4-((4-(6-methyl-1,2,4,5-tetrazin-
3-yl)benzyl)amino)-4-oxobutyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid 
DOTA-Tz 2,2′,2″-(10-(2-((4-(6-Methyl-1,2,4,5-tetrazin-3-
yl)benzyl)amino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid 
Dppf     1,1'-Bis(diphenylphosphino)ferrocene 
DTPA     Diethylene triamine pentaacetic acid  
2D     2-Dimensional space 
3D     3-Dimensional space 
EDTA     Ethylenediaminetetraacetic acid 
EGFR     Epidermal Growth Factor Receptor 
EMA     European Medicines Agency 
EWG     Electron-withdrawing group 
E&Z     Eckert & Ziegler 
FBA     4-Fluorobenzaldehyde 
FBS     Fetal bovine serum 
FEA     2-Fluoroethylazide 
FET     Fluoroethyltyrosine 
FDA     Food Drug Administration 
FDG     2-Fluoro-2-deoxy-D-glucose 
FII Flourescence Intensity Imaging 
FLT Flourothymidine 
FT Fourier Transform 
GFP Green fluorescent protein 
HBTU O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate 
HER Human Epidermal growth factor Receptor   
HOMO     Highest occupied molecular orbital 
HPLC     High performance liquid chromatography 
HRMS     High Resolution Mass Spectrometry  
IBX     O-Iodobenzoic acid 
ID     Infected Dose  
IeDDA     Inverse-electron-Demand Diels-Alder 
IgG     Immunoglobulin G 
IHC     Immunohistochemistry  
KHMDS    Potassium bis(trimethylsilyl)amide 
LDA                                               Lithium diisopropylamine     
LiHMDS                                         Lithium bis(trimethylsilyl)amide 
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LOR     Line of Response 
LogP     Log (partition coefficient) 
LUMO     Lowest unoccupied molecular orbital 
mAb     Monoclonal antibody 
m-CPBA    meta-Chloroperoxybenzoic acid 
MOFO     Mono-fluorinated cyclooctyne 
MRI     Magnetic Resonance Imaging  
MSA     Murine Serum Albumin 
NaHMDS    Sodium bis(trimethylsilyl)amide 
NB     Norbornene 
NCA     No-carrier-added  
NCE     New Chemical Entities 
n.d.c     Non-decay-corrected 
NHS     N-Hydroxysuccinimide 
NIR     Near Infrared 
NIS     N-Iodosuccinimide 
NMR     Nuclear Magnetic Resonance spectroscopy  
NOTA     2,2',2''-(1,4,7-Triazacyclononane-1,4,7-triyl)triacetic 
     acid 
NOTP     1,4,7-Triazacyclononane-1,4,7-    
     tris(methylenephosphonate) 
NOTPME    1,4,7-Triazacyclononane-1,4,7-   
     tris(methylenephosphonate monoethylester) 
OCT     Cyclooct-1-yn-3-glycolic acid (and derivatives) 
ORTEP    Oak Ridge Thermal-Ellipsoid Plot 
PBS     Phosphate Buffered Saline 
PCC     Pyridinium chlorochromate 
PEG     Polyethelene glycol 
PTC     Phase-transfer Catalyst 
PET     Positron Emission Tomography  
pNP para-Nitro phenyl 
PyBOP    Benzotriazol-1-yl-oxytripyrrolidinophosphonium  
     hexafluorophosphate 
pyr     Pyridine  
RCM     Ring-Closing Metathesis 
RCY     Radiochemical yield 
RF     Radio-frequency  
Rf     Retardation factor 
RIT     Radioimmunotherapy 
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RT     Room temperature  
Ruppert's reagent   Trifluoromethyltrimethylsilane 
SelectfluorTM Chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane 
bis(tetrafluoroborate) 
SNAr     Nucleophilic Aromatic Substitution 
SN2 Bi-molecular Nucleophilic Substitution 
SPAAC Strain-Promoted Azide-Alkyne Cycloaddition 
SPDC     Strain-Promoted ‘Double-Click’    
SPECT     Single-Photon Emission Computed Tomography 
TACN     1,4,7-Triazacyclononane 
TBAF     Tetra-n-butylammonium fluoride 
TBS     tert-Butyl dimethylsilyl group  
TCO     (E) or trans-cyclooctene 
TESCl     Triethyl silyl chloride 
TFA     Trifluoroacetic acid  
THF     Tetrahydofuran 
TLC     Thin Layer Chromatography   
TMDIBO 3-Hydroxy-2’,3’,2”,3”-tetramethoxy-7,8-didehydro-
1,2:5,6-dibenzocyclocta-1,5,7-triene 
TMSCl     Trimethyl silyl chloride 
TMSI     Trimethyl silyl iodide 
TOCA     [Tyr3]Octreotate 
TogniTM reagent   3,3-Dimethyl-1-(trifluoromethyl)-1,2-benziodoxole (and 
     derivatives) 
Traut’s reagent   2-Imino thiolane  
UV     Ultra-violet 
VEGF     Vascular Endothelial Growth Factor 
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1.1 Cancer and Detection  
Cancer may be defined in broad terms as being a set of diseases in which there is an 
uncontrolled multiplication and spread within the body of abnormal forms of the body’s own 
cells.[1] There are numerous causes of cancer, and these remain only partially understood, 
due to the complexity and invasive nature of the diseases. Understanding cancer is essential 
to the development of new therapies, and one important way in which this can be explored is 
through the use of molecular imaging.  
1.1.1 The Hallmarks of Cancer  
There are relatively few exploitable chemical differences between cancerous and normal 
cells, and hence it remains highly challenging to target. In 2000, however, six main 
characteristic hallmarks were defined as being the integral components of most forms of 
cancer. These hallmarks include sustaining proliferative signalling (uncontrolled cell 
division), resisting cell death, inducing angiogenesis, enabling replicative immortality, 
activating invasiveness and metastases, and evading growth suppressors.[2] Although these 
hallmarks are still considered to be the main characteristics of most cancer types, these are 
now described in more detail due to the increased understanding of oncology (Figure 1).[2, 3] 
 
Figure 1. The characteristic hallmarks of cancer, taken from Cell, 2011[3] 
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The change in our understanding of the cancer phenotypes are partly a result of the 
improved therapies that have been developed, as well as monitoring the mechanisms by 
which these therapies are controlling the diseases. The basis of cancer lies at the 
fundamental difference between the cells which contain one or more of these defined 
hallmarks and healthy cells.  
For example, cell proliferation and cell death are both essential during an organism’s 
development, and these two features are tightly controlled by the cell cycle. Each phase of 
the cell cycle is responsible for dictating and controlling a particular cellular event, and these 
are strongly monitored by specific molecular checkpoints.[4] These checkpoints determine 
whether progression from one phase of the cell cycle to another is allowed, and small 
irregularities are corrected quickly by repair mechanisms, whereas larger defects may 
instead be committed to programmed cell death or apoptosis (Figure 2). 
 
Figure 2. A general overview of the cell cycle, showing the key checkpoints which determine the progression from one stage to 
another[4] 
Deregulated cell proliferation and apoptosis lie at the foundation of all tumour development 
and are obvious targets for anticancer therapeutics for this reason. However, cancer is much 
more complex than at first glance; proliferative signals are coupled to a variety of growth-
inhibitory processes such as apoptosis, differentiation and senescence, making the 
development of cancer therapeutics a highly complex process. 
Chapter 1 - Introduction 
 
19 
 
Coupled to this is the fact that design and development of cancer therapeutics is a lengthy 
and costly process, and the drug candidates often have adverse effects, with low response 
rates relative to  drugs in other therapeutic areas.[5] For these reasons, rationalising and 
shortening drug discovery and development is critical to improving cancer drug discovery, by 
characterising compounds in the early phases of the discovery and development, and within 
clinical use. In addition, the key to successful cancer therapeutics lies in early diagnosis and 
monitoring the response to therapy, and one way in which this may be achieved this is 
through the discovery, development and validation of oncology biomarkers, including 
molecular imaging biomarkers.[6]  
1.1.2 Molecular Imaging Biomarkers for Cancer Detection 
Biomarkers are used to measure and evaluate normal biological processes, pathological 
processes, or pharmacological responses to therapeutic intervention.[7, 8] Molecular imaging 
biomarkers may improve the precision, and decrease the invasiveness of cancer diagnosis, 
and may allow non-invasively imaging of whole tumour masses. New imaging biomarkers 
that fulfil these criteria allow for the non-invasive imaging of cancer before, during and after 
therapy, and could increase our understanding of cancer biology, as well as providing earlier 
diagnosis, and act as a useful method to monitor the responses to therapy.[1] 
Molecular imaging requires the use of multimodality techniques, involving the collaboration 
between chemists, biologists, physicists and clinicians, and is developing both in terms of 
the range of modalities available, and in the diversity of the molecular probes used. Several 
stages are required for the development of new molecular imaging probes, starting from the 
identification of molecular targets and the development of chemistry, through to cell and 
small animal imaging, and finally computer modelling and clinical imaging (Figure 3).  
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Figure 3. An overview of the process of molecular imaging; from deciding the molecular target to imaging in a clinical setting 
via in vitro models and small animal studies.[9]  
Molecular imaging allows for the characterisation and quantification of biological processes 
at the cellular and molecular level in intact living subjects, and new methods now have 
enough spatial and temporal resolution for studying biological processes in vivo. Small 
animal imaging may be used to determine the biodistribution of a molecular probe before 
use in humans, and may be used to mechanistically understand biological responses to 
treatment. Repetitive, non-invasive, uniform and relatively automated studies of the same 
living subjects may be carried out, using biological imaging assays at different time points, 
which is statistically more powerful and more cost-effective than using single experiments 
with numerous subjects.[10]  
Imaging modalities include optical imaging (bioluminescence and fluorescence), ultrasound, 
magnetic resonance imaging (MRI), X-ray computed tomography (CT), and the nuclear 
imaging methods; positron emission tomography (PET) and single photon emission 
computed tomography (SPECT).[6, 11] Each of these modalities has its own strengths and 
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weaknesses, varying in terms of sensitivity, spatial resolution, temporal resolution, cost, and 
depth of tissue penetration for carrying out small animal imaging (Table 1). 
 
Table 1. Examples of imaging modalities and their advantages and disadvantages for carrying out small animal imaging, 
adapted from Workman, 2010.[10] 
Optical Imaging 
Optical molecular imaging techniques image photons using charge-coupled device (CCD) 
cameras.[6] This allows for the imaging of light in both the ultraviolet (UV) and near infrared 
(NIR) regions. Most in vivo optical imaging is obtained using fluorescence, whereby light is 
emitted from an electronically excited molecule when the energy of the molecule drops from 
its lowest singlet state to its ground state. Optical imaging is widely available due to the low 
cost of the technique, and the most utilised modalities are bioluminescence and 
fluorescence imaging (FLI). Bioluminescence is limited due to the requirement of the 
production of cross-species of proteins, making the method irrelevant in clinical applications.  
However, FLI has seen the development of numerous molecular probes, and is a highly 
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sensitive technique. The wide range of fluorophores that are available, as well as the use of 
non-ionising radiation, make this an attractive method for molecular imaging. However, the 
method is limited due to the poor methods of quantification that exist, as well as the depth of 
tissue penetration in a clinical setting, which is much lower than for the other imaging 
modalities. For this reason, in the clinic, FLI imaging probes are most useful for studying 
superficial tissues; for example breast cancers and lymph nodes, or when coupled with 
invasive techniques (e.g. using an endoscope or open surgery).  
Ultrasound  
Ultrasound is a fairly robust and inexpensive method for imaging soft tissue, and uses high-
frequency sound waves, which are reflected or refracted back to the transducer, allowing for 
reconstruction of the tissue under study. An image known as a sonogram is produced, and is 
used particularly for measuring the progression of pregnancy.[12] In oncology, this technique 
is useful for imaging tumours by contrast to other tissue, and distinguishing these areas from 
fluid-filled compartments such as cysts. Ultrasound is useful for diagnostic purposes, and for 
measuring changes in tumour size, particularly when aided by 3D techniques and through 
the use of contrast agents.[13] It is possible to distinguish between benign and malignant 
tumours when microbubble contrast agents are employed. 
The main advantages for use as a molecular imaging modality include the low risks 
associated with the technique (as unlike CT it does not use ionising radiation), and the small 
size of the equipment, making the method widely available at relatively low cost. However, 
the technique is limited to studying areas that are not overlaid by bone, and the waves are 
reflected more strongly at air-tissue interfaces.[14] This modality also has the disadvantage of 
being operator dependent, making reproducibility of the procedure for a wide range of 
applications challenging. 
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Magnetic Resonance Imaging (MRI) 
MRI is one of the most highly utilised methods for imaging cancer, and, unlike the nuclear 
imaging methods (PET and SPECT) and CT, this method does not rely on the use of 
ionising radiation.[15] Instead, nuclear magnetic resonance (NMR) is used to visualise nuclei 
inside the body. A strong magnetic field is used to align the protons inside the subject, which 
is then exposed to a varying electromagnetic field (pulse).[6] This electromagnetic field has 
the correct resonance frequency to alter the spin of the nuclei within the magnetic field, and 
when this radiofrequency pulse is turned off, the protons re-align to the bulk magnetic field. 
This is known as the relaxation, and the radiofrequency produced from this event is recorded 
by the receiver coils in the MRI scanner. Additional magnetic fields may be used in order to 
obtain useful 3D information, and a Fourier Transform (FT) is used in order to 
mathematically determine the distribution of protons within the subject. Protons in different 
tissue-types display differing relaxation rates, and hence this can be used to generate, or 
construct images, based upon variables such as theT1 and T2 relaxation times, spin density, 
flow and spectral shifts. Contrast between different tissue may be visualised using this 
method, and for this reason it is particularly useful for imaging tissues that contain many 
hydrogen nuclei and low density contrast, such as the brain, and most types of tumours. 
The main advantages of MRI over other molecular imaging modalities are the high contrast 
to other tissue, and high spatial resolution that may be obtained, providing superior 
anatomical information when compared to optical and nuclear imaging. A significant 
advantage of MRI over modalities such as CT is the use of non-ionising radio frequency 
(RF), which has a lower overall risk to patients than the use of ionising radiation.[16] However, 
there are some limitations associated with the sensitivity of the technique. In order to 
achieve imaging of disease biomarkers using MRI, targeted MRI contrast agents are 
required, such as gadolinium-based chelates, which improve the visibility of internal body 
structures by altering the relaxation times of atoms within the treated tissue.[17] The sensitivity 
may be enhanced by increasing the molecular field strength, or by use of hyperpolarisation. 
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A significant disadvantage is that the technique is relatively expensive, having a similar 
overall cost to nuclear imaging modalities.[6] 
X-Ray Computed Tomography (CT) 
CT is a medical imaging technique that produces tomotographic images through the use of 
computer-processed X-rays. Since its introduction in the 1970s, it remains the most widely 
used method of transaxial imaging, and is used for both diagnosis and staging of most soft-
tissue and bone cancers, as well as to assess response to treatment. This is largely due to 
the fact that this method provides excellent tissue contrast, allowing for the disease to be 
visualised in 3 dimensions (3D), by use of a series of 2D X-ray images around a single axis 
of rotation. CT allows for a quantitative assessment of the change in tumour volume in 
response to treatment, and the functional properties of tumours may be assessed with the 
aid of contrast agents.[18]  
This method is useful for determining the boundaries of the tumour, and therefore the extent 
to which invasiveness into other tissue has occurred, due to the detailed anatomical image 
that may be obtained. Another advantage is the wide availability of the technique, coupled 
with the low cost as compared to other imaging modalities, as well as the speed of the scan 
acquisition. For assessing cancer, CT is most commonly used to evaluate the primary 
tumour size, as well as determining the levels of metastasis, but it may be used in 
combination with other imaging modalities in order to obtain further molecular 
information.The main limitation of this method for imaging cancer is the use of ionising 
radiation, which has many health implications for the patient.[19]  The use of this modality for 
some particular applications is currently being eclipsed by other imaging modalities such as 
MRI.  
Single Photon Emission Computed Tomography (SPECT) 
Nuclear imaging may be defined as being the temporal and spatial detection of ionising 
radiation from injected radionuclides.[6] SPECT and PET are two key molecular imaging 
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modalities that are able to functionally map the distribution in the body of a radiotracer. Both 
of these techniques are 3D, and are ‘powered’ by use of nuclear imaging. These imaging 
modalities are, in a simiar manner to CT, limited in terms of radiation exposure.  
SPECT relies on the delivery of a gamma-emitting radioisotope, which is usually 
administered through the blood stream. In most circumstances, the radioisotope is attached 
to a ligand which is of interest due to its chemical binding, forming a radioligand which may 
be delivered selectively to the part of the body under study. The concentration of the 
radioligand may subsequently be detected by a gamma camera, creating a series of 2D 
images, which when combined and reconstructed allows a 3D dataset to be produced. Due 
to the functional images that may be obtained, SPECT is often coupled with CT in order to 
obtain more detailed anatomical information (Figure 4).  
 
Figure 4. 111In-DOTA-exendin-4 whole-body planar images (A–C) and 111In-DOTA-exendin-4 SPECT/CT images (D, E) from 
the same patient. 111In-DOTA-exendin-4 uptake visible in the head of the pancreas (arrow) on whole-body (B) and SPECT/CT 
(D) scans. Reproduced from Christ, 2009[20, 21] 
SPECT is a relatively low-cost nuclear imaging technique, using longer-lived and more easily 
obtained radioisotopes than PET. However, the resolution of a SPECT image is limited due 
to the use of measurement of directly emitted gamma rays. PET, however, detects 
emissions in coincidence, providing more information on the exact radiation event, and is 
subsequently 2 to 3 times more sensitive than SPECT.  
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1.2 Positron Emission Tomography (PET)  
PET is a powerful molecular and functional imaging modality, which can be used to non-
invasively measure in vivo biodistribution of molecular probes which are labelled with a 
positron-emitting nuclide, and allows for biological processes in intact living systems to be 
imaged.[22-24] PET involves the administration of a positron-emitting isotope, which is bound 
to a targeting ligand, and may either be a substrate for a normal physiological pathway, or is 
designed to have specific binding interactions with a particular biological target.[25] These 
radiolabelled probes are administered intravenously in trace amounts, so as to not interfere 
with normal physiological processes, and for this reason are known as radiotracers. PET can 
be used to observe complex biological processes such as metabolism and receptor/enzyme 
interactions, and can also be used to image tissue function at the molecular level.[26] Unlike 
with CT and MRI, PET is a functional imaging modality, and a detailed anatomical image is 
not produced. 
A PET scan can, however, enable early detection of a potential disease through an 
observation of chemical changes which may already have occurred.[27] This is an advantage 
over other imaging techniques such as MRI and CT, which rely upon observation of 
structural changes, and do not provide any information on metabolic or molecular events.[15] 
For these reasons, PET has now become an invaluable technique in drug discovery and 
development due to the ability to facilitate the early detection of disease.[28] PET requires the 
use of multidisciplinary resources, and on the expertise in a number of scientific areas 
including synthetic organic chemistry, radiochemistry, pharmacology, cell biology, physics, 
image analysis and oncology.  
1.2.1 Principles of PET Imaging 
Probes designed for use in a PET study are labelled with a positron-emitting nuclide, such 
as 18F, 11C or 68Ga. These radionuclides achieve stability either by electron capture; whereby 
a nearby orbital electron is captured by the nuclei, or by emission of a positron, which has 
equal mass but opposite charge to an electron (β+).[24, 29, 30] Each radionuclide has a 
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characteristic kinetic energy profile, and the positron emitted during this process loses its 
relative kinetic energy whilst travelling through the host system, via electrostatic interactions 
with neighbouring electrons and protons. These particles of antimatter travel very short 
distances (~2 mm) within a living organism, dependent upon the particular energy of the 
positron and hence the radioisotope used, eventually slowing and colliding with an electron 
from surrounding tissue, forming an ultra-short-lived entity called a positronium (Figure 5).[31]  
 
Figure 5. The principal of PET imaging, showing the decay of a positron-emitting isotope, and subsequent collision of the 
positron with an electron, forming two high-energy γ rays. Adapted from Nguyen, 2010[1] 
Two high-energy γ-rays (511 keV) are formed as a result of the positronium annihilation, at 
approximately 180° angles from each other, which travel at the speed of light (30 cm ns-1) 
through the host system.[32] A radiation detector can be used to detect both of the γ-rays from 
an external source, generating detailed information on the origin of the annihilation event. 
By use of an array of detectors circulating the object under study, the annihilation information 
can be used to produce a time resolved image of the distribution of radioactivity within the 
human body, with very little perturbation of the biological system.[33] PET scanners consist of 
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a series of pairs of opposing radiation detectors, arranged geometrically to approximately a 
circle in 2D, and a cylinder in 3D. A line of response (LOR) is defined by a combination of 
the detection of the coincident event (photons detected in opposite directions) within a finite 
time span (nanosec). These events are reconstructed into images of representative slices of 
the subject, using mathematical tomographic image algorithms.[34]  
The instruments used for PET are frequently being developed and improved, and their 
enhancements have been a cornerstone in the development of PET and its introduction into 
the clinic. These have developed from being solely confined to whole-body scanners, to 
organ-dedicated instruments such as positron emission mammography, as well as dedicated 
brain and prostate scanners, and systems designed specifically to image small animals.  
1.2.2 Clinical Applications of PET Imaging  
Labelling a molecule which targets a specific biological process or marker allows for the 
spatial distribution of a labelled molecule to be imaged dynamically in vivo. PET imaging has 
already had a large number of applications in disease; the most predominant of these being 
the non-invasive imaging of cancer.[35] The method not only allows us to visualise the 
disease, but can also be used to plan suitable therapies and monitor the effectiveness of 
these treatments.[36, 37] Existing radioligands have been used, for example, to study blood 
flow, metabolism, cell surface receptor expression, angiogenesis, gene expression, 
proliferation and apoptosis (Table 2).[25]   
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Table 2. Radiotracers that are currently reported in clinical studies or are listed as in the clinical trial on the clinicaltrials.org 
website[25] 
Although PET has obvious uses in the imaging of cancer, it is a potential ‘multipurpose’ 
imaging tool, and has numerous applications in other biomedical, clinical and research 
areas. PET has also been used to gain a greater understanding of complex receptor 
systems and their relevance to a particular disease. In particular, imaging agents have been 
designed to bind to various receptors in the human brain, and can allow for detailed analysis 
of the role of these receptors in brain diseases such as Parkinson’s and Alzheimer’s 
diseases.[29, 38] As well as having the ability to diagnose some neurologic and psychiatric 
disorders, the technique may also be used for the non-invasive quantification of cerebral 
blood flow and metabolism, as well as other disease types.  
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1.2.3 Advantages and Limitations of PET as an Imaging Technique 
PET imaging displays a number of advantages as an imaging modality; in particular, it has 
higher sensitivity (up to 10-12mol I-1) than all of the other techniques, meaning that tracers 
with very low (i.e. nano or pico molar) concentrations can be detected, therefore lowering the 
requirement to inject harmful levels of ionising radiation. The method also allows for the 
distribution of radiotracer to be measured quantitatively; accurately measuring the amount of 
tracer transported to, and deposited in, the tissue under study, and it is largely independent 
of the thickness of the object and depth of the source within the subject.   
A significant disadvantage of PET as a molecular imaging modality is the low spatial 
resolution of the images that may be obtained as compared to other imaging techniques, 
owing to the fact that PET is essentially a functional imaging modality. Hybrid PET/CT 
systems are now most commonly used, as these allow for the functional information 
obtained by a PET image to be combined with the morphologic data obtained from a 
diagnostic CT scan.[36] Merging of two techniques allows for an overall more confident and 
accurate diagnosis, and has led to an increase in the success of patient diagnosis, disease 
staging, and therapy monitoring (Figure 6).  
 
Figure 6. From left to right: A whole body CT scan, a PET scan, and A PET/CT scan[39] 
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The use of a combined technique also increases patient comfort, and importantly, has a 
higher clinical throughput and success rate than when the two modalities are used 
separately. The main limitation of combining these two techniques is the fact that the use of 
ionising radiation in CT outweighs some of the main advantages of PET, and subsequently 
the overall risk to patients is higher.  
The future of PET may in fact lie in alternative hybrid systems such as PET/MRI, which 
again allows for the combination of metabolic and anatomical information.[40] This certainly 
has advantages of improving the success of disease detection, as well as involving lower 
exposure to ionising radiation; these advances suggest that the diagnostic research area 
will, in the future, be dominated by hybrid molecular approaches.  
1.3 Designing and Synthesising Radiotracers for PET Imaging  
When designing a new radiotracer for PET imaging applications, a number of factors must 
be taken into consideration. This is due to the use of short-lived, positron emitting isotopes, 
which have unique properties to enable their function for imaging applications. As discussed, 
the development of molecular imaging probes involves collaboration between scientists of a 
number of different disciplines, and this begins with the identification of the molecular target, 
which is followed by the development of the chemistry (Figure 7).[41]  
 
Figure 7. Development of a radiotracer for PET, including target selection, choice of a suitable biomarker, and radiochemistry 
development  
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1.3.1 Molecular Target Selection  
A radiotracer is most often designed with a particular biological target in mind; for oncology 
applications this is usually a receptor that is up-regulated in particular tumour types, and may 
be related directly to one of the hallmarks of cancer (e.g. proliferation, apoptosis etc.). Once 
the target has been chosen, the biomarker may be designed based upon either an existing 
ligand for this receptor (for example an existing cancer therapy), or by structure-based 
design. Many types of compound may be considered as potential radioligands, varying from 
small molecules to macromolecules, such as peptides and antibodies.[25] 
Often, a library of radioligands is synthesised with the target in mind, and this may consist of 
a series of structural analogues of a parent compound, which has a known affinity for the 
molecular target. The chosen radioligand should ideally have sub-nanomolar or nanomolar 
affinity for the target, so that only trace amounts are required. In addition to these factors, the 
structure of the ligand or biomarker should not be significantly altered by the introduction of 
the radionuclide, so as not to alter the overall binding affinity of the labelled compound 
relative to its unlabelled parent compound.  
Isotopes of carbon (11C t1/2 = 20.3 min), nitrogen (13N, t1/2 = 9.97 min), oxygen (15O; t1/2 = 2.03 
min), and fluorine (18F; t1/2 = 109.8 min) are particularly useful as they correspond to some of 
the most common naturally-occurring elements in living systems. This means that the 
introduction of the radionuclide may be possible via direct isotopic substitution; for example, 
the radioligand may have the same fundamental structure as the biologically active molecule 
(e.g. 12C may be replaced directly by 11C). This means that radiolabelled versions of 
molecules of biological interest can often be synthesised without significantly altering the 
biological function of a molecule; and in fact, the labelled version may sometimes be 
modified to be more biologically active than the native form.  
Chapter 1 - Introduction 
 
33 
 
1.3.2 Suitable Radionuclides 
One of the most challenging aspects of probe development for PET imaging is the short half-
lives of the isotopes involved; the fast decay rate means that the tracer must be synthesised 
rapidly, as imaging must take place within one or two half-lives after completion of 
radiosynthesis in order to attain useable levels of signal-to-noise. This often suggests that 
there is a requirement for isotopes to be produced within an on-site cyclotron facility, 
significantly increasing the cost of this method. However, 18F (t1/2 = 109 min) has a longer 
half-life than other isotopes used, and may be outsourced from non-site-based facilities, 
making this a more popular isotope when costs are an issue. A preferred metal-chelating 
isotope may also be considered in this case; 68Ga (t1/2 = 68 min) may be produced by a 
relatively low-cost 68Ge generator (see sections 1.5 and 1.6).  
As well as the synthetic considerations that must be taken into account, when deciding upon 
the radionuclide used for the specific tracer, the half-life of the isotope must be tailored 
towards the application and pharmacokinetic properties of the radiotracer. Different 
radionuclides for PET have varying properties in terms of radioactive half-life, decay pattern 
and positron energy (Table 3).[42] 
 
Table 3. Physical data for common PET radionuclides used in oncology applications. The quoted specific activity is the 
maximum achievable (or theoretical) value for the given isotope[42] 
These properties have a significant effect on the image that may be obtained, as the 
radioisotope chosen will alter the image resolution due to the differing decay properties. The 
isotopes displaying the highest positron energy (for example gallium-68 and Iodine-124) will 
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produce the lowest resolution images, and will subsequently require the highest level of 
expertise to reconstruct. 
11C is an ideal nuclide for labelling molecules of biological interest, due to the ideal positron 
energy and range in physiological (aqueous) tissue. However, the half-life of the isotope is 
too short for use in tracers that require significant distribution and commercialisation, and is 
therefore most applicable for labelling small molecule tracers. 18F displays a good balance 
between positron energy and physical half-life, and has a number of other properties that 
make it attractive for the synthesis of tracers (see section 1.5). Metallic nuclides such as 
64Cu and 86Y are appropriate for developing tracers based on peptides and proteins, as 
these ligands take a longer time to accumulate sufficiently at the target. 124I is good for 
labelling peptides and larger proteins such as antibodies, due to its long half-life, but this is 
balanced by a relatively low achievable specific activity compared with other positron-
emitting nuclides. 
1.3.3 Synthetic Considerations  
Once the radionuclide has been chosen, the synthetic strategy by which to incorporate the 
isotope into the tracer must be developed. The radioisotope chosen is produced by charged 
particle nuclear reactions, usually from a cyclotron. A cyclotron is an instrument which 
contains a gas or liquid target, which is bombarded by either protons or deuterons, and once 
obtained, the isotope is usually formulated for use in the synthesis of the radiotracer.[25] 
In order for a radiotracer to be developed, the following characteristics of the synthetic 
strategy must be achievable: 
- Sufficient radiochemical yields 
- An adequate radiochemical purity (95 % or higher for human clinical scans) 
- High enough specific radioactivity for imaging by administration of trace amounts 
- Formulation of the radiotracer into a form which is approved by the European 
Medicines Agency (EMA) or the Food and Drug Administration (FDA) 
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Fast and robust strategies are preferred when working with short-lived isotopes, and 
generally, the total time from the start of the radiosynthesis to the time when the tracer is 
ready for injection should be no longer than 2 times the half-life of the isotope chosen. For 
obvious reasons, the synthesis should be as high yielding as possible, and the isotope is 
ideally introduced at the last stage of the synthesis in order to reduce the amount of time 
pre-injection that the radionuclide is allowed to decay. Long synthetic strategies may hinder 
the use of a radiopharmaceutical in a clinical setting, and so careful consideration must be 
taken to insure that the synthetic time and complexity is kept to a minimum.[43] Often, a multi-
step synthetic pathway is chosen, where a prosthetic group containing the radionuclide is 
synthesised first, and is subsequently introduced onto the compound of interest (see section 
1.5).[25] The method of purification of a radiotracer is also of high importance, and isolation is 
often achieved using High-Performance Liquid Chromatography (HPLC), which would 
eliminate any unreacted precursors and by-products obtained from the reaction.  
Due to the use of high levels of radioactivity during radiosynthesis, adequate shielding is 
required for the radiochemist and the exposure to radiation must be kept as low as possible 
by taking all necessary safety precautions. For this reason, as well as keeping the synthesis 
time low and reproducibility high, automated synthesis platforms are often developed for 
well-established radiosynthetic procedures; and these are particularly useful when 
synthesising radiotracers for routine clinical use.  
1.3.4 Specific Activity  
One of the most important considerations when designing and developing the synthesis of a 
new radioligand is the specific activity; which is the amount of radioactivity per mole of the 
‘cold’ or non-radiolabelled compound. This value is usually stated in units of GBq or µCi 
µmol-1, which gives a quantitative value for the ratio of radionuclide to non-labelled material. 
Each radionuclide has a maximum theoretical specific activity, which is inversely proportional 
to the physical half-life and mass number of the isotope (cf. Table 3).[41] 
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This maximum theoretical value is almost impossible to achieve, and so the precise specific 
activity of the particular radiolgiand must be calculated. A high specific activity is often 
necessary in order to achieve maximum accumulation of the radioligand over the non-
labelled compound, especially when the ligand binds irreversibly to the receptor (Figure 8).   
 
Figure 8. A schematic representation of the difference between a high specific activity (top) low specific activity (bottom) 
radioligand in vivo, using a ligand that binds irreversibly to the receptor 
This in turn may alter the required dose of the tracer, and therefore the amount of radiation 
exposure to the subject. The required specific activity will, however, be dependent on the 
relative affinity of the radiopharmaceutical for the receptor, balanced by the number of 
receptors available for binding.   
1.3.5 Pharmacokinetics  
Even when a radioligand has been designed for a specific biological target, the in vivo 
stability and metabolic fate may be difficult to predict. Due to the fact that only trace amounts 
are injected, there is not so much interest in the pharmacodynamic fate of the radioligand; it 
is more important to determine how the distribution of the tracer will alter the outcome of the 
PET measurement. There are numerous ways to predict the pharmacokinetics profile of a 
molecule; including measuring its LogP, which has a significant effect of the binding of the 
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ligand to the receptor target, and on the adsorption, distribution, metabolism and excretion 
(ADME) of the tracer (see chapter 3 for more details). Additionally, the metabolic fate of the 
tracer may have an effect on the outcome of the PET experiment; one specific example is in 
vivo defluorination, which is a common occurrence with 18F-labelled radiotracers. For 
example, the defluorination of [18F]arenes and [18F]fluoromethyl groups attached to 
heteroatoms, leads to the production of ‘free’ 18F-flouride, which accumulates in bone tissue, 
and therefore affects any PET measurements in these areas.[44]  
1.4 Radiolabelling with 18F 
1.4.1 Properties of 18F as a Radionuclide for PET 
Fluorine is the most electronegative element in the periodic table (4 on the Pauling scale), 
and the element forms extremely strong bonds with carbon (105.4 kcal mol–1).[45] This 
combination of factors makes fluorine an attractive choice for introduction into biologically 
active compounds for the development of pharmaceuticals and radioligands.[46] The C-F 
bond is consequently found in approximately one-fifth of pharmaceuticals and generally 
displays good metabolic stability; probably a result of the electrostatic attraction between the 
polarised C and F atoms. In addition to this, fluorine acts as a bioisostere of the hydrogen 
atom, possessing the smallest atomic radius of the Period 2 elements due to its high nuclear 
charge (Table 4).[47] 
 
Table 4. The van der Waals radii and average C–X bond lengths of some common elements, adapted from O’Hagan 2008[46] 
The C-H bond is often replaced directly by a C-F bond with minimal perturbation of the 
molecule on steric grounds. However, on electronic grounds, this substitution has a much 
more significant effect, often altering the pharmacokinetic properties of the molecule. 
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18F has a number of important characteristics that make it an attractive radionuclide for PET 
imaging applications. Most importantly, it displays relatively low positron energy (maximum 
0.635 MeV), which means it has a relatively short range in tissue, allowing for the production 
of high resolution images. 18F has a half-life of 109.7 min (97% β+ decay), which is 
significantly longer than other positron-emitting nuclides such as 11C (20.4 min), 13N (9.9 
min) or 15O (2.1 min), increasing the synthetic feasibility of introduction of the isotope. This 
also allows for potential transportation of the isotope or synthesised tracer from a production 
site (or site containing a cyclotron) to an off-site facility. However, the costs associated with 
this are still high for the user, and additional transportation may have certain time-associated 
problems, especially when carrying out radiosynthesis that has a clinical end-point.  
As discussed, the specific activity of a radioligand is very important in order to obtain 
maximum uptake of the labelled over the non-radioactive or ‘cold’ compound. When 
obtained as nucleophilic [18F]fluoride, 18F can display a higher specific activity (maximum = 
6.3 x 1010 GBq mol-1), compared to other isotopes such as 64Cu, making tracers labelled by 
18F potentially more efficient than those incorporating other radionuclides. 18F may also be 
produced in large quantities by a cyclotron (>10 Ci) and the labelling techniques often allow 
for PET tracers to be produced in high radiochemical yields. Importantly, due to the relatively 
low positron energy of this isotope, as well as the high specific activity of these tracers, the 
radiation dosimetry received by a patient is usually acceptable in order for multiple studies to 
be carried out.  
1.4.2 Obtaining [18F]Fluoride for Probe Synthesis 
 [18F]Fluoride may be used as a nucleophile for the direct incorporation onto aliphatic and 
aromatic carbons, provided that a precursor is available for carrying out traditional SN2 and 
SNAr reactions. There are numerous methods which have been adopted for the preparation 
of nucleophilic 18F, and in all cases there is of course a charged counter-ion.[48] The most 
effective method for the initial production of aqueous [18F]fluoride is by use of a cyclotron, 
which produces 18O-enriched water (Figure 9). 
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Figure 9. Example of a PET cyclotron used to produce18F 
The very high yielding nuclear reaction 18O(p,n) forms the [18F]fluoride ion as a solution in 
the irradiated target water, producing no-carrier-added (NCA) [18F]fluoride.[23] This is a useful 
attribute of radiotracers, as it improves the specific activity of the final tracer by removal of 
the non-radioactive species.  
Usually, nucleophilic fluoride is used directly for synthesis, as it is the most straight-forward 
to obtain, and allows access to the most synthetic possibilities, but it is possible to obtain 
electrophilic fluorine-18 (18F+) (see section 1.6.3). The nucleophilic species may be obtained 
by a variety of different methods, which should be achievable in time-periods within the half-
life of the isotope.[23] The first step always involves the removal of the bulk [18O]water, 
followed by solubilisation in a suitable organic solvent. The [18O]water is recovered by use of 
an ion exchange resin, adsorbing the [18F]fluoride ion which can then be eluted into a small 
volume of aqueous weak base such as potassium carbonate.  
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The next stage of recovering [18F]fluoride involves the removal of water, which may be 
achieved by azeotropic evaporation with acetonitrile. The [18F]fluoride ion is solubilised into 
an organic solvent such as acetonitrile during this process, which can be achieved using a 
kryptand such as aminopolyether 2.2.2 (K2.2.2) (Figure 10).  
 
Figure 10. The [18F]fluoride ion – K2.2.2-K+ complex[23] 
The kryptand is responsible for capturing the positive counter-ion, separating it from the 
nucleophilic [18F]- and enhancing its reactivity. A truly ‘naked’ fluoride ion is thought not to be 
obtained during this process, as some degree of hydration will still remain when any residual 
water is present, and so careful consideration must be taken when carrying out a reaction 
that does not tolerate water. 
Purification of [18F]fluoride is often carried out before it can be applied to a chemical reaction, 
as a number of contaminants may result from the cyclotron sources and may become more 
concentrated after evaporation of the irradiated water.[23] These impurities may cause 
problems with probe synthesis if not properly removed. For example, the ion may be 
converted into [18F]fluorotrimethylsilane, which can be distilled and then converted back to 
purified [18F]fluoride, which may be particularly useful when carrying out more challenging 
reactions for probe synthesis.  
1.4.3 Electrophilic Fluorinations for the Introduction of 18F 
Elemental fluorine, F2, is one of the most reactive known substances, due to the weak bond 
formed between two atoms of fluorine, and the contrastingly strong bonds that are formed 
with other elements, such as carbon, hydrogen and silicon. Electrophilic fluorinations may be 
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carried out using elemental fluorine, and for radiosynthesis, a number of electrophilic 
fluorinating reagents now exist.[47]  For example, 18F-F2 is a widely-applicable electrophilic 
fluorinating reagent, in which fluorine is transiently highly polarised with a partial positive 
charge (Figure 11). 
 
Figure 11 Examples of electrophilic fluorinations using 18F-F2, adapted from Alauddin 2012
[47] 
Using these methods, electron-rich arenes and aliphatic compounds act as nucleophiles and 
become fluorinated. Electrophilic fluorinations are fairly fast and efficient, making these 
reactions feasible for obtaining 18F-labelled tracers. However, the products obtained from 
this type of reaction are often formed with low specific activity due to the necessity that 18F2 
is contaminated with non-radioactive F2, and hence is carrier-added.[47] 
1.4.4 Nucleophilic [18F]Fluoride for Radiolabelling  
A number of methods now exist for carrying out nucleophilic [18F]fluorinations. Aryl C-18F 
bonds generally have a greater in vivo stability than alkyl C-18F bonds, but the chemistry 
involved in the synthesis of aromatic C-18F bonds is significantly more challenging. Large 
biomolecules and electron-rich arenes are not readily labelled directly using NCA 
nucleophilic fluorination due to the low reactivity and high proton affinity of [18F]fluoride. The 
traditional methods to introduce fluorine atoms onto an aromatic ring usually require harsh 
conditions such as those involved in direct fluorination, the Balz-Scheimann reaction 
between anilines and HBF4/NaNO2, nucleophilic substitutions of bromo- or chloro- arenes 
with KF, and reaction of aryl iodides with CuF2.[49]  
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Improved methods for introducing 18F onto aromatic rings include the reactions of 
[18F]fluoride with diaryliodonium salts, triarylsulfonium salts, or diaryl sulfoxides.[50] These 
methods, have improved the ability to incorporate [18F]fluoride onto electron-rich arenes, and 
the nuclide may be introduced onto the meta- as well as ortho- and para- positions relative to 
existing substituents (Figure 12).  
 
Figure 12. The use of diaryliodonium salts for nucleophilic 18F-fluorination, adapted from Chun and Pike 2013[50] 
This method is still utilised mainly for the synthesis of small molecule, or low molecular 
weight radiotracers (< 500 Da), and so alternative methods are still required for the 
introduction of 18F into more complex, higher molecular weight structures. This may require 
the use of prosthetic groups, which are readily prepared reactive species’ containing 18F, and 
can be used to introduce the radioisotope into the target compound.[49] A number of methods 
may be used for the synthesis of such prosthetic groups, which can be used to label both 
small molecules and macromolecules, and may be either aliphatic or aromatic.[51, 52] 
Examples of these groups, also known as labelling synthons, include 18F-labelled 
haloketones, esters, benzyl halides, and benzaldehydes. These have been used for labelling 
PET radiotracers of more complex molecules, such as amino acid receptor ligands, peptides 
and proteins.[50]  
Peptides are particularly useful targets for cancer detection, as highly specific tissue uptake 
may be achieved. A radiolabelled small molecule prosthetic group, once synthesised, may 
be attached to the peptide without significant alteration of its biological function, which is 
usually achieved using simple reactions with fast reaction kinetics.[53] Chemoselective 
reactions which proceed under mild conditions have been increasingly utilised for 
introduction of suitable NCA 18F-labelled prosthetic groups. 
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One type of reaction in particular has been used for the synthesis of [18F]fluoropeptides, 
known as ‘click’ chemistry.[54] The term ‘click’ chemistry usually refers to the highly 
regioselective copper(I) catalysed reaction between azides and terminal acetylenes to form 
1,4-disubstituted 1,2,3-triazoles, also known as the copper-catalysed azide/alkyne 
cycloaddition (CuAAC) reaction.[55] Reactions between azides and alkynes originally involved 
the use of elevated temperatures to increase the rate of this reaction and typically resulted in 
an ~1:1 mixture of the 1,4- and the 1,5-disubstituted triazoles.[56] The formation of catalytic 
copper(I) in situ from copper(II) salts using sodium L-ascorbate allows for the regiospecific 
preparation of a large spectrum of 1,4-triazole products in high yield (Figure 13).[57-59]  
 
Figure 13. a) Huisgens 1,3-dipolar cycloaddition between azides and alkynes, b) The modified version using copper(I) 
catalysis, known as the CuAAC reaction 
The product triazoles have desirable physiological properties, being topologically and 
electronically similar to naturally occurring secondary amide functional groups.[29] The former 
are more stable to hydrolysis and contain very rigid linking units, placing the carbon atoms 
within the triazole ring at distances of 5.0 Å to one another, compared to 3.8 Å in the C-α 
amide bond. Unlike benzene derivatives and related aromatic heterocycles, the triazole 
group is very difficult to oxidise or reduce, and has a large dipole moment of 5 debye, which 
allows it to form stable hydrogen bonds.[60] 
For example, the synthesis of peptidic radioligands using the CuAAC reaction was 
demonstrated using a series of [Tyr]3octreotate (TOCA) analogues, which are used to target 
somatostatin receptors, and have been labelled in one step from readily-synthesised [18F]2-
fluoroethyl azide ([18F]FEA) (Figure 14).[54, 61, 62]  
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Figure 14. Aboagye’s use of ‘click’ chemistry for radiolabelling TOCA peptides using [18F]FEA as a prosthetic group[61] 
By incorporating an alkyne moiety onto the peptide, radiolabelling was achieved by reaction 
with the 18F-labelled azide using a copper(I) catalyst. This method allowed for the synthesis 
of a library of 18F-labelled octreotate analogues in good radiochemical yields. The stability of 
the triazole group had little impact on the biological efficacy of the peptides, as compared to 
analogues that had been labelled by alternative methods.[61]  
Click chemistry has been highly utilised for radiolabelling peptides using prosthetic groups, 
due to the accessibility of 18F-labelled azides, as well as the high radiochemical yields that 
may be obtained; a combination of properties that is ideal when working with short-lived 
isotopes.[53, 63, 64] This method is useful for labelling small molecules and peptides using 
isotopes such as 18F, but is less efficient for labelling larger biomolecules such as antibodies 
due to the requirement for the use of higher concentrations, and hence toxic dose levels, of 
copper(I) catalyst. A number of alternative methods for 18F-labelling are being developed, 
relying on either the synthesis of prosthetic groups as mentioned, or by direct labelling 
methods, and these often rely upon the use of metal catalysts.  
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1.4.5 Existing 18F Radiotracers in Oncology 
The most significant example of the use of 18F in oncology is [18F]2-fluoro-2-deoxy-D-glucose 
(FDG), which was originally designed to study glucose metabolism.[23] [18F]FDG was 
developed in 1977 by Ido and coworkers, and it was considered to be the first major 
breakthrough in terms of radiopharmaceutical development.[65] The discovery that an 
increase in glucose uptake in tumour cells as compared to normal cells meant that [18F]FDG 
became a very useful radiotracer for imaging cancer. Phosphorylated [18F]FDG accumulates 
in cells where glycolysis and glucose transport is enhanced, making the radiotracer more 
highly concentrated in these areas.[66], [67]  The synthesis of [18F]FDG was improved in 1986, 
which led to the increased use of this tracer for clinical applications (Figure 15). 
 
Figure 15. Stocklin’s formation of 2-[18F] fluoro-2-deoxy-D-glucose ([18F]FDG) from 2-deoxyglucose.[68] 
The compound is most commonly synthesised via a straight-forward nucleophilic substitution 
of a triflate by cyclotron-produced [18F]fluoride,  and may now be produced on automated 
synthesis platforms, allowing for large-scale synthesis of the tracer. The tracer may, 
however, be synthesised via both nucleophilic and electrophilic fluorination methods.[47] The 
development of [18F]FDG led to a gradual increase in developing the technology associated 
with PET, especially towards a clinical end-point. However, although this major breakthrough 
in PET radiopharmaceuticals dates back to the 1980s, this is still the most significant 
advancement in PET radiotracers to date, and [18F]FDG remains the most important 
compound for carrying out PET measurements for oncology. 
There are now, however, a number of 18F-labelled radiopharmaceuticals that have been 
developed for PET imaging in oncology, and which are in clinical use (Figure 16).  
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Figure 16. Some of the key clinically used [18F]-labelled tracers for oncology 
Cancer cells also demonstrate an increase in uptake of particular amino acids such as 
[18F]fluoroethyltyrosine ([18F]FET), which has particular use in imaging brain tumours.[69] 
Other examples of 18F-labelled tracers include analogues of choline (for example 
[18F]fluoromethylcholine) which are involved in the synthetic pathway for forming cell 
membranes, and are particularly useful for prostate cancer detection.[70] [18F]Fluorothymidine 
([18F]FLT) is another important tracer, which is used to determine response to therapy, and is 
designed to target the up-regulated cell proliferation observed in cancerous cells.[71] 
Resistance to radiotherapy is another key area which may be evaluated using PET, an 
example being the imaging of hypoxia in tumours. For example [18F]fluromisonidazole was 
designed as a biomarker for hypoxia in order to identify when radiotherapy treatments are 
likely to be most effective.[72] [41] 
Increasing interest has been placed recently upon designing alternative compounds for 
better tumour characterisation, which have higher tumour specificity and should aid better 
patient management through improved diagnosis of disease and in evaluating response to 
treatment. A greater range of more accurate probes would also be of benefit in clinical trials 
to evaluate the efficacy of New Chemical Entities (NCEs).[12]  
1.5 Radiolabelling with Gallium-68 
68Ga, although having a shorter half-life (67.71 min) than 18F, and emitting a higher energy 
positron (E+βmax = 1899 keV), (decaying to 89% via positron emission, and to 11% by 
electron capture) has some attractive properties for the synthesis of radiolabelled probes for 
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PET imaging.[73] This is largely due to the relatively low production costs of the isotope, 
which relies on a generator containing the parent radionuclide 68Ge, as well as the relatively 
simple and short radiolabelling methods that are used for metal isotopes, utilising chelating 
ligands attached to a targeting molecule. The half-life of 68Ga, although lower than that of 
18F, is also compatible with the pharmacokinetics of most radionuclides of relatively low 
molecular weight, such as antibody fragments, peptides, aptamers and oligonucleotides.  
1.5.1 68Ga Generation  
68Ga is produced by electron capture from its parent nuclide 68Ge (t1/2 = 270.95 days), and 
must be separated from 68Ge into its ionic form in order to be useful for chelation chemistry. 
This separation is achieved by use of a chromatographic methods; the 68Ge is adsorbed 
onto the stationary phase, which is usually alumina, TiO2, or SnO2, whereas the mobile 
phase is a solvent which is able to elute the 68Ga (usually 1 M or 0.1 M HCl).  
The production of 68Ga is achieved using relatively low-cost generators, which allow for 
clinical studies to be carried out without requiring the use of an on-site cyclotron, and may 
provide the radionuclide for synthesis of radioactive probes at any time, and on demand. 
Automated synthesis platforms now exist, for example Eckert & Ziegler (E&Z) Modular Lab 
system,[74] that allow for both the generation and synthesis of 68Ga labelled compounds to be 
controlled by a computer platform (Figure 17). 
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Figure 17. A Modular Lab system (by E&Z) for the elution, purification and synthesis of 68Ga radiotracers[74] 
These automated platforms are very robust, and when properly utilised may allow for 68Ga 
radiotracer production, from elution to purification of the product, without the need for 
carrying out hands-on radiochemistry. This is particularly advantageous from a safety 
perspective, as it significantly lowers the dose of radiation to the radiochemist, as well as 
lowering the overall time of the synthesis.  
1.5.2 Use of 68Ga for Radiolabelling  
Methods for the incorporation of metal isotopes for radiolabelling are often more efficient 
than those for non-metal isotopes, and usually involve the use of suitable chelating ligands. 
In addition to this, solid-phase purification methods may often be used, minimising the 
problems associated with isotope decay during synthesis.[75] 
Ga(III) is the only stable and relevant oxidation state of gallium in aqueous solution, and the 
free hydrated Ga3+ ion is only stable under acidic conditions. If the concentration of the Ga3+ 
exceeds nanomolar level within pH ranges 3-7, then it can become the insoluble Ga(OH)3 
form; however, at physiological pH, the much more soluble [Ga(OH)4] form dominates.[76, 77] 
Ga3+ may be incorporated into a radiotracer via use of a suitable chelating ligand, and a 
number of these ligands now exist, several of which have become popular, and form the 
basis of robust methods for introduction of this radionuclide into the target compound.  
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1.5.3 68Ga Coordination Chemistry  
Ga3+ has similar coordination chemistry to Fe3+; both species have a similar ionic radius and 
have a dominant coordination number of six (Ga3+ can also, however, display a coordination 
number of four or five). Ga3+ is a hard Lewis acid, and consequently it will form 
thermodynamically stable complexes with ligands that exhibit hard Lewis base properties. 
The types of ligand fulfilling these criteria typically contain a combination of oxygen and 
nitrogen donor atoms. Examples of the kind of functional groups that may be appropriate for 
coordination to Ga3+ include carboxylates, phosphonates, hydroxamates, and amines, as 
well as softer functional groups such as phenolates and thiols.  
1.5.4 Development of Chelators for 68Ga Labelling  
Suitable chelators for Ga3+ must be stable to hydrolysis, and must also be kinetically inert 
within the period of clinical use, in order to avoid any ligand exchange with the protein 
transferrin. This protein is found in blood serum and any ion exchange with this protein 
would lead to liver and lung accumulation of the metal.  
The majority of chelators for incorporation of 68Ga3+ are hexadentate, due to the preferred 
coordination number of six of the Ga3+ ion.[78] Usually, the chelate also contains a functional 
group which allows it to be incorporated into the targeting moiety (e.g. peptide), and in this 
situation is referred to as a bifunctional chelator. As discussed, the chelate formed must be 
kinetically stable within the pH range 4-8, and in the presence of other metal cations such as 
Ca2+, Zn2+ and Mg2+. The method for introduction of the radiometal (i.e. 68Ga) must 
additionally be rapid and high yielding, due to the relatively short half-life of the isotope. 
Other considerations when choosing an appropriate chelating group include the compatibility 
with peptide synthesis (e.g. ability to incorporate protecting groups) and solvent solubility, 
and each of these will be specific to the particular situation and the chemistry required in 
order to introduce the chelating group.[79] 
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An octreotate analogue of desferrioxamine-B (DFO) was one of the first molecules to be 
labelled with 68Ga, and this was achieved in high radiochemical yield (Figure 18).  
 
Figure 18. Van Dongen’s use of Desferrioxamine-B (DFO) as a 68Ga chelator[80] 
The three hydroxamate groups in DFO are available for rapid and high affinity metal 
coordination to Ga3+ ions, and the molecule serves as a bifunctional chelator through its 
available amine group. However, the main limitation of this first-generation chelator is the 
fact that high concentrations (>5 µM) are required in order to achieve acceptable 
radiochemical yields. It was found, through use of assays into the stability of a series of 
mercapto amino ligands, that sufficiently stable complexes may be formed with tetra- and 
pentadentade ligands, but hexadentate ligands demonstrate far superior properties in terms 
of bifunctional chelation through covalent linkage to biomolecules.[79] 
The tetraaza tetraacetic acid chelator DOTA is one of the most common chelators for 
radiometals possessing the +3 oxidation state, including many examples of 68Ga 
incorporation (Figure 19).[81-84]  
Chapter 1 - Introduction 
 
51 
 
 
Figure 19.  Structures of DOTA and NOTA chelates for 68Ga-labelling 
Ga(DOTA)- has now been extensively studied as a potential prosthetic group for 
radiolabelling targeting groups, and demonstrates sufficient stability for use in a clinical 
setting.[85] It is possible to introduce DOTA to peptides efficiently using the tri-tert-butyl 
protected synthon DOTA(t-Bu)3, which has one available acid functional group for reaction 
with an N-terminus. Deprotection under acidic conditions will afford the DOTA-functionalised 
peptide, which will now be available for chelation to the 68Ga3+ ion.[86]  
Crystal structures of the model peptide Ga3+-DOTA-D-PheNH2 have indicated that the 
chelated DOTA adopts a cis-pseudooctahedral geometry, whereby the macrocycle is in a 
folded conformation. The two transannular nitrogens and two of the oxygens from the 
carboxylate groups occupy the equatorial plane, whereas the axial positions are formed by 
the remaining two cyclen nitrogens (Figure 20).[79] 
 
Figure 20. Molecular structure (ORTEP plot) of 6-coordinate [GaIII-DOTA-D-PheNH2] as suggested by the single crystal X-ray 
structure, adapted from Hennig 2009.[87] 
More recently, it was found that triaza triacetic acid chelators (e.g. NOTA) have a greater 
thermodynamic stability constant with 68Ga3+ (logK = 30.98)[88] than the tetraaza tetraacetic 
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acid chelators (e.g. DOTA) (logK = 21.33)[89], due to the fact that this ligand has a smaller 
cavity in which the Ga3+ ion can sit. These macrocycles demonstrate high conformational 
and size selectivity towards Ga3+ ions, and for this reason they can encapsulate the metal 
ions with high efficiency. Examples of some of the most common hexadentate triaza 
chelators for 68Ga include TACN-TM, a ligand with three mercaptoethanol arms[90]; NOTA, a 
tricarboxylic acid ligand[89, 91, 92]; as well as phosphonate-bearing ligands such as NOTP and 
NOTPME.[93, 94] Due to the particularly high affinity of this family of chelators towards 68Ga3+, 
radiolabelling is usually achieved at lower temperatures than with DOTA compounds, and a 
smaller amount of precursor is required, resulting in a higher specific activity (cf. Figure 
19).[95]  
1.5.5 Existing 68Ga Radioligands in Oncology 
A number of radioligands using gallium-68 as the isotope now exist, and some are now 
routinely used in a clinical setting. [68Ga-DOTA, Tyr3] octreotide ([68Ga]DOTA-TOC) is 
probably the most important of these (Figure 21).[79, 96] 
 
Figure 21. Structure of DOTA-TOC 
[68Ga]DOTA-TOC was developed in order to target somatostatin receptor subtype-2, and this 
compound was found to exhibit promising in vitro and in vivo properties. It has been tested in 
a clinical setting, where it exhibits higher tumour specificity than the analogous [111In]DTPA-
octreotide (Figure 22).[96]  
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Figure 22. Comparative images of the same tumour patient obtained using [111In]DTPA-octreotide and [68Ga]DOTA-TOC, 
respectively. Taken of the same patient, with a metastatic gastrinoma, adapted from Graham and Menda 2011[97] 
Other similar structures were developed as tracers for different subtypes of somatostatin 
receptors: [68Ga-DOTA, 1-Nal3] octreotide (DOTA-NOC), [68Ga-DOTA, Tyr3Thr8] octreotide 
(DOTA-TATE) and [68Ga-DOTA-2-Nal, Tyr3, ThrNH82] octreotide (DOTA-lanreotide). Other 
gallium-68 labelled radiopharmaceuticals also exist, including [68Ga]-DOTA-bombesin, which 
binds to three bombesin receptor subtypes, and has been studied for imaging 
gastrointestinal, colon and prostate tumours. 
1.5.6 Limitations and Advantages 
68Ga emits a higher energy positron (1.899 keV), than 18F, and subsequently this leads to a 
lower image resolution. As discussed, however, gallium-68 is produced by a relatively low-
cost generator, making the isotope more accessible to the user than other isotopes. In 
addition to this, the use of chelators such as DOTA and NOTA are highly robust, and result 
in very reproducible and high radiochemical conversions. The combination of these factors 
often results in short synthetic strategies, which may now be fully automated, and produce 
the 68Ga radioligand in high radiochemical yields, and with reasonable to good specific 
activity.  
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1.6 Pretargeting as a Molecular Imaging Tool 
Pretargeting is a two-step targeting approach, by which the delivery of a radionuclide is 
separated from that of a functional biomolecule. This may involve the biomolecule being 
modified with a group which has high affinity for the radiolabelled compound, or more 
specifically, it may contain a moiety which is highly reactive under physiological conditions 
towards a functional group on the radiolabelled partner.[98]  
Pretargeting is particularly advantageous when monoclonal antibodies are used as the 
tumour-targeting species. These have a high specificity for tumours, and may be considered 
very useful PET imaging agents for this reason. However, they also have the disadvantage 
of displaying slow tumour accumulation and retention, as well as long blood clearance time, 
especially when compared to small targeting molecules. Pretargeting may therefore be used 
as a tool to allow the non-radiolabelled antibody to achieve maximum tumour uptake and 
sufficient blood clearance, before administration of a radiolabelled probe, which has affinity 
for the targeted antibody. The small and fast clearing molecule, will bind rapidly to the 
accumulated antibody, while any unbound radiolabel will be quickly cleared from the subject 
(Figure 23).  
 
Figure 23. A schematic representation of the principle of pretargeting using monoclonal antibodies for molecular imaging 
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This method leads to a desirable combination between the high tumour affinities of 
monoclonal antibodies, with the fast distributing and clearing properties of small molecule 
probes. More specifically, this method has the advantage of demonstrating greater tumour-
to-background activity than with direct targeting approaches.  
1.6.1 Existing Methods for Pretargeting 
Pretargeting was first demonstrated in 1985 by Frincke and co-workers, during research into 
the development of radiochemistry chelates. This concept was based upon the principle that 
chelated radiometals clear much more quickly from the body than radiolabelled antibodies, 
as well as the fact that the radiolabelling methods for small molecule chelates are more 
efficient than those for large molecules such as antibodies.[99] This consequently led to the 
development of a new construct, which involved the design of a monoclonal antibody which 
could bind independently to both the tumour and to the radiolabelled chelate EDTA. Pre-
injection of a non-radiolabelled antibody, followed by subsequent administration of the 
radiolabelled chelate, resulted in specific binding of the radiolabelled small molecule to the 
pre-localised antibody.  
A number of pretargeting approaches have now been demonstrated, and the application of 
this method to PET imaging has had a significant contribution to this field. In addition, the 
technique has been found to be a particularly useful strategy in the area of 
radioimmunotherapy (RIT) for the delivery of bifunctional monoclonal antibodies (Figure 24). 
Chapter 1 - Introduction 
 
56 
 
 
Figure 24. A general schematic of prertargeting for radioimmunotherapy (RIT), adapted from Sharkey and Goldenberg, 
2011[98] 
Pretargeting for RIT has several distinct advantages; it has the potential to increase the 
achievable dose to tumours, improve tumour tissue: normal tissue dose ratios, and 
subsequently improve the overall therapeutic index of pretargeted monoclonal antibodies 
over direct targeting methods.[100] 
Two strategies in particular have received a large amount of attention; the first of these 
involves the use of bispecific antibodies which are capable of binding both a radiolabelled 
hapten and an antigen, and the second are modified antibodies that contain both oligomeric 
nucleic acids (acting as targeting vectors) and radioligands. There are, however, significant 
problems associated with the current methods of pretargeting; the synthesis of bispecific 
antibodies is often not simply achieved using direct modification of the parent antibody, and 
is a highly complex and expensive procedure involving molecular engineering (Figure 25).[101] 
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Figure 25. Assembly of bispecific antibodies using ‘Dock-and-Lock’ modules, demonstrating the complexity and high costs 
associated with this approach, adapted from Goldenberg, 2010[101] 
There are also a number of concerns around the use of these olignomeric nucleic acid 
systems which involves the use of non-natural nucleic acids. They constitute expensive 
processes, and additionally, these complexes potentially do not demonstrate sufficient in 
vivo stability for use in a wide range of pretargeting applications.  
Another specific example is a strategy that is based upon the high binding affinity (KD = 1015 
M) of the avidin-biotin complex, which is the strongest known non-covalent interaction 
(Figure 26).[102] 
 
Figure 26. Structure of biotin, which binds to the protein avidin with a high binding affinity.  
The bond formed is extremely stable to changes in pH, temperature, organic solvents and 
other denaturing agents, and avidin may bind up to four biotin molecules, making this 
interaction attractive for pretargeting applications. In one approach, streptavidin (which has a 
similar structure to avidin) may be first ligated to an antibody, which is intravenously injected. 
After a time-point of several days, a radiolabelled biotin is injected, which rapidly binds to the 
streptavidin localised at the tumour. A clearing agent may be used to remove any of the 
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excess streptavin-antibody conjugate from the blood, prior to injection of the radiolabelled 
probe. The opposite method may alternatively be used, by which biotin is attached to the 
targeting molecule (antibody), and streptavidin is used as the labelled tag.[102] The former 
approach has been applied in a clinical setting using a three-step method involving the 
sequential introduction of a streptavidin-antibody followed by 90Yttrium-DOTA-biotin. This 
approach allowed doses of the radiolabelled partner to be five times higher than when the 
antibody was directly labelled, due to a significantly lower radioactive concentration in the 
blood, and this significantly increased survival time of the patients (33.5 months vs. 8 months 
for the control group).[100, 103, 104] The main disadvantage of this approach, however, is that any 
biotin-rich tissue (biotin is a biological molecule) will cause unwanted background and 
specificity issues, by binding competitively with the streptavidin complex.[102]  
A more general problem with using pretargeting is associated with the potential 
internalisation of antibodies, which will result in difficulties in accessing the modified antibody 
by the radiolabelled small molecule. For these reasons, methods are being developed in 
order to overcome these problems, and to allow for a pretargeting system to be established 
that is more versatile for a wider range of imaging applications, including using short-lived 
isotopes for PET imaging.   
1.7 Development of Bioorthogonal Chemistry  
The term ‘click’ chemistry was defined by Sharpless et al. as being a set of reactions that are 
able to proceed under mild conditions and can be applied to the efficient synthesis of a 
broad variety of compounds.[105],[29] These reactions are characterised by fast kinetics and 
high selectivity for covalent linking of molecular compounds and are particularly useful for 
the production of non-natural heteroatom linkages.[106] ‘Click’ reactions are modular and wide 
in scope, give consistently high yields, and form products which are stable under 
physiological conditions.[105]  
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Bioorthogonal chemical reactions are closely associated with the characteristics of ‘click’ 
chemistry, and are defined as being a set of reactions which may occur under physiological 
conditions, without interfering with any of the native biological processes to which they may 
be exposed (Figure 27).[57, 107, 108] 
 
Figure 27. Cartoon of a bioorthogonal chemical reaction[106] 
These reactions are also considered to be fast, occurring at low reactant concentrations, 
without the need for metal catalysts. For these reasons, bioorthogonal chemistry has 
received increasing interest as a tool for chemical reporter strategies, including pretargeting, 
and it may be envisioned that the two reactive partners may be separately incorporated into 
the targeting biomolecule and the radiolabelled probe, respectively, allowing for this fast and 
highly stable reaction to occur in vivo.[106]  An advantage over the previously discussed 
methods for pretargeting is the fact that these reactions form strong covalent bonds, and 
therefore the introduction of the radiolabelled partner is irreversible.  
A number of bioorthogonal chemical reactions now exist, and handles which have been 
shown to be applicable to modifications within biological settings include aldehydes, azides, 
nitrones, nitrile oxides, diazo compounds, tetrazines, tetrazoles, quadrocyclanes, alkenes, 
and iodobenzenes.[109] The two most utilised functional handles for carrying out 
bioorthogonal ligations are carbonyl groups (which were the first non-natural functional 
groups to be incorporated for protein modifications) and organic azides (the most commonly 
used reagents for the modification of biological systems). Some of the most important 
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bioorthogonal reactions are summarised in the following table. Only the bioorthogonal 
reactions not requiring metal catalysis or some other form of activation (such as UV-light) are 
included (Table 5).[109] 
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aMore than one regioisomer is obtained, but only one is shown in the table 
Table 5. Summary of the reaction partners for bioorthogonal conjugation, which have been used in the modification of 
biomolecules 
Aldehydes and ketones form stable covalent bonds with alkoxyamines in the form of oxime 
ethers, and this reaction has been applied to chemical reporter strategies, including the 
labelling of living cells, virus particles, and cell surfaces.[110, 111] Organic azides are 
particularly inert, making them very popular functional handles, and their small size means 
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that they only minimally perturb the substrate to which they are introduced.[112] Azides are 
reactive towards a number of different functional groups (Entries 4-6, Table 5) and the most 
significant bioorthogonal reactions involving this functional handle are the Staudinger-
Bertozzi Ligation and the Strain-promoted Azide/Alkyne cycloaddition (SPAAC).[113, 114] In 
addition to these two functional handles is the tetrazine (Entries 13-18,Table 5) which is 
reactive towards a number of unsaturated compounds with a high level of biocompatibility, 
and with improved reaction rates over the ligations involving azides.[115, 116] These three 
functional handles, coupled with their appropriate reaction partners, have particularly gained 
interest for chemical reporter strategies, and will later be discussed in more detail as 
potential tools for pretargeted PET imaging.  
1.7.1 The Staudinger-Bertozzi Ligation 
The first bioorthogonal reaction to be reported for use in living systems was the ‘traced’ 
Staudinger ligation, a modification of the Staudinger reaction involving an azide and an 
ester-derived phosphine to form an amide bond [Figure 28, pathway (b)].[107, 108, 117]  
 
Figure 28. The Staudinger reaction and the Staudinger ligation (‘traced’ and ‘traceless’). 
This reaction exploits the selective acylation of the α-nitrogen on the intermediate, the 
product of which is capable of undergoing an intramolecular reaction with a methoxycarbonyl 
group at the R1 position, forming an amide-linked phosphine oxide upon hydrolysis.[57] This 
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pathway was designed to overcome the problems associated with the instability of the 
azaphosphorane intermediate in water, by trapping this with an ester. 
A ‘traceless’ Staudinger ligation was later developed to minimise interference from the 
phosphine oxide by incorporating a cleavable linkage between the aryl group and the newly 
formed amide (R1).[107] Upon nucleophilic attack from the nitrogen, the phosphine-containing 
aryl group is liberated, forming an amide as a separate molecule from the phosphine oxide 
[Figure 28, pathway (c)]. The traceless reaction is highly chemoselective and proceeds at pH 
7 with no observable azidephosphorane hydrolysis in aqueous solution. [118], [108] Adding to the 
reaction’s high level of utility is the small size of the azide and the structural resemblance 
between the product and biological compounds, such as proteins and lipids.[58] The 
phosphine and the azide are both stable in a biological environment, and they react 
selectively, with the intramolecular reaction occurring fast enough for it to be carried out in 
aqueous medium on the surface of cells.[108] 
The Staudinger ligation has been utilised in a number of biological applications for these 
reasons, and importantly shows very low levels of toxicity in mammalian cells.[119] The 
reaction can be used to covalently attach probes to azide-bearing biomolecules but is not 
able to detect species in low abundance or processes which are occurring within the body on 
a fast time-scale; problems which can both be attributed to non-optimised reaction kinetics 
(second order rate constant with benzyl azide = 2.5 x 10-3 M-1s-1).[57], [120] For this reason, the 
Staudinger ligation has not been demonstrated as a potential tool for carrying out in vivo 
pretargeted imaging, and a reaction which with more desirable reaction kinetics at low 
reaction concentrations is required for this purpose.  
1.7.2 The Strain-Promoted Azide/Alkyne Cycloaddion (SPAAC)  
The CuAAC reaction, as previously described, allows for high-sensitivity detection of azides, 
suggesting its potential usefulness in vivo for use in a chemical reporter strategy. However, 
the reaction is only useful in this regard when toxicity is irrelevant; for example in probing 
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enzyme activity in cell lysates or in visualising biomolecules in stationary cells.[58],[121] Copper 
is an essential trace element but is toxic at dose levels above about 5 mgL-1, causing 
nausea, cramps, emesis and diarrhoea in some cases.[122] [123] [124]  As well as the apparent 
toxicological effects associated with copper accumulation in the body, the difficulty in 
delivery of copper to the tumour hinders the usefulness of this reaction for in vivo 
pretargeting. The copper-free ‘click’ reaction however makes use of a strained ring system to 
promote the well-established [3+2] cycloaddition, with little or no observed cytotoxicity.[125] A 
combination of the biocompatibility observed with the Staudinger ligation and the fast 
reaction kinetics of ‘click’ chemistry were demonstrated by Bertozzi’s strain-promoted, 
copper-free azide-alkyne [3+2] cycloaddition (SPAAC) (Figure 29).[58]  
 
Figure 29. a) Cu(I)-catalysed Huisgen ‘click’ chemistry. b) Strain-promoted [3+2] cycloaddition between azides and 
cyclooctynes[126] 
The cyclooctyne is the smallest ring size that can accommodate the alkyne functional group 
and still be isolated as a stable molecule. The strained system has been found to improve 
the rate of the copper-free reaction by lowering the activation energy, which was achieved by 
distorting the bond angles of the sp-hybridised carbons by about 17° from the idealised 180° 
angles of a C-C triple bond, forming comparable angles to those involved in the transition 
state of the cycloaddition (~160°). Much of the ring strain which is contained in the 
cyclooctyne skeleton (~18 kcal mol-1) is released upon [3+2] cycloaddition with the azide, 
making this a favourable process.[127] The relationship between strain energy and reactivity is 
therefore related to the degree of strain in the alkyne as well as the amount of relief of ring or 
twist strain upon conversion to the corresponding alkene.  
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Increased reactivity of the cyclooctyne may be achieved by certain structural modifications. 
For example, the introduction of electron-withdrawing groups onto one side of the alkyne 
moiety withdraws electron density away from the triple bond, making reaction with the azide 
more favourable (Figure 30).[55]  
 
Figure 30. A series  of modified cyclooctynes, with the number of synthetic steps, overall chemical yield and 2nd order rate 
constants for reaction with simple azides[128] 
This was demonstrated by Bertozzi and coworkers by introduction of fluorine; the 
monofluorinated analogue MOFO (k = 4.3 x 10-3 M-1s-1) showed improved kinetics in the 
strain-promoted cycloaddition with benzyl azide as compared to the equivalent non-
fluorinated analogue OCT1 (k = 2.4 x 10-3 M-1s-1), and the addition of a second fluorine atom 
(DIFO2) increased the rate by approximately 60 times more (k = 4.2 x 10-2 M-1s-1) than with 
MOFO (see section 2.2).[106] The rate of reaction with azides can similarly be modulated by 
inducing greater ring strain in the core cyclooctyne, which  could be achieved by conjugation 
of the alkyne with aromatic groups, such as those in dibenzocyclooctynol (DIBO) reagents 
such as TMDIBO (9.4 x 10-2 M-1s-1) (see section 2.3).[127] It was found by Bertozzi et al., that 
addition of a further sp2-like centre to the already highly strained system in the DIBO 
template could lead to greater enhancement of 1,3-dipolar cycloaddition reaction kinetics, for 
example by incorporation of an amide group within the cyclooctyne ring in 
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biarylazacyclooctynes such as BARAC (0.96 M-1s-1).[129, 130] More recently, 
bicyclo[6.1.0]nonyns (BCN) have been developed, which introduce increased ring strain over 
earlier analogues, and can be synthesised in 61% overall yield (in the case of the endo-
isomer). The increased strain over first-generation reagents such as OCT1 and DIFO2 gave 
rise to improved second-order rate constants for cycloaddition reactions with azides, which 
were comparable to those demonstrated by TMDIBO (k = 0.14 M-1s-1).[131] 
Although a number of cyclooctynes have now been developed, and their reaction kinetics 
with azides demonstrated as being superior to the first-generation reagents, the chemical 
synthesis of cyclooctynes remains one of the most challenging aspects of the SPAAC 
reaction, and some of the later generation cyclooctynes may take up to 8 steps to synthesise 
(see chapter 2). In general, more steps are required in order to prepare the cyclooctynes 
with the highest rate constants, and the time required to access most is still greater than that 
for the corresponding Staudinger ligation substrates.  However, optimisation of the synthetic 
procedures is possible, and groups are working on ways to improve the synthetic 
accessibility of these compounds.[128]   
The application of the SPAAC reaction towards pretargeting was first successfully validated 
by Bertozzi and co-workers, who established that this reaction could occur on the surface of 
living cells.[58] In this first breakthrough in pretargeting using bioorthogonal chemistry, DIFO 
was modified with fluorescent tags, which were subsequently reacted with azide modified 
glycans on Jurkat cells. This early demonstration of the SPAAC reaction in vitro has since 
been demonstrated in different settings; for example, the reaction was achieved on zebrafish 
embryos, where the pretargeted area was successfully visualised after incubation with the 
fluorescently-labelled cyclooctyne (Figure 31).[132-134] 
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Figure 31. Bertozzi’s demonstration of pretargeting using fluorescence on living cells[132] 
Although this was a major advancement in the field of pretargeting, the method was only 
demonstrated using fluorescence, which is not useful for a clinical application as it involves 
imaging of the subject ex vivo (and therefore is an invasive technique). Another major 
drawback of this reaction as a potential pretargeting tool is the apparent binding of 
cyclooctynes to albumin in red blood cells and plasma proteins, as well as their generally 
poor pharmacokinetic profile (see chapter 2). This is due to the generally lipophilic nature of 
the cyclooctyne structure, which renders the compounds poorly soluble in aqueous media, 
and ultimately leads to poor in vivo biodistribution due to a large amount of uptake in all 
tissue types.  
Perhaps the most significant flaw to this method, however, is the less than ideal reaction 
kinetics that may be obtained, which, although substantially improved over the Staudinger 
ligation, are still inferior to the CuAAC reaction (k = 1-10 M-1s-1).[135] This combination of 
factors means that this reaction has yet to be demonstrated as a tool for pretargeted imaging 
using short-lived isotopes in vivo. The reaction is arguably too slow to be carried out in this 
setting, as discussed in Chapter 3.  
1.7.3  An Inverse Electron Demand Diels-Alder (IeDDA) Reaction 
A more recent advancement in the field of bioorthogonal chemistry is the use of the Inverse-
electron-Demand Diels-Alder (IeDDA) reaction between tetrazines and strained alkenes, 
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which was initially recognised as being bioorthogonal by Fox and co-workers in 2008.[116] 
This reaction was first demonstrated as early as 1959, where the reaction between a 
fluorinated tetrazine and polystyrene was observed to occur rapidly at room temperature 
(Figure 32).[136]  
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Figure 32. The IeDDA reaction between a tetrazine and an alkene 
In a similar manner to the reaction of cyclooctynes with azides, norbornenes and (E)-(or  
trans-)cyclooctenes (TCOs) were shown to be the most reactive partners in this 
cycloaddition, due to the large amount of relief of ring strain upon reaction with the tetrazine 
(second-order rate constants of up to k = 6000 M-1s-1).[116, 137] The reaction was shown to 
occur rapidly in aqueous media, suggesting a high level of biocompatibility. Moreover, this 
reaction demonstrated some significant improvements over the SPAAC reaction in relation 
to its use for pretargeting (see chapter 5).[115, 138-143] The reaction kinetics are up to 5 orders of 
magnitude higher than those demonstrated by the SPAAC reaction, and up to 7 orders of 
magnitude higher than the Staudinger Ligation, making this ligation far more comparable to 
the rates displayed by biochemical processes. 
In addition to the greatly enhanced reaction kinetics over earlier reported bioorthogonal 
reactions, as well as the improved pharmacokinetic profile, is the reduced number of steps 
required in order to synthesise the reaction partners, as compared to the cyclooctyne 
substrates (See Chapter 4).[144, 145] The reaction was initially demonstrated in a pretargeting 
setting using fluorescence on living cells, whereby the tetrazine partner was ligated to a 
fluorophore, and was subsequently reacted with an antibody modified with a norbornene 
moiety (Figure 33).[115]  
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Figure 33. Hilderbrand’s use of the IeDDA reaction for fluorescence imaging on live cells[115] 
The kinetics of the reaction may be improved using the more reactive TCO reaction partner, 
which has been ligated to the anti-EGFR (a receptor over-expressed in cancer cells) 
monoclonal antibody Cetuximab.[140] The results of these in vitro experiments showed that 
the tetrazine is highly selective for cells expressing the ligated antibodies, suggesting that 
the reaction is occurring on the surface of the cells.  
For these reasons, this reaction is currently receiving significant attention in the field of 
pretargeting for PET, and it is thought that it may display kinetics which are sufficient in order 
for the reaction to occur using short-lived isotopes in the time-scale of a PET experiment 
(see Chapter 5).[138, 143, 146, 147]  
1.8 Aims and Hypothesis  
For the reasons discussed, bioorthogonal chemistry has become a very useful method for 
developing radiolabelling methods towards the synthesis of tracers for PET imaging. The 
aim of this project was to validate bioorthogonal chemistry as a potential tool for 
pretargeting, and ultimately for PET imaging.  
The two main reactions that were considered as prospectively demonstrating the ideal 
properties required for this application were the strain-promoted azide-alkyne cycloaddition 
(SPAAC) between cyclooctynes and azides, and the Inverse-electron-Demand Diels-Alder 
(IeDDA) reaction between tetrazines and strained alkenes.  
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This would first involve the design and synthesise a library of cyclooctynes, as well as 
radiolabelled azides (using both 18F and 68Ga), as precursors for application to the SPAAC 
reaction. The relative reactivity of the cyclooctynes with different azides will be 
demonstrated, highlighting the relevance of the use of different solvents and temperatures in 
applying this reaction to a pretargeting strategy (Figure 34).    
 
Figure 34. A general scheme for labelling cyclooctynes with 18F-labelled azide prosthetic groups 
Once a full range of these precursors have been developed and optimised through kinetic 
studies of the SPAAC reaction, the cyclooctynes may be ligated to a chosen biomolecule 
and reacted with radiolabelled azides, with the intention that this reaction could ultimately be 
utilised for pretargeted in vivo imaging.  
A similar strategy could be applied to the IeDDA reaction between tetrazines and strained 
alkenes. This would first involve synthesis of tetrazine precursors, which would be evaluated 
in terms of their reactivity towards dienophiles such as norbornene and TCO. A radiolabelled 
version of this reaction could be developed, in a similar manner to that described for the 
SPAAC reaction, for example using a 68Ga-labelled tetrazine and a series of strained 
alkenes (Figure 35).  
 
Figure 35. A general scheme for radiolabelling norbornenes with 68Ga-labelled tetrazine prosthetic groups 
This reaction may be applied to a pretargeting strategy in a similar manner, for example by 
ligating norbornene to a chosen biomolecule and reacting with the radiolabelled tetrazine 
prosthetic group. The reaction will be optimised in a vial and in vitro, before being applied to 
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an in vivo pretargeting strategy for PET imaging, by which the modified biomolecule will be 
administered prior to introduction of the radiolabelled prosthetic group.  
It is hypothesised that one, or both of these reactions, will display the desired balance 
between reaction kinetics and stability, under the conditions and low concentrations that are 
observed in vivo, for a pretargeting strategy for PET imaging to be successfully 
demonstrated.  
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2.1  First generation cyclooctynes (OCTs)  
2.1.1 Introduction to OCT Cyclooctynes 
As discussed, the SPAAC reaction is one of the key bioorthogonal reactions that may be 
considered for pretargeting applications. The basic cyclooctyne structure was initially 
modified by Bertozzi and co-workers by the addition of carboxylic acids, which can be 
regarded as simple and easily functionalised side chains. These first-generation reagents 
were known as OCT1 and OCT2 (Figure 36).[109, 126, 148]  
 
Figure 36.  Bertozzi’s first-generation cyclooctyne (OCT) reagents[126]  
These compounds were found to have suitable properties for application to copper-free click 
ligation chemistry, such as good solubility in a number of solvents, and were found to exhibit 
promising reaction kinetics in their cycloaddition reactions with benzyl azide (k = 2.4 x 10-3 
M-1s-1 for OCT1 and k = 1.3 x 10-3 M-1s-1 for OCT2), which are comparable to those 
demonstrated by the Staudinger ligation (k = 2.4 x 10-3 M-1 s-1).[57]  These reagents have 
been used for a number of applications, including for the functionalisation of quantum 
dots.[149]  
The main drawbacks of compounds OCT1 and OCT2 include their relatively short shelf-lives, 
showing decomposition when stored at -20°C for long periods. This led to the development 
of a more stable analogue of these compounds, OCT3, in which the ether linkage is replaced 
by an alkyl chain (Figure 1).[113, 148] However, this increase in stability was counter-balanced 
by a lower reactivity (k = 1.2 x 10-3 M-1s-1) towards cycloaddition with benzyl azide (see 
chapter 3).  
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2.1.2 Synthesis of OCT2 
The most simple cyclooctyne structure (OCT2) was chosen to be synthesised, as this was 
considered to be a useful first-generation compound to use as a reference for comparison 
with future cyclooctynes. The best described strategy in the literature towards the synthesis 
of this type of compound was carried out in three steps from cycloheptene 1.[113, 149, 150] The 
carboxylic acid group was expected to allow for the introduction of further functionality and 
would provide a useful point of attachment for chemical probes (Figure 37).  
 
Figure 37. The total synthesis of OCT2 from cycloheptene 1[113] 
The first step towards the synthesis of OCT2 involved treatment of cycloheptene 1 initially 
with potassium tert-butoxide and subsequently with bromoform to afford 8,8-
dibromobicyclo[5.0.1]octane 2. This reaction was complete after stirring at room temperature 
over night and was purified using column chromatography yielding cyclopropane 2 as a 
colourless oil in 80% yield. Initial conditions using cycloheptene and potassium tert-butoxide 
in tert-butanol rather than pentane provided lower yields of approximately 50%, and so the 
aforementioned conditions were chosen as the standard procedure.  
The next step was to perform a ‘ring-expansion’ using methyl glycolate and silver perchlorate 
to form methyl 2-bromocyclooct-1-en-3-glycolate 3. This reaction proceeded within 1.5 h at 
room temperature in reasonable yields of 60%. However, the silver precipitate had to be 
removed and the purification carried out immediately upon completion of the work-up, as the 
product was unstable to the silver salts formed.  
The final step was the elimination of the bromine to give the alkyne and ester deprotection to 
give the carboxylic acid to form the final cyclooctyne OCT2. Initial attempts towards the 
synthesis of this compound relied upon the use of sodium methoxide as base, but 
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elimination of bromine did not occur under these conditions, and the major isolated 
compound was the hydrolysed starting material. Attempts were made to improve the 
conditions of this reaction by ensuring that the solvents were completely dry, and also by 
synthesising the sodium methoxide in situ through the use of sodium metal and methanol. 
Low yields of the final compound were observed using this method (approximately 8%), and 
so attempts were made to improve the synthesis using alternative bases (Table 6).  
 
Table 6. Attempted elimination of bromine to form cyclooctyne OCT2. 
DBU and potassium tert-butoxide were both investigated as potential bases in order to 
eliminate bromine, but were found to be unsuccessful, and so only the strategy involving the 
in situ formation of sodium methoxide allowed for the product to be isolated upon scale-up, 
be it in low overall yield.  
An analogue of OCT2 was synthesised in order to test the versatility of the ‘click’ reaction 
with cyclooctynes containing different side-chains (see chapter 3).[151] 4-Methoxy 
benzylamine 4 was reacted with the first-generation cyclooctyne OCT2 at room temperature 
using HBTU as a coupling agent, to form OCT4 in 60% yield after column chromatography 
(Figure 38).  
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Figure 38. Synthesis of OCT4 via an amide coupling using HBTU 
2.1.3 Conclusions  
The difficulties involved with the final step of the synthesis of OCT2 limits the attractiveness 
of this particular compound towards the hypothesised pretargeting application. It was 
therefore concluded that a cyclooctyne with more advanced structural modifications, 
displaying more desirable physicochemical properties, would be more useful for this 
purpose. However, significant material was obtained for carrying out example SPAAC 
reactions with OCT reagents, as demonstrated in Chapter 3.  
Although the first-generation OCT reagents developed by Bertozzi and co-workers 
demonstrated comparable reaction kinetics to the Staudinger ligation, one of the main 
limitations of these compounds is that they have less than desirable physicochemical 
properties.[113, 114] Although these properties could be partially improved by attaching different 
side-chains onto the molecule, such as with the OCT4, the core cyclooctyne is still highly 
lipophilic. This may lead to problems such as plasma-protein binding and poor in vivo 
biodistribution, which would limit their application to pretargeting, a problem which has been 
observed when applying these systems in vivo.[114, 128] It was additionally considered that the 
OCT compounds probably did not show rapid enough reaction kinetics for the SPAAC 
reaction to be demonstrated in vivo, as discussed in Chapter 3, as the reaction needs to 
occur at very low concentrations under biological conditions.[151] For these reasons, 
alternative cyclooctynes were explored as potential compounds for use in the proposed 
pretargeting strategy.  
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2.2  Halogenated Cyclooctynes  
2.2.1 Introduction to MOFO and DIFO Analogues  
Bertozzi found that the lower reactivity observed upon introduction of the alkyl moiety in the 
OCT3 reagent, as compared to the less stable OCT1 reagent, could be overcome by 
introduction of a fluorine substituent.[55, 113] The mono-fluorinated cyclooctyne MOFO (k = 4.3 
x 10-3 M-1s-1) showed enhanced reaction kinetics in the strain-promoted cycloaddition over 
the equivalent non-fluorinated analogue (OCT1) due to the addition of one fluorine atom on 
the carbon adjacent to the alkyne moiety (Figure 39).[113]  
 
Figure 39. The structures of the mono- and di- fluorinated cyclooctynes MOFO and DIFO1[57] 
The incorporation of a suitable electron-withdrawing group (EWG) within the cyclooctyne 
skeleton lowers the activation energy of the SPAAC reaction through electronic effects. One 
way of understanding this effect is by use of the molecular orbital theory (Figure 5).[55] During 
a reaction, the HOMO of one species and the LUMO of another interact to form a bonding 
orbital (and an antibody orbital) in the newly formed species. The LUMO and HOMO are the 
two orbitals which lie closest in energy between the two reacting species, which allows them 
to interact most strongly. By addition of an EWG on one side of the alkyne, the empty orbital 
(LUMO) of the alkyne bond becomes lower in energy, making this reaction more 
favourable.[55]  
It was observed that the addition of a second fluorine atom, to form a di-fluorinated 
cyclooctyne such as DIFO1 (Figure 39) increased the rate by approximately 60 times (k = 
7.6 x 10-2 M-1s-1) relative to MOFO.[55, 58, 113, 148] This can be  explained by the shorter C-F bond 
lengths that are observed with di-fluorinated (C*H)2-C-F2 (1.348 Å) as compared to mono-
fluorinated groups C2CH-F (1.399 Å).[106] Enhancing the polarity of both C-F bonds has a 
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greater effect on the kinetics than would be expected for two isolated C-F groups, such as 
with the equivalent 3,8-difluorocyclooctyne skeleton.[152] As a consequence of these electron-
withdrawing effects, the energy barrier for the [3+2] cycloaddition of methyl azide to DIFO1 is 
computed to be 2.1 kcal mol-1 lower than its parent non-fluorinated cyclooctyne.  
DIFO1 was found to exhibit particularly promising reactivity and properties, reacting with 
azides on intact proteins at a comparable rate to that observed with copper-catalysed ‘click’ 
chemistry.[148] The syn regioisomer, whereby the R1 group is adjacent to the CF2 group, is 
favoured over the opposite anti orientation (ΔΔE ≈ 1.2 kcal mol-1) due to an enhanced 
alignment of atoms in the transition state (Figure 40).[137, 153] 
 
Figure 40. Bertozzi’s reaction of DIFO reagents with functionalised azides[55] 
The use of the difluoromethylene moiety in DIFO1 is significant as it not only acts as a good 
EWG through inductive effects, but it is also particularly inert. Unlike other potential 
substituents that might have been incorporated, such as carbonyl groups, the difluoro 
functionality does not create a Michael acceptor capable of alkylating biological 
nucleophiles.[148] DIFO1 is stable in water, suggesting that this compound will be similarly 
stable in a biological environment, lowering the likelihood of cross-reactions with 
biomolecules. It should be noted that the rate of reaction of DIFO1 with azides was between 
17-63 times greater than any of the reactions previously reported with either the Staudinger 
ligation or other strain-promoted cycloadditions, displaying encouraging biocompatibility.[148] 
In the literature, DIFO reagents were successfully applied to in vitro studies, such as the 
imaging of glycans in developing zebrafish.[154] DIFO1 was also compared to other 
cyclooctyne reagents for staining Jurkat cells, where a biotinylated version of the 
cyclooctyne was shown to have excellent intrinsic reactivity with cells bearing SiaNAz 
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(azides), with the reaction occurring up to 20-fold faster than with previously identified 
cyclooctynes such as OCT1 and MOFO.[155]  
DIFO1 was originally synthesised by Bertozzi et al. in 12 steps and in an overall yield of only 
~1% (Figure 41).[106, 148] 
 
Figure 41. Bertozzi’s initial synthesis of DIFO1[148] 
This synthesis involves an often problematic elimination step to install the alkyne functional 
group, which is an issue observed with the formation of the cyclooctyne structure in general. 
This limitation led to the development of a second generation of DIFO related compounds, 
whereby a more practical synthetic route was adopted.[55] The Bertozzi group aimed to 
reduce the synthetic complexity involved with the difluorinated core by replacing the ether 
linker on the C-4 substituent with a more simple alkyl linker. It was hoped that by doing so, 
the SPAAC reaction could be utilised in a more diverse range of applications.  
The literature synthesis of a second-generation compound DIFO2 was completed in 6 steps 
from 1,3-cyclooctanedione 5, which itself is synthesised in ~67% overall yield, as described 
in section 2.2.2 (Figure 42).[55, 156] 
 
Figure 42. The improved synthesis of DIFO2 which was completed in 36% yield from 1,3-cyclooctanedione 5[55] 
Difluroination of 1,3-carbonyls had been previously carried out using SelectfluorTM, and the 
studies have shown that elevated temperatures and pressures, or the formation of enamine 
intermediates were required in order for the reactions to proceed successfully.[157] However, 
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Bertozzi et al. found that 2,2-difluoro-1,3-cyclooctanedione could be produced in 73% yield 
via simple treatment of diketone 5 with SelectfluorTM and Cs2CO3, which aids the 
deprotontaion of the α-carbon.[55] The next step of the synthesis involved a Wittig reaction 
using a phosphonium salt in order to produce the carbon-carbon linker.[156] The alkene was 
then reduced, which was followed by triflation of the enol form of ketone 6, which could 
subsequently be converted to the alkyne 7 by use of a strong base. DIFO2 was finally 
formed in an overall yield of 36% from the synthesised diketone 5 (in 21% overall yield and 
10 steps from the diester). 
DIFO2 and DIFO3 (a derivative not containing the phenyl ring), were termed 2nd generation 
DIFO compounds, and shown to display comparable reaction kinetics to DIFO1 (k = 4.2 x 
10-2 M-1s-1 for DIFO2 and k = 5.2 x 10-2 M-1s-1 for DIFO3) in their 1,3-diploar cycloadditions 
with benzyl azide.[55, 158] The lack of the phenyl ring in DIFO3 also improved the 
physicochemical properties, showing lower background labelling in the staining of Jurkat 
cells, which was attributed to the lower lipophilicity of this compound.[55, 109, 132, 134, 148, 159] 
2.2.2 Hypothesis for a ‘Trifluoromethylated’ Cyclooctyne 
Due to the promising reaction kinetics demonstrated by Bertozzi’s DIFO analogues, as well 
as the relatively short total synthesis, it was postulated that these compounds could be a 
useful class of compound for application to pretargeting.[55] Based upon the improved 
synthetic route towards DIFO compounds (Figure 8), we hypothesised that it might be 
possible to introduce other electronegative atoms or groups may be introduced into the 
same position as the fluorine atoms, due to the acidity of the methylene proton positioned 
between the two ketone functional groups in 1,3-cyclooctanone 5. It could be envisaged that 
a trifluoromethyl group would be similarly electronegative to the difluorine moiety, whilst also 
introducing a significant amount of steric bulk onto the position. It has been demonstrated 
that the CF3 group is significantly larger (2.70 Å) than the CH3 group (2.29 Å), but not as 
sterically demanding as a tert-butyl substituent (2.83 Å). A single fluorine atom, on the other 
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hand, has a van der Waals radius that is only marginally larger than that of a hydrogen atom, 
and subsequently does not have a significant steric effect (Figure 43).  
 
Figure 43.  The difference in reported van der Waals radii of methyl, trifluoromethyl and tert-butyl substituents adjacent to a 
ketone moiety 
It was anticipated that introduction of the CF3 group would lead to an increase in the 
formation of one regioisomer over the other upon reaction with the azide in the SPAAC 
reaction (i.e. make the reaction more stereoselective), by making one end of the alkyne bond 
less accessible. Two trifluoromethyl groups could potentially be introduced onto this position 
simultaneously, to increase the electronegativity and the steric bulk even further (Figure 44).  
 
Figure 44. Hypothetical effect of addition of a) one and b) two trifluoromethyl groups, respectively onto the carbon α- to the 
alkyne on the SPAAC reaction with a substituted azide 
The difluorine moiety in the DIFO class of cyclooctynes is introduced to 1,2-cyclooctadione 
using SelecfluorTM, and it was imagined that an electrophilic trifluoromethylating reagent 
such as the a TogniTM  reagent, could be used to introduce one or two trifluoromethyl groups 
into the same position.[55] The subsequent steps towards the synthesis of the cyclooctyne 
would then be identical to the conditions employed for the synthesis of DIFO2 (Figure 45).   
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Figure 45. Proposed trifluromethylation of diketone 5 using an electophilic trifluromethylating (TogniTM) reagent, as a parallel to 
the difluorination using SelectflourTM towards the synthesis of DIFO2[55] 
Several literature procedures have been described towards the synthesis of 1,3-
cyclooctadione 5, which would be the precursor for carrying out the synthesis of halogenated 
analogues.[156, 160] However, two main routes are employed; both of which start from 
commercially available diethyl pimelate 8 (Figure 46).  
 
Figure 46. Literature procedures for the synthesis of 1,3-cylooctadione 5[156] 
The first method utilises the cyclooproponation of silylated alkene 9 via treatment with 
diiodomethane and diethylzinc to form a strained bicyclo[5.0.1]octane 10. Two methods are 
then reported for the catalytic oxidation of the cyclopropane 10.[156, 160] The first uses FeCl3, 
forming the dione 5 in 73% yield, but a sub-optimal work-up procedure is reported, which 
renders this route less favourable. An alternative oxidation is carried out using periodic acid, 
in which diketone 5 may apparently be formed cleanly in 65% yield from the cyclopropane. 
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The second method instead forms the bromocarbene in situ using bromoform and 
diethylzinc directly from alkene 9, which is then treated with molecular oxygen to form the 
ring expansion product 5 in 78% yield. 
After optimisation of the synthetic route to compound 5, the most succesful method was 
acheived in three steps from diethyl pimelate 8, and in a good overall yield of 54%. This 
strategy followed the literature procedure via the cyclopropane 10 fairly closely, 
demonstrating camparable (and in some cases improved) yields.[156] The first step to form 
alkene 9 was fairly straight-forward, but relied on the use of elemental sodium, which is 
difficult to handle. This step formed the trimethylsilyl protected alkene 9 in excellent yield 
(84%), and was shown to be reproducible when carried out on different scales of up to 5 g of 
diethyl pimelate 8. Diiodomethane and diethyl zinc were found to be the most effective for 
the formation of cyclopropane 10, which could be synthesised in 81% yield. The final step of 
the synthesis was similarly high yielding, and treatment of cyclopropane 10 with periodic acid 
afforded the 1,3-substituted diketone 5 in 80% yield following column chromatography 
(Figure 47).  
 
Figure 47. The optimised route for synthesis of 1,3-cyclooctadione 5 
The diketone 5 obtained from this synthesis was used to reproduce the synthesis of DIFO2 
(cf. Figure 45), and was also used to carry out attempted trifluoromethylations, towards the 
synthesis of a triflouromethylated cyclooctyne analogue.[55, 113] 
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The development of fluoro-alkylated compounds has received significant attention in the 
context of medicinal chemistry due to the interesting properties that these functional groups 
can display, for example by enhancing the lipophilicity of a molecule or by modifying its 
metabolic behaviour.[161, 162] The use of reagents such as SF4, SbF3, BrF3, and HF as 
reagents for the conversion of CH3 to CF3 groups, usually require harsh conditions, which 
may have detrimental effects towards other functional groups within the target molecule.[162] 
A number of less harsh strategies now exist for the introduction of the CF3 group, with the 
most widely-explored methods being based upon the use of nucleophilic trifluoromethylating 
reagents such as (trifluoromethyl)trimethylsilane (Me3SiCF3), or Ruppert’s reagent.[163] 
Although nucleophilic reagents remain the most popular choice for carrying out these 
transformations, methods relying on the use of radical and electrophilic trifluoromethylations 
also exist, and allow for the CF3 group to be introduced into a wider range of compounds.[164, 
165] 
In 2006, Togni et al. developed a family of formally electrophilic CF3 transfer reagents, based 
upon hypervalent iodine, with the two most significant and widely-used compounds being the 
acid-derived reagent 11 and the alcohol-derived reagent 12 (Figure 48).[162]  
 
Figure 48. The two most commonly utilised TogniTM reagents based upon trifluoromethylated hypervalent iodine 
These reagents have now been successfully applied to the trifluoromethylation of both soft 
nucleophiles (such as phosphorous-, sulfur-, and carbon-centred nucleophiles, thiols, α-
nitroesters, β-ketoesters, phosphorothiolates and aromatics), and more recently hard O-
centred nucleophiles (such as alcohols, sulfonic acids and hydrogen phosphates).[166]  
The initial work carried out by Togni and co-workers demonstrated that the alcohol-derived 
reagent 12 could be applied to the trifluoromethylation of β-ketoester 13 using polar, aprotic 
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and nucleophilic solvents, under phase-transfer catalyst (PTC) conditions and in the 
presence of a mild base.[162] Both reagents 11 and 12 have been used for carrying out similar 
transformations with α-nitroesters, with the alcohol-derived reagent 12 being the most widely 
used reagent for the trifluoromethylation of this type of compound. The same reagent could 
be used to successfully introduce the CF3 group into Evans-type chiral enolates, as well as 
more recently being applied to α-trifluoromethylation of aldehydes when combined with 
organocatalysts.[166] The acid-derived reagent 11, however, has primarily been used for the 
introduction of CF3 onto soft nucleophilic centres, and it is generally acknowledged that the 
‘alcohol’ reagent 12 is preferred for carrying out triflouromethylations of carbonyl compounds 
(Figure 49).[167]   
 
Figure 49. Togni’s transformation of β-keto esters to their trifluoromethylated products using reagent 12[168] 
Based on the findings reported by Togni et al., as well as more recent developments into this 
type of transformation, we hypothesised that we could apply the TogniTM reagent 12 to our 
diketone precursor and achieve a trifluoromethylation at the targeted α-carbon centre in 
compound 5. However, it should be noted that these reagents have yet to be demonstrated 
for the introduction of CF3 onto ketone substrates. 
The trifluoromethylation step was carried out as a test reaction on a small amount of 
diketone 5 (10 mg).[169] The initial conditions investigated were standard conditions for the 
electrophilic triflouromethylation using reagent 12, with potassium carbonate as base and 
under PTC conditions. The stoichiometry of the reaction was controlled using 1.1 equivalents 
12 so that only one trifluoromethylation would occur. However, under these conditions, the 
only isolated compound was the diketone starting material 5, suggesting that these 
conditions are not optimal for carrying out trifluoromethylation of the diketone (Figure 50).  
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Figure 50. Attempted triflouoromethylation of diketone 5 using TogniTM reagent 12 
Raising the temperature of the reaction may additionally lead to competing nucleophilic 
attack on the ketone. It was therefore hypothesised that an alternative base could be 
employed for this reaction, which would allow for the formation of the anion on the α-carbon, 
rendering this position more reactive towards the electrophilic trifluoromethylating reagent. 
By using a stronger base, such as n-BuLi, it could be anticipated that the deprotonation 
could be rendered irreversible, making the introduction of the trifluromethyl group highly 
selective at this position. Diketone 5 was first treated with n-BuLi at -78°C, and was then 
allowed to stir for 30 min in order to fully deprotonate the α-position. After warming to room 
temperature, the mixture was treated with reagent 12, and the reaction progress was 
monitored by TLC. However, after several attempts at this reaction, the product 13 still 
remained to be isolated. It is possible that in the presence of strong bases such as n-BuLi, 
defluorination may occur, as trifluoromethyl groups tend to be unstable, especially when the 
α-carbon is not fully substituted (Figure 51).  
 
Figure 51. Attempted triflouoromethylation of diketone 5 using 12 via the anion intermediate using n-BuLi 
It was concluded that this is a very challenging transformation to achieve, and this is 
supported by the fact that, as far as we are aware, no electrophilic α-trifluoromethylations of 
ketones have been reported in the literature. Coupled to this is the apparent instability of the 
trifluoromethane group towards strongly basic conditions; LDA is required in order to 
eliminate the triflate in the final step of the cyclooctyne synthesis (cf. Figure 42), potentially 
resulting in defluorinations during the final step of the synthesis. It was considered that it 
would potentially require a large amount of optimisation to attain the product, and we 
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therefore postulated that it would be easier to introduce an alternative moiety, which would 
display similar properties to the trifluoromethane group, without having the associated 
synthetic complexity. 
2.2.3 Hypothesis for an Iodinated Cyclooctyne 
Iodine has a larger van der Waals radius (between 2.03 and 2.15 Å) than fluorine (between 
1.35 and 1.47 Å), but it still has a relatively high electronegativity on the Pauling scale (2.66 
vs. 3.98 for fluorine).[170] However, an iodine is often more straight-forward to introduce than 
a CF3 group, and subsequently it could be envisaged diketone 5 could be α,α-diiodinated, 
and subsequently used to synthesise diiodinated analogue 16, in a similar manner to the 
proposed route to the di-trifluoromethylated compound (Figure 52).[55] 
 
Figure 52. Proposed approach to diiodinated cyclooctyne 16 
The α-idoination of ketones has been reported several times in the literature, and the most 
promising conditions could be evaluated in the context of synthesising compound 16.[171-173] It 
is possible that Iodine in this position would be unstable to the strongly basic conditions 
required to carry out the subsequent synthetic steps to cyclooctyne 16, and consequently it 
was important to test this before applying this chemistry to the synthesised diketone 5.  
Therefore, the same synthetic procedure was initially tested by carrying out a similar 
synthesis using α-iodo cyclooctanone 17 (Figure 53).[55] 
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Figure 53. Proposed synthetic route to a mono-iodinated cyclooctyne 21 
If the synthesis were to be successful, this compound could potentially be used to synthesise 
a mono-iodinated cyclooctyne 21, following a similar procedure to the synthesis of MOFO, 
and would additionally enable us to compare the effects of addition of one or two iodines 
onto this position.[113] The α-proton must be blocked in this case, as with compound 19 by 
addition of an alkyl group, in order to afford the subsequent triflate 20 by deprotonation from 
only one side of the ketone. 
The conditions for the synthesis of α-iodo cyclooctanone 17 were first tested and optimised, 
as this would enable us to test the feasibility of introducing iodine α- to the ketone in only a 
few steps. Introduction of iodine was carried out according to literature procedures (Table 
7).[172-174] 
 
Table 7. Methods employed for the synthesis of α–iodocyclooctanone 17[172-174] 
N-Iodosuccinimide (NIS) 14 is commonly used for carrying out α-iodinations, and has been 
used to synthesise cyclic α-iodo ketones from the respective cyclic alkene, including for the 
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synthesis of α-iodocyclooctanone 17.[173] This method is advantageous as it uses 
cyclooctene 22 (which is cheaper than cyclooctanone 23) but requires the use of o-
iodoxybenzoic acid (IBX) (Figure 54).  
 
Figure 54. Nidhi’s proposed mechanism of the formation of α-iodo ketones from alkenes using NIS/IBX in DMSO[173] 
This reaction allowed for the formation of 17 in good yield (70%), and it could be achieved in 
2 h at room temperature in DMSO (Table 7, Entry 1). However, although this proved very 
efficient for the formation of 17, the proposed mechanism of the reaction prohibits the 
formation of the α,α-diiodinated product.  
NIS has similarly been used to introduce Iodine α- to ketones in DMSO at room temperature, 
in high selectivity and without the need for catalysis.[172] This method has been used for the 
successful α-iodination of cyclic ketones such as cyclohexanone and 1,3-cyclohexadione, 
and for this reason was anticipated to be a useful method for the synthesis of α-iodoketone 
17. Cyclooctanone 23 was consequently treated with 1.05 equivalents of NIS in DMSO, and 
the reaction was monitored by TLC. Using this method, a significant amount of the ketone 
starting material remained, even when the reaction time was increased, although it was 
possible to isolate the product using distillation (Table 7, Entry 2). It may also be difficult to 
achieve bis-iodination using this method, as relatively mild reaction conditions are used; 
harsher conditions are usually necessary in order to achieve the α,α-diiodination. 
An alternative method for the iodination was explored, which would allow for the compound 
to be synthesised in greater yield.[174] This method reportedly allows for almost quantitative 
formation of α-iodinated ketone 17, and the mechanism of the reaction should permit for 
introduction of two iodines onto the α-carbon (Figure 55).  
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Figure 55. Proposed mechanism for the α- iodination of ketones using the NaI/H2O2/H+ system
[174] 
Both alcohols and ketones may be treated with sodium iodide in water, in the presence of an 
acid to form the α-iodinated ketone. Cyclic ketones were shown to be the most reactive 
substrates for these transformations, and sulfuric acid was found to be the most effective 
acid to aid the reaction, and the conditions were successfully applied to the synthesis of α-
iodocyclooctanone 17 from cyclooctanone 23, forming the product in ~90% yield under the 
literature conditions (Table 7, Entry 3).[174] The formation of the enol is the driving force for 
this reaction, and so it may be hypothesised that two iodinations may be achieved by 
forming a second enol, using two equivalents of sodium iodide.  
The iodinated product 17 was subsequently treated to the alkylating conditions employed by 
Bertozzi et al (cf. Figure 53).[55, 113] This first involved treating the ketone with LDA at -78°C, 
followed by dropwise addition of the alkylating agent in THF upon warming to room 
temperature. Complete consumption of the starting material had occurred after stirring for 1 
h at room temperature, however after work-up and purification, it was determined by NMR 
that the Iodine had been eliminated forming ketone 24. It is possible that the elimination was 
occurred via halophilic attack of the LDA on the iodine to generate the lithium enolate 25 in a 
Reformatsky-type process (Figure 56).  
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Figure 56. Attempted alkylation of α-iodocyclooctanone 19, forming only the de-iodinated product, and plausible mechanism for 
the elimination of iodine 
Due to the poor stability of Iodine under highly basic conditions, it was concluded that the 
iodinated cyclooctyne 19 would be very difficult to synthesise, as the formation of the 
cyclooctyne requires the use of a strong base. Therefore, attempts were not made to 
synthesise 19, as it could be anticipated that diiodinated compound 15 would be equally 
unstable. The product obtained from this reaction was instead used to synthesise the first-
generation methyl ester of cyclooctyne OCT3 (Figure 57).[113]  
 
Figure 57. The synthesis of OCT3 from ketone 24 
This compound was used to evaluate the SPAAC reaction in terms of the kinetics of first-
generation cyclooctynes as compared to later-generation compounds (see chapter 3). 
2.2.3 Conclusions 
It was found that introduction of a trifluoromethyl group, and similarly an iodine atom, into the 
α-position to the cyclooctyne, was difficult to achieve. It could be hypothesised that an 
alternative bulky substituent, such as a tert-butyl group, may be introduced more easily. 
However, the lack of electronegativity which would be attained as compared to the 
halogenated substituents, would most probably result in a reduction in the rate of reaction of 
the derived cyclooctyne with azides. It was considered that a balance of reactivity and steric 
bulk must be achieved, whilst maintaining a low level of synthetic complexity. Future work 
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would therefore be to design a cyclooctyne which combines these factors, for example by 
incorporation of steric bulk onto one side of the alkyne, and electronegative moieties on the 
other (Figure 58).[175]  
 
Figure 58. Proposed cyclooctyne containing steric bulk (tert-butyl group) and electron-withdrawing groups (diflourine) 
Such a molecule should enable favourable reaction kinetics to be maintained, whilst 
introducing improved regioselectivity, in terms of 1,3-dipolar cycloadditions, over existing 
cyclooctynes. 
2.3  Dibenzocyclooctynol (DIBO) Cyclooctynes 
2.3.1 Introduction to DIBO Reagents 
Boons and co-workers aimed to enhance the rate of the reaction of cyclooctynes in click-
type reactions by increasing the amount of ring strain and conjugation in the cyclooctyne 
partner, using dibenzocyclooctynol reagents DIBO1 and DIBO2 (Figure 59).[127] 
 
Figure 59. Boons’ dibenzocyclootynol reagents DIBO1 and DIBO2[106] 
Boons anticipated that these reagents might react quickly enough with azides to be 
applicable to a wider range of applications than previous designs.[127] These compounds may 
be functionalised via the hydroxyl group; which is a useful handle for radiolabelling 
applications or for attaching the cyclooctyne to biologically active compounds. 
The incorporation of two aromatic rings in these compounds proved to increase the reactivity 
of the cyclooctyne, as they impose increased strain on the alkyne, and also result in a 
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reduction in the energy of the alkyne LUMO as the electron density is distributed more 
evenly across the conjugated system.[127, 176] The aromatic rings also improved the biological 
stability of this compound over the earlier generation cyclooctynes, as these rings appear to 
help to block the attack of nucleophiles onto the alkyne.[106]  DIBO1 importantly showed 
comparable reaction kinetics (k = 5.7 x 10-2 M-1s-1) to second-generation cyclooctynes such 
as the difluorinated compound DIFO1 (k = 7.6 x 10-2 M-1s-1) when reacted with benzyl azide, 
thus displaying a reasonable balance between stability and reactivity.[57, 127] The synthesis of 
DIBO1 was described by Boons et al. in 5 steps from phenylacetaldehyde, in an overall yield 
of 10% (Figure 60).[127, 177]   
 
Figure 60. Boons’ synthesis of DIBO1 from phenylacetaldehyde in overall yield of 10%[127] 
A modified variant of this compound was later developed by Leeper and co-workers.[178, 179]  
3-Hydroxy-2’,3’,2”,3”-tetramethoxy-7,8-didehydro-1,2:5,6-dibenzocyclocta-1,5,7-triene 
(TMDIBO) is a compound which shows structural resemblance to the DIBO reagents; but 
displays enhanced stability due to the introduction of four methoxy groups onto the aromatic 
rings (Figure 61).  
 
Figure 61. Leeper’s TMDIBO cyclooctyne[178] 
As well as improving the stability of the cyclooctyne, the methoxy groups also stabilise the 
intermediates en route to this type of compound, making the synthesis of TMDIBO more 
straight-forward than that of DIBO1.[127] The rate constant of the reaction with benzyl azide, 
Chapter 2 - Synthesis and development of cyclooctynes for the SPAAC reaction 
 
94 
 
as measured in methanol (k = 9.4 ± 0.4 x 10-2 M-1s-1), was also found to be even greater than 
that of DIBO1, demonstrating an attractive balance between reactivity and stability.[180] 
2.3.2 Synthesis of TMDIBO1 
The pNP carbonate analogue, TMDIBO1 showed promising reactivity in the SPAAC reaction 
(see chapter 3), as well as apparently displaying a promising level of biocompatibility, and for 
this reason was chosen as a suitable cyclooctyne to synthesise.[151] The synthesis of 
TMDIBO1 was achieved as described by Leeper et al. who described the synthesis in 8 
steps, in an analogous manner to the synthesis of DIBO1 (Figure 62).[178]  
 
Figure 62. The synthesis of TMDIBO-pNP carbonate TMDIBO1 from 2-(3,4-dimethoxyphenyl)ethanol 27[178] 
The first step towards the total synthesis of TMDIBO1 involved the oxidation of 2-(3,4-
dimethoxyphenyl)ethanol 27 to aldehyde 28 using the Dess-Martin periodinane (DMP). This 
reaction proceeds at ambient temperature in 1 h, to yield pure aldehyde 28 after column 
chromatography. This reaction was successfully carried out on various scales from 1g to 8g 
and, forming 28 in excellent yield (80-90%) in each case.  
Subsequent addition of TMSI to a solution of aldehyde 28 in methylene dichloride at -78°C, 
followed by warming to room temperature for 2 h afforded the dimerised ether 29 after 
quenching with sodium thiosulfate. This could be recrystallised from methanol to produce 
pure product 29 in a yield of 45%. This dimerization step is far more efficient than is reported 
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for the equivalent compound without the methoxy groups, which is evidence of the enhanced 
stability of this class of compound.[127] Ether 29 was consequently treated with n-BuLi to 
promote ring-opening to give alcohol 30. This reaction was complete after 2 h at room 
temperature and gave alcohol 30 in 57% yield after column chromatography. The next step 
was protection of 30 to give the silyl ether 31, which went to completion at room temperature 
in 16 h.  
The alkene in derivative 31 was di-brominated using elemental bromine, which could be 
achieved in 5 min; a significant improvement over the formation of brominated compound 26, 
which takes 7 days, allowing for isolation of the product in only 50% yield. The brominated 
product 31 was reported to be labile, and so the subsequent dehydrobromination reaction 
was carried out in one-pot without any workup or isolation. The dehydrobromination to afford 
the cyclooctyne 33 was achieved in 70% yield over 3 steps, by treating 32 with 1-
methylpiperazine and KOtBu for 1 h at room temperature, as reported. The silyl ether was 
deprotected using TBAF, which could be achieved in 1 h at 0°C, to form the alcohol 
derivative 34 and the side-chain was functionalised by generation of the 4-nitro-phenyl 
carbonate to give TMDIBO1 as the final product after recrystallisation.   
2.3.3 Conclusions  
TMDIBO1 has been synthesised with only a small decrease in the overall yield as compared 
to the literature procedure.[178] The stability that may be achieved by introduction of the 
methoxy groups makes the synthesis of this compound more efficient and more reproducible 
than for DIBO1, and with no observed sacrifice of its reaction kinetics with azides. The 
carbonate side-chain also allows for simple structural modifications to be made to this 
compound, and TMDIBO may be introduced to a biomolecule or radiolabel by direct 
substitution with a primary amine to form the respective carbamate. For these reasons, 
TMDIBO1 was chosen as the first cyclooctyne to be used for demonstrating the utility of the 
SPAAC reaction towards the pretargeting application (see chapter 4).[151]  
Chapter 2 - Synthesis and development of cyclooctynes for the SPAAC reaction 
 
96 
 
2.4  A Strain Promoted ‘Double-Click’ (SPDC) Reagent  
2.4.1 Introduction to the ‘SPDC’ Reaction 
Hosoya and co-workers aimed to improve the incorporation of cyclooctynes into a biological 
setting through the use of a new mechanistic concept, referred to as the strain-promoted 
double-click reaction (SPDC), by which two alkyne groups are available for reaction with 
azides, such as with sym-dibenzo-1,5-cyclooctadiene-3,7-diyne (DIBOD) (Figure 63).[181]  
 
Figure 63. Hosoya’s strain-promoted double-click (SPDC) reaction using DIBOD[181] 
For example, it was shown that it was possible to form a mono-cycloadduct containing a 
small molecule prior to incorporation into the biomolecule, potentially opening up the 
possibility of introducing a large range of functionality using a relatively simple synthetic 
strategy. In particular, the second alkyne group could then be available for reaction with the 
azide-containing biomolecule by the SPAAC reaction.  
The capabilities of the SPDC reaction have been demonstrated by Hosoya et al. in living 
cells.[181] DIBOD was reacted with excess amounts of simple azides, in which the trans-
isomer 36 was generally shown to dominate over the cis-isomer 37, the geometries of which 
were determined by single crystal X-ray crystallography. The mono-cycloadduct 35 was 
found to be more reactive than the starting alkyne, possibly due to the amount of steric 
repulsion between the triazole substituent and the ortho-proton on the benzene ring, 
producing a distorted and more reactive alkyne bond.[181] The reaction was similarly 
demonstrated using an equimolar amount of two different azides, showing the hetero-
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cycloadducts as the major products and producing two sets of homo-cycloadducts (Figure 
64).  
 
Figure 64. Hosoya’s reaction of the SPDC reagent DIBOD with an azide, showing the formation of mono-cycloadduct a as a 
more reactive intermediate[181] 
The reaction of the dialkyne DIBOD was found to have reaction kinetics comparable to that 
of the second-generation reagent DIFO1, when reacted with benzyl azide under similar 
conditions (k~ 62.9 x 10-3 M-1s-1).[55, 181] 
2.4.2 Synthesis of the ‘SPDC’ Reagent DIBOD 
The SPDC compound DIBOD was identified as being particularly interesting from a 
pretargeting perspective as there is potential for two ‘click’ reactions to be carried out in vivo, 
or for functionality to be introduced by one ‘click’ reaction and for the other alkyne to be 
available for reaction with an azide. The synthesis of DIBOD was therefore carried out in 
four steps from commercially available α-bromotolunitrile 38, as described by Otera et al. 
(Figure 65).[182] 
 
Figure 65. Otera’s synthesis of the SPDC reagent DIBOD from α-bromotolunitrile 38[182] 
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The first step of the synthesis involved sulfonylation of α-bromotolunitrile 38, which is 
commercially available, but also easily synthesised from ortho-tolunitrile. The reaction uses 
benzenesulfinic acid sodium salt in DMF to form ortho-(phenylsulfonylmethyl)benzonitrile 39, 
which was formed in 81% yield after purification by recrystallisation. The second step was 
reduction to aldehyde 40 using DIBAL-H, which was complete after 2 h at -78°C, giving a 
yield of 50%.  
The final step of the synthesis was a Wittig-Horner reaction using POCl(OEt)2 to  form a 
bicyclic ether, which upon treatment with strong base was reduced to DIBOD in just 15% 
yield when carried out on a 500 mg scale. The Wittig-Horner reaction is a modification of the 
standard Wittig reaction, forming alkenes from phosphonates (Figure 66).[183]  
 
Figure 66. The Wittig-Horner reaction as applied to the formation of the ‘SPDC’ reagent DIBOD 
In this case, aldehyde 40 is dimerised using two molecules of POCl(OEt)2. A carbon-
phosphorous bond is first formed with the methyl carbon adjacent to the phenyl sulfonyl 
group, and the subsequently formed ylid reacts with the aldehyde carbon, forming a carbon-
carbon bond. PO(OEt)2(OLi) is eliminated as a by-product via a 4-membered transition state, 
driven by the formation of a strong P=O bond. The E-isomer subsequently undergoes a 
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second intermolecular Wittig-Horner reaction to form the di-cyclooctene ring. In the final 
step, the phenyl sulfonyl groups are eliminated by use of a strong base in order to afford the 
dialkyne. The final elimination step towards the synthesis of this cyclooctyne was found to be 
low yielding, as is observed with a number of the other cyclooctynes, exemplifying the 
difficulty involved in introducing such a large amount of strain into a medium-sized ring.  
Although there were difficulties involved in the final step, and only a small amount of this 
compound was isolated, attempts to improve the yield of this compound using this strategy 
were not carried out, and it was instead envisioned that dialkyne, or ‘SPDC’ reagents such 
as these could be synthesised via an alternative route.  
2.4.3 A ‘Dual’ Sonogashira Reaction for the Synthesis of ‘SPDC’ Reagents 
One of the main challenges in synthesising cyclooctynes is often the final elimination step, 
resulting in low yields, and often requiring harsh conditions. This is due to the large amount 
of strain that is contained in the newly formed cycloalkyne as compared to the preceding 
cycloalkene, meaning that the formation of the cyclooctyne core is disfavoured. This is 
demonstrated through their spontaneous reaction towards azides; it is this ring strain which 
drives the SPAAC reaction to go to completion and form the more stable triazole product.  
It can therefore be imagined that a method to form the cyclooctyne which does not involve 
this final and problematic elimination step may be preferred, and may result in a more 
efficient overall synthesis. One particularly useful method for forming carbon-carbon bonds is 
through the use of metal catalysis.[184] The use of metal catalysis is particularly 
advantageous, as this often enables carbon-carbon bonds to form which are otherwise 
difficult to achieve. For this reason, it was postulated that metal catalysed reactions may be 
a useful and robust method for forming the cyclooctyne core, and if successful, could be 
applied to the synthesis of a number of structural analogues with only minor modifications to 
the synthetic route.  
The Sonogashira reaction is one of such metal catalysed reactions, which is used to form 
carbon-carbon bonds between terminal alkynes and either vinyl or aryl halides. The reaction 
Chapter 2 - Synthesis and development of cyclooctynes for the SPAAC reaction 
 
100 
 
usually uses a combination of a palladium catalyst and a copper catalyst, and the couplings 
can usually be achieved using mild conditions, and are often carried out at ambient 
temperature (Figure 67).[185]  
 
 
Figure 67. Sonogashira reaction catalytic cycle, involving both palladium and copper[185] 
The first key step of the Sonogashira reaction involves insertion of palladium into the 
halogen-containing species, and parallel insertion of copper into the species containing the 
triple bond. Trans-metallation followed by trans/cis isomerism and reductive elimination 
results in the formation of the desired alkyne, as well as catalytic formation of the original 
palladium species.   
As mentioned, DIBOD, or ‘SPDC’ reagent may be considered useful in a pretargeting 
setting. For this reason, a one-step synthetic procedure to synthesise this type of compound 
could be a valuable contribution to the field, and could allow for the synthesis of more 
suitably functionalised analogues via a robust and straight-forward route. In a retro-synthetic 
manner, it can be imagined that DIBOD could be prepared via two identical Sonogashira 
coupling reactions, whereby two alkynes react with two halogens through metal catalysis in 
order to construct the dialkyne core (Figure 68).  
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Figure 68. Reterosynthesis of the dialkyne DIBOD via two different ‘dual’ Sonogashira reactions (routes a and b) 
This transformation would either be achieved by having both halogens on one aromatic ring 
(41), and having both of the acetylene functional groups on the other (42) (Route A, Figure 
68); or, it could be envisioned that two equivalents of an α–halogen substituted phenyl 
acetylene 43 may be reacted together in a similar manner (Route B, Figure 68). 
It was first necessary to synthesise the acetylene precursors that would be required for 
carrying out the Sonogashira coupling reactions. Two silyl protected acetylene analogues 44 
and 45 were synthesised from commercially available 1,2-diiodobenzne 41, using a 
Sonogashira coupling with varying equivalents of trimethylsilyl acetylene (Figure 69).[186, 187]   
 
Figure 69. Synthesis of the acetylene precursors 42 and 43 for application to Sonogashira reactions 
Dependent upon the number of equivalents of trimethylsilyl acetylene used, and upon the 
reaction time, the reaction could be adapted to favour either the single Sonogashira product 
or the double-Sonogashira product, which could be easily separated using column 
chromatography. The silyl protected compounds 44 and 45 were then deprotected to the 
free alkynes 42 and 43, respectively, under basic conditions, and up to 90% yields were 
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observed for this step, ensuring that care was taken during isolation, due to the volatile 
nature of these two compounds. The two products were subjected to different Sonogashira 
reaction conditions, towards the synthesis of the SPDC reagent DIBOD. The first attempts 
towards the ‘dual’ Sonogashira coupling step were carried out using 2 equivalents of iodo 
acetylene 43 under standard Sonogashira coupling conditions (Figure 70).  
 
Figure 70. First attempts towards a ‘dual’ Sonogashira reaction towards the synthesis of DIBOD on using palladium and 
copper catalysts 
Complete consumption of the starting material 43 was observed, however DIBOD was not 
formed under these conditions. It was hypothesised that this could be attributed to Glaser 
couplings due to the presence of Cu(I) salts in the reaction mixture, leading to catalysis of 
linear diyne products, and this idea was supported by the presence of numerous fluorescent 
spots on the TLC plate. These products were not easily separable by column 
chromatography, and therefore full characterisation of these compounds was not carried out.  
The copper-catalysed reaction was also attempted using the alternative precursors 41 and 
42, as formation of the diyne may be more likely to occur with 2-iodo acetylene 43 than a 
combination of 41 and 42; the former may easily react with itself linearly, whereas the 
second Sonogashira reaction (an intramolecular ring closure) is less favourable. However, 
the alternative reagents 41 and 42 also showed similar results, showing a large number of 
inseparable by-products but no desired product. This suggests that formation of the linear 
diyne by-products is a result of the presence of the copper salts, and is independent of the 
reactants used. One possible method to overcome the observed formation of the linear 
products was to use the silyl-protected alkyne precursors, and to generate the ‘free’ alkyne 
in situ.[188] The reaction was carried out in two steps; first adding the palladium catalyst, and 
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subsequently adding the copper after 20 min, in order to try and avoid the formation of the 
Cu(I) salts (Figure 71). 
 
Figure 71. Attempted Sonogashira reaction using protected dialkyne 44 towards the synthesis of the SPDC reagent DIBOD 
This was initially attempted under reflux, whereby methanol was added dropwise to the 
mixture in order to generate the ‘free’ alkyne slowly. This resulted in deprotection of the 
starting materials, but no formation of the desired product was observed, with trace amounts 
of the diyne by-products. The reaction was subsequently attempted at lower temperatures 
(40°C), but this resulted in poor deprotection of the starting material, and no Sonogashira 
products. 
It was therefore envisaged that using a copper-free method for the Sonogashira coupling 
step might result in fewer side reactions, and would not require deprotection in situ. A 
number of copper-free ‘Sonogashira’-type conditions have now been described in the 
literature in order to try and circumvent the problems associated with formation of the 
undesired diyne products.[189, 190] The one which was chosen to be applied to this synthesis 
relied on gold(I) iodide as catalyst and dppf as a ligand (Figure 72).[190] 
 
Figure 72. Attempted Sonogashira reaction using gold catalysis, towards the formation of the SPDC reagent DIBOD[190] 
These conditions were initially tested with precursors 41 and 42, and the mixture was stirred 
at 130°C for 24 h. After filtration of the reaction mixture, only 1,2-diiodobenzene 41 was 
isolated, and no other compounds were visible by TLC. It was found that diacetylene 42 is 
volatile (bp = 80°C) and therefore the reaction was repeated in a sealed pressure tube in 
order to avoid any loss of the starting material from the reaction mixture. The reaction was 
also carried out at higher dilution, in the hope that this would aid the second intramolecular 
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Sonogashira reaction over the competing linear reactions.  TLC analysis after the reaction 
was carried out under these conditions indicated that no reaction had occurred.  
Due to the difficulties in obtaining DIBOD using this method, it was deduced that the gold-
catalysed reaction conditions would be tested on some standard reagents, which had been 
reported as being able to form the Sonogashira products under these conditions.[190] The 
chosen reaction conditions were subsequently applied to different starting materials, in order 
to validate the reaction conditions for carrying out a ‘simple’ Sonogashira coupling (Figure 
73).[190]  
 
Figure 73. Validation of the Sonogashira reaction conditions using gold catalysis 
These reactions were both complete after 24 h under reflux, and the crude products 46 and 
47 were isolated and characterised. This result suggests that the conditions are suitable for 
carrying out simple Sonogashira couplings, and that it is the nature of the product that is 
preventing from the reaction from occurring in the case of the transformation shown in Figure 
72.  
Therefore, future work could include activating the aromatic rings to make them more 
reactive towards the Sonogashira coupling reaction. Additionally, different catalyst loadings 
and concentrations could be investigated, which might result in preferential formation of the 
desired product over the ‘linear’ Sonogashira products. Alternative catalysts may also be 
considered, which also do not involve the use of copper as a co-catalyst, and could result in 
a higher probability of the second intramolecular Sonogashira reaction occurring towards the 
formation of the SPDC reagent DIBOD. 
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2.4.3 Conclusions 
It is possible that through further optimisation, this type of double Sonogashira coupling 
reaction could allow for preparation of a number of symmetrical cyclooctynes such as 
DIBOD. However, due to the low observed reactivity in the SPAAC reaction, it may also be 
necessary to increase the hydrophilicity of this type of compound, for example through the 
addition of methoxy groups onto the aromatic ring, in order to make them more suitable for a 
pretargeting application (see Chapter 3).[106, 151] 
2.5  Overall Conclusions 
In general, the synthesis of cyclooctynes is challenging, requiring multiple steps, and often in 
low overall yield. The most reactive cyclooctynes are often the most difficult to synthesise, 
which may be attributed to the introduction of further strain into the 8-memebered ring.[125] 
Subsequently, the final step of the synthesis, which involves introducing this strain, is usually 
the most demanding.[106, 109] For this reason, we sought to find an alternative method for the 
synthesis of such cyclooctynes, for example using Sonogashira-type reactions, which could 
potentially allow access to a range of functionalised cyclooctyne structures in only a few 
steps. It may be possible to optimise these conditions towards the synthesis of analogues of 
the SPDC reagent, and potentially alternative metal-catalysed reactions (for example Heck 
and ring-closing metathesis (RCM)) could be considered towards similar structures.  
Sufficient material was obtained of each of the literature cyclooctynes to take forward into 
the hypothesised SPAAC reaction, and the application of these compounds is discussed in 
detail in chapter 3. The recent development of more water-soluble cyclooctynes, which may 
be synthesised in a few steps, has additionally led to the commercial availability of such 
compounds, and these may be considered as alternatives for application to in vivo 
applications such as pretargeting (see chapter 3).[176]  
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3.1 Radiolabelled SPAAC Reaction between Cyclooctynes and [18F]FEA 
3.1.1 Hypothesis for an 18F-labelled SPAAC Reaction 
In order to validate the SPAAC reaction between cyclooctynes and azides in the context of 
pretargeting, a radiolabelled version was developed. The radiolabelled partner (or chemical 
reporter) in this reaction was chosen to be the azide, as cyclooctynes have been reported to 
demonstrate poor physicochemical properties, including high lipophilicity and potential 
binding to murine serum albumin (MSA).[114, 155] 
The purpose of the planned study was to determine which cyclooctynes are most reactive 
towards our radiolabelled azide, and ultimately which would be most suitable for application 
to a pretargeting strategy for PET, which would involve attaching the cyclooctyne to a 
suitable targeting biomolecule. Six literature cyclooctynes were chosen for carrying out the 
radiolabelled SPAAC reaction, and these were chosen based upon the different levels of 
reactivity that were displayed by these compounds previously in the SPAAC reaction with 
azides (Figure 74). 
 
Figure 74. The six cyclooctynes used in the radiolabelling study 
The first two cyclooctynes are derivatives of the first-generation OCT reagents; OCT2 
contains a carboxylic acid side-chain, whereas OCT4 has been modified with an amide 
functional group (see section 2.1).[113, 126] These compounds are expected to demonstrate the 
lowest overall reactivity in the SPAAC reaction with azides, as discussed in chapters 1 and 
2.[113]  
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The second class of reagents are analogues of the TMDIBO structure developed by Leeper 
et al., containing a pNP carbonate side-chain (TMDIBO1), and a maleimide (TMDIBO2), 
respectively.[191] These compounds show improved reactivity over the first-generation 
cyclooctynes due to the introduction of further strain (a result of the addition of two aryl rings 
onto the ring), and improved water solubility over dibenzocylooctynes (DIBO) due to the 
addition of four methoxy groups onto the aromatic rings (see section 2.3).[127] 
DIFO3 is a derivative of the difluorinated cyclooctyne, which was originally developed by 
Bertozzi, and was synthesised via a modified procedure as reported by Leeper et al., 
incorporating a pNP carbonate side-chain.[55, 178] These cyclooctynes are expected to show 
improved reactivity over OCT reagents with azides, as the fluorine atoms adjacent to the 
alkyne moiety act as electron-withdrawing groups, enhancing the reactivity of the triple bond 
towards cycloaddition reactions (see section 2.2).  
The final compound used in this study was the SPDC reagent DIBOD, which was developed 
by Hosoya and co-workers. This compound is reported to be able to react with two azide 
molecules (see section 2.4).[181] 
3.1.2 Evaluation of the 18F-labelled SPAAC Reaction   
[18F]2-fluoroethyl azide ([18F]FEA) may be synthesised via a well-established procedure, and 
is commonly used for radiolabelling prosthetic groups using the CuAAC reaction.[54, 61, 62] 
[18F]FEA was synthesised from tosylethyl azide 48 using the method of Glaser et al (Figure 
75).[62] 
 
Figure 75. Synthesis of [18F]FEA 
Tosylate 48 was reacted with a mixture of [18F]fluoride and K[2.2.2] in MeCN under basic 
conditions, forming the desired labelled [18F]FEA in 30% radiochemical yield (RCY), non-
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decay-corrected (n.d.c), after distillation.[62]  
Each cyclooctyne was subsequently reacted with the radiolabelled azide at 40°C and at 
90°C, primarily using MeCN as solvent. The reactions were carried out in a sealed reaction 
vial (initially for 15 min), and the experiments were repeated at least three times in order to 
ensure that the results were reproducible.[151] In certain cases, the reactions were carried out 
for 1 h in order to determine how the reaction proceeds within the time-frame of a PET scan 
(which is limited by the half-life of 18F), and additionally in water in order to replicate close to 
physiological conditions.  
The relative reactivity of the different cyclooctynes (Entries 1-6) with [18F]FEA clearly varied 
when using different solvents and temperatures. These reactions were monitored by HPLC, 
and the conversions (%) were determined by the relative proportion of the [18F]FEA 
reference radio-HPLC trace against the 18F-labelled triazole product HPLC traces, which are 
quoted as the summation of the two regioisomers formed (Table 8).  
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a Each reaction carried out using 50 µL of [18F]FEA (typical activity of ~ 5 MBq); n = 3 in all cases. 
bRadiochemical yield as determined via radio-HPLC showing conversion of [18F]FEA into the summation of the regioisomers. 
Table 8. The results of radiolabelling cyclooctynes with [18F]FEA under different reaction conditions 
As anticipated, OCT2 showed relatively low reactivity, giving conversions of only 4.4% after 
15 min in MeCN at 40°C (Entry 1, Table 8). Significantly higher reactivity was observed at 
90°C, producing conversions of 24.9% conversion after 15 min in the same solvent (Entry 3, 
Table 8). Its lack of reactivity at 40°C (0.3% conversion after 15 min) in water (Entry 2, Table 
8) may be attributed to the lipophilic structure of the first-generation cyclooctynes, which had 
not been developed in terms of their physicochemical properties (see chapter 2). The 
relatively low overall observed reactivity towards the azide is not entirely surprising, as OCT2 
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has reportedly lower reaction kinetics in the SPAAC reaction than the cyclooctynes 
developed later (k = 1.3 x 10-3 M-1s-1).[57, 113]  
OCT4 showed improved reactivity over OCT2, and introducing an amide side-chain 
increased its reactivity at 90°C in MeCN (Entry 4, Table 8) by more than two-fold (60% vs. 
25% conversion after 15 min), suggesting that addition of a side-chain may enhance its 
reactivity towards azides. This result is promising, as it demonstrates the feasibility of 
introducing a different functional group onto the cyclooctyne structure without interfering with 
the reactivity of the compound, and it can be imagined that a biologically active molecule 
may be introduced in a similar manner. It could be anticipated that the introduction of an 
antibody could, in addition, significantly improve the solubility of these first-generation 
cyclooctynes in water, and therefore will not prohibit these as potential compounds for use in 
vivo.  
TMDIBO1, showed lower reactivity than DIFO3 in MeCN at 40°C, giving conversions of only 
7% after 15 min (Entry 5,Table 8), and at 90°C the conversion to the triazole products was 
only improved to 31.5% (Entry 8, Table 8). In contrast, this compound showed slightly 
enhanced reactivity in water, giving conversions of 33% after 15 min (Entry 6, Table 8) vs. 
26% conversion for DIFO3 (Entry 12, Table 8) under the same conditions. The reactivity was 
not compromised at a longer time-point of 1 h, showing conversions of 36% (Entry 7, Table 
8). 
Pleasingly, it was observed that TMDIBO1 was particularly stable in aqueous media, and no 
decomposition products were observed over 1 h when the reaction was carried out in water 
at 37°C. These results suggest that TMDIBO1 may be a potential compound for application 
to the pretargeting strategy, showing more promising reactivity and stability in solvents and 
temperatures that are closer to physiological conditions.[178] It should still be noted, however, 
that the highest radiochemical yield observed using this compound was 36%, and these 
yields may not be achievable at very low reaction concentrations such as those found in 
vivo. 
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Replacement of the pNP-carbonate in TMDIBO1 with a maleimide substituent, to form 
TMDIBO2 compromised some of its reactivity in MeCN (Entries 9 and 10,Table 8) at both 
40°C (3% vs. 7% conversion after 15 min) and at 90°C (10% vs. 35.5% conversion after 15 
min), which could be a result of an increase in flexibility of the side-chain as compared to the 
carbonate linker, potentially causing an increase in the steric bulk onto one side of the 
molecule. The maleimide functional group is a useful handle by which to incorporate the 
cyclooctyne onto a biomolecule through a thiol moiety (see section 3.2.1), and it is hoped 
that this compound will maintain its reactivity with azides even when substituted with a much 
larger group.  
DIFO3 showed the highest overall levels of reactivity in the SPAAC reaction with [18F]FEA, 
especially when the reactions were carried out in MeCN. At the higher temperature of 90°C, 
almost quantitative conversions were observed within 15 min (Entry 14, Table 8). At 40°C 
not much of the reactivity was compromised, showing conversions of 62% within 15 min 
(Entry 11, Table 8) (Figure 76).  
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Figure 76. Reaction of DIFO3 with [18F]FEA to form the triazole regioisomers and example radio-HPLC trace at 40°C in MeCN 
after 15 min 
Conversely, when the reaction with DIFO3 was carried out in water, a greater than two-fold 
drop in reactivity was observed, giving conversions to the triazole regioisomers of only 26% 
(Entry 12, Table 8), owing in part to the formation of many decomposition products. Bertozzi 
and co-workers previously observed similar results when the cycloaddition reactions of 
fluorinated cyclooctynes (MOFO) were carried out in aqueous media (Figure 77).[113] 
 
[18F]53 
[18F]FEA 
Chapter 3 - Evaluating the SPAAC Reaction for Pretargeting 
 
114 
 
 
Figure 77. The deflourination reaction observed by Bertozzi et al. of the mono-fluorinated cyclooctyne MOFO[113] 
Bertozzi et al. attributed this observation to the displacement of fluorine by a hydroxyl group 
in the least sterically hindered of the two triazole regioisomers, which was confirmed by 
characterisation of the products formed by mass spectrometry.[113] It was subsequently 
concluded that with the fluorinated cyclooctynes, the reaction was non-ideal in aqueous 
media at longer-time points such as those used in PET experiments, as this led to the 
formation of a greater number of decomposition products.[114] 
Surprisingly, the SPDC reagent DIBOD did not show any of the previously observed 
reactivity in the SPAAC reaction when carried out in MeCN at 40°C after 15 min, showing no 
observed conversion to the triazole products (Entry 15, Table 8).[181] This lack of reactivity 
may be a result of poor solubility of the cyclooctyne in the solvents used, or compound 
decomposition over the time frame of the experiment, as this cyclooctyne has lower reported 
stability than the other cyclooctynes. 
3.1.3 Synthesis of the ‘Cold’ Reference Compounds 
The synthesis of 2-fluoroethyl azide (FEA) was carried out in order to make the reference 
triazole compounds with each of the cyclooctynes (Entries 1-6, Table 8) used in the 
radiolabelling study (Figure 78).[62, 192]  
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Figure 78. Synthesis of FEA from 2-flouroethanol 55 
This first involved tosylation of 2-fluoroethanol 55, which proceeded at ambient temperature 
in 12 h. The next step was to form FEA from the tosylate 56 using sodium azide. This 
reaction was monitored by TLC and was complete after 24 h at ambient temperature. After 
this time, the white precipitate formed was filtered off and the crude filtrate was used for the 
copper-free ‘click’ reactions with each of the cyclooctynes, as it has been reported that 
isolation of FEA may result in an explosion.[62] All of the cyclooctynes used in the 
radiolabelling study were reacted with FEA in CDCl3, by heating to 40°C for 2 h (Figure 79).  
 
Figure 79. Reaction of the cyclooctynes (Table 8) 
The resulting reaction mixtures were concentrated in vacuo in order to remove any excess 
FEA, as this compound is volatile, and the crude compounds were re-dissolved in CDCl3 for 
NMR analysis. Initial confirmation that the reactions had occurred was obtained by 
examination of the 19F NMR spectra of these crude mixtures, which indicated the presence 
of the triazole fluorine substituents at δF ~-225 ppm. The ratio of regioisomers could 
additionally be determined as the two regioisomeric triazole fluorine peaks are clearly 
separated by their relative chemical shifts (δF). Further proof that the triazoles had been 
formed was obtained by 1H NMR, HRMS and HPLC analysis and by 13C NMR analysis when 
possible (see experimental section for further details and for example spectra). 
Each of the ‘cold’ reference compounds was used to confirm the identity of the products 
formed in the radiolabelled SPAAC reaction with [18F]FEA, by comparing the retention times 
of the HPLC UV trace with the radio-HPLC trace of the 18F-labelled compounds (see 
experimental section).  
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3.1.4 Conclusions 
In conclusion, the radiolabelled SPAAC reaction between [18F]FEA and the six cyclooctynes 
used in this study gave a good overview of the ability of these reactions to be carried out 
under different conditions of solvent, temperature and duration.[151] The early-generation 
cyclooctynes (Entries 1-4, Table 8) as expected, showed relatively low conversion to the 
triazole regioisomers, as compared to the more developed cyclooctyne structures, DIFO3 
and TMDIBO (Entries 5-14, Table 8). 
The optimum conditions for carrying out the SPAAC reaction were in MeCN, and required 
elevated temperatures in order for the reaction to proceed efficiently. Using media that 
replicates in vivo conditions, such as using water and longer reaction times, resulted in lower 
conversions, or decomposition in the case of the fluorinated cyclooctyne DIFO3. However, in 
some cases this may be considered to be a result of the poor water solubility of these 
compounds, and should not hinder their application to pretargeting, as attaching to a large 
biomolecule such as an antibody would be expected to greatly enhance the solubility of the 
cyclooctynes. The TMDIBO1 construct was to be taken forward to in vivo studies, as this 
derivative displayed the most optimal combination of stability and reactivity in the reaction 
with [18F]FEA in water at 40°C, over a time-point of 1 h. In addition, a cell viability assay was 
carried out in HCT116 human colon cancer cells, and no toxicity of TMDIBO1 was observed 
at concentrations up to 100 mM (see experimental section for further details). 
3.2  Evaluation of [18F]FEA as a Chemical Reporter 
3.2.1 Introduction to [18F]FEA as a Potential Chemical Reporter 
Based on the results obtained from the 18F-labelling, it was hypothesised that the most 
promising cyclooctyne could be ligated to a chosen biomolecule, and applied to a 
pretargeting strategy using [18F]FEA as the radiolabelled ‘tag’. Due to the reasonable 
reactivity demonstrated by the most reactive cyclooctynes (in particular TMDIBO1), we 
decided to apply the SPAAC reaction in our pretargeting strategy in vivo (Figure 80).  
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Figure 80. The SPAAC reaction as applied to the proposed pre-targeting strategy 
Prior to attempting the in vivo SPAAC reaction, it was necessary to validate [18F]FEA as a 
potential radiolabelled pull-down reagent or ‘tag’, by predicting and evaluating the behaviour 
of the compound in vivo.  
3.2.2 Measuring the LogP of [18F]FEA 
For a pretargeting application, it is important that [18F]FEA reaches the site at which the 
biologically active molecule containing the cyclooctyne is localised. This is essential for the 
reaction to occur in vivo, and for the targeted tissue to be imaged successfully in contrast to 
the background tissue. One method which will aid prediction of the fate of the azide in vivo is 
by measuring its LogP. 
The value of LogP is an important consideration when designing a radiotracer, as the 
relative hydrophilic vs. hydrophobic properties have a large influence on the tracer’s, 
absorption, distribution, metabolism and excretion (ADME).[193] For example, highly 
hydrophilic compounds are more prone to plasma protein binding and will not cross the cell 
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membrane, but very hydrophobic compounds often suffer from poor absorption. It is 
consequently important that a correct balance is achieved and that LogP is considered when 
designing a radiotracer.  
LogP can be measured experimentally by observing the relative distribution of the 
compound in a mixture of n-octanol and water.[194]  Hydrophilic molecules will prefer the 
aqueous phase, whereas more hydrophobic molecules will dissolve more readily in the 
organic layer. The partition coefficient (P) is a measure of the concentration of the tracer that 
is dissolved in the n-octanol layer relative to the aqueous layer, and therefore a very 
hydrophobic compound will have a high partition coefficient, and consequently the LogP 
scale is a measure of the hydrophobicity of a tracer. The LogP value of [18F]FEA was 
measured using this method, and the average value was found to be -0.44 (Table 9).  
 
Table 9. Calculating the logP of [18F]FEA 
This value suggests that [18F]FEA is relatively hydrophilic, but tracers such as [18F]FDG also 
have similar measured LogPs (LogP = -0.67).[195] This implies that although the azide has a 
slightly lower than ideal LogP, it does not inhibit the use of [18F]FEA as a radiotracer. It 
should be noted, however, that the azide was shown to be relatively volatile, and 
evaporation may have affected the outcome of the LogP determination.  
3.2.3 In vivo Biodistribution of [18F]FEA 
We planned to evaluate the behaviour of the azide in vivo prior to attempting pretargeting.[151] 
Therefore, we injected [18F]FEA into normal Balb/c mice (n = 3), enabling the biodistribution 
of the compound to be observed and to test for any associated toxicity. This would enable us 
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to determine the level of background radiation due to the distribution of the azide alone, 
which could be expected when applying the SPAAC reaction in vivo. This study generally 
showed that the radiotracer distributed evenly throughout the tissues, but that a small 
accumulation occured in the liver and bone joints (Figure 81).  
 
Figure 81. In vivo Biodistribution of [18F]FEA* Representative small animal PET images of a Balb/c nude mouse at: t = 15 
sec and t = 60 min after intravenous injection in the tail of 3.7 MBq of [18F]FEA. *In vivo work was carried out by Dr Quang-De 
Nguyen. 
The image suggests a small amount of elimination to the [18F]fluoride anion, due to 
accumulation in the bone, however this is only observed in small amounts relative to the 
initial injection. A decrease in the overall amount of radiotracer in the animal was observed 
over the 60 min time-course of the experiment, possibly attributable to the volatile nature of 
this compound, but perhaps also caused by bodily excretion. The azide was found to be 
stable in PBS (pH = 7.4), MeCN and DMSO for up to 6 h at room temperature, and 
displayed relatively rapid clearance from the body over the 60 min time frame, suggesting 
that this could initially be a useful azide for the proposed pretargeting strategy. The volatility 
of this compound, as well as the undesirable LogP, may however cause some problems for 
the long-term use of this azide as the radiolabelled reaction partner. 
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3.2.3 Conclusions 
[18F]FEA demonstrated reasonable in vivo biodistribution, showing clearance of the 
compound from the body within 1 h. The good stability of this compound in different media 
also makes it attractive as a chemical reporter, as does its demonstrated reactivity with the 
cyclooctynes used in the radiolabelling study. However, the small size of this compound 
renders it volatile, making it difficult to handle, and the LogP may need to be improved if it 
were to be used for a wider range of applications. The ease of synthesis of this compound, 
which could be achieved by an automated process, meant that this azide was used for initial 
in vivo validation of this reaction, and optimisation of the compound would be postponed 
until required for future studies.  
3.3  Attempted In vivo SPAAC Reaction Using Her-TMDIBO and [18F]FEA 
It was anticipated that the TMDIBO structure would be the most suitable cyclooctyne for 
ligation to a monoclonal antibody, as it demonstrated the most promising combination of 
stability and reactivity in the SPAAC reactions with [18F]FEA (Entries 5-10, Table 8).[113, 126]  
Cyclooctynes OCT2 and TMDIBO were therefore conjugated to the Trastuzumab 
(Herceptin) monoclonal antibody, which would be used to target high HER2 receptor 
expressing tumours. After 2 days, the cyclooctyne-ligated antibodies were considered to 
have had enough time to localise at the targeted tissue, and [18F]FEA was then to be 
injected, allowing for the SPAAC reaction to occur at the HER2 target (cf. Figure 80). The 
distribution of 18F within the whole body would then be monitored over a time point of 60 min, 
with the intention that the SPAAC reaction would occur specifically in the tumour, allowing 
for effective visualisation using PET imaging, with minimal background signal. 
3.3.1 Introduction to Herceptin as an Antibody for the HER2 Receptor 
Herceptin is a monoclonal antibody (mAb) which is used to treat particular forms of breast 
cancer, and does so by interfering with the HER2/neu receptor.[196, 197] The Human Epidermal 
Growth Factor Receptors (HER1, HER2, HER3 and HER4) are responsible for regulating 
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cell growth and survival, adhesion, migration and differentiation, as well as other cellular 
responses. Amplification of the HER2 gene is observed in 20-30% of early stage breast 
cancers, leading to an over-expression of the receptors in the cell membrane and 
uncontrolled proliferation of the cells. Herceptin contains two antigen-specific sites that bind 
to the extracellular domain of the HER2 receptor. 
As discussed (see chapter 1 – Introduction), antibodies have desirable characteristics for 
targeting tumours, including a high specificity and affinity for the targeted receptor. Herceptin 
is one of such monoclonal antibodies, and could therefore be used to target cells over-
expressing the HER2 receptor.[196] The long circulation time of the antibody, combined with 
slow clearance means that it would be difficult to use such an antibody for direct labelling 
using short-lived isotopes (such as 18F or 68Ga), for use as a radiotracer, and traditionally this 
may only be achieved using long-lived isotopes (for example 111I).[198] The pretargeting 
strategy may be used to overcome some of these limitations by separating the delivery of 
the antibody with that of the radionuclide. Additionally, Herceptin was considered as a 
suitable antibody for pretargeting as it is not rapidly internalised into the cell, which is a 
common problem when separating the delivery of the antibody with that of the chemical 
reporter.  
3.3.2 Synthesis of Herceptin-Ligated Cyclooctynes   
In order to conjugate the two cyclooctynes OCT2 and TMDIBO1 to Herceptin (which has a 
molecular weight of approximately 145 kDa) it was necessary to introduce a suitable linker to 
each of the compounds that would allow a point of attachment to the protein. The maleimide 
group was chosen as a suitable linker group as this can specifically react with free thiol 
groups in the antibody to form a stable carbon-sulfur bond. OCT2 and TMDIBO1 were both 
reacted with N-(2-aminoethyl) maleimide 57 under amide coupling conditions to form the 
maleimide-substituted amides OCT5 and TMDIBO2 respectively.  (Figure 82).[199]  
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Figure 82.  Coupling of OCT2 and TMDIBO1 to introduce a maleimide linker 
HBTU was used as the coupling agent for the synthesis of OCT5, in order to introduce an 
active ester (Scheme 28), however the pNP-carbonate group on TMDIBO1 allowed for the 
reaction to occur without the aid of a coupling agent.[178] 
Herceptin, as well as a control antibody, Immunoglobin (IgG1), (which possesses a similar 
size to Herceptin, but lacks specificity to the Her2 target), were both modified so that they 
would be reactive towards the maleimide moiety (Figure 83).  
 
Figure 83.  Example of the use of ‘Traut’s’ reagent to introduce thiol groups to free lysine residues onto the Herceptin and IgG1  
Traut’s reagent (2-imino thiolane) 58 was used to introduce ‘free’ thiol groups to the 
antibodies, via the available lysine residues.[200] Traut’s reagent is highly electrophilic at the 
tertiary carbon centre, allowing for nucleophilic substitution of the amine and subsequent 
ring-opening of 2-imino thiolane to form the available thiol group.[201] Use of this reagent also 
introduces a short linker for attachment to the small molecule, increasing the availability of 
the thiol towards reaction with the maleimide. 
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The maleimide-substituted cyclooctynes OCT5 and TMDIBO2 were subsequently 
conjugated to the respective antibodies using the newly formed thiol groups as points of 
attachment (Figure 84). 
 
Figure 84. Reaction of thiol-functionalised Herceptin with maleimide-containing OCT5 and TMDIBO2 
The conjugated products were purified by passing through a NAPTM-5 column, and were 
eluted using a sodium acetate buffer. The characterisation of products Her/IgG1-OCT and 
Her/IgG1-TMDIBO was carried out by mass spectrometry in order to confirm the number of 
cyclooctynes conjugated to the antibody. These results indicated that a mixture of 1, 2 and 3 
small molecules were attached to each of the antibodies, with 2 being the major isoform. 
This could be seen by the average difference in mass between the antibody alone and the 
cyclooctyne conjugated antibody (see experimental section for further details). 
The ligated antibodies were tested for their immunoreactivity by western-blot, which showed 
that the ligated (Herceptin) antibodies were still active towards the HER2 receptor (Figure 
85).  
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Figure 85. Immunoreactivity assessment of Her-TMDIBO* Human ovarian carcinoma SK-OV-3 cells were incubated in the 
absence or presence of 40µg/mL Herceptin, Her-TMDIBO or IgG1-TMDIBO for the indicated time. Whole cell lysates were 
prepared and 30µg processed for immunoblot analysis using primary antibodies against phosphorylated-HER2 (p-HER2), total 
HER2 (HER2), phosphorylated-AKT (p-AKT), and total AKT (AKT).*Immunoreactivity assessment by western blot was carried 
out by Dr Quang-De Nguyen.  
This data showed that the modified Herceptin and IgG1 antibodies maintained the same 
levels of affinity for the HER2 receptor as the unmodified antibodies, and a similar level of 
expression was observed after both the 1 and 24 h time-points. Phosphorylation of HER2 
was only observed with the Herceptin antibodies, as expected, and the IgG1 antibody did not 
activate the receptor. This confirmed the use of each of the antibodies for use in the 
hypothesised pretargeting model, with the modified IgG1 being used as a negative control.  
3.3.4 Attempted Pretargeting Using the SPAAC Reaction  
Once the biodistribution of [18F]FEA had been evaluated, and the chemical reporter was 
confirmed as having a reasonable in vivo profile in terms of distribution and clearance, the 
SPAAC reaction was evaluated in a tumour-bearing mouse model. The mice were treated 
with SKOV-3 human ovarian adenocarcima (HER2 over-expressing) cells, forming tumours 
suitable for imaging 14-days post-implantation.  
Three main steps were carried out with the tumour-bearing mice, which would validate the 
pretargeting strategy in vivo: 
Chapter 3 - Evaluating the SPAAC Reaction for Pretargeting 
 
125 
 
a) Pre-treatment with cyclooctyne-ligated Herceptin (or corresponding negative 
controls), 48 h before imaging, 100µg in 100µL i.v. per mouse. 
b) CT/ 60 min dynamic PET imaging, bolus i.v. injection of ~3.7MBq (~100µL) [18F]FEA 
per mouse. 
c) Post-imaging biodistribution and IHC tumour HER2/neu assessment 
The main observations from this experiment were that there was a slight increase in uptake 
in the tumour tissue that was pretargeted with the Her-TMDIBO antibody, as compared to 
the tissue that was treated with the non-ligated cyclooctyne (TMDIBO1), or with the vehicle 
(PBS) (Figure 86).  
 
Figure 86. A significant difference in 18F uptake was not observed between control and pretargeted HER2 over-
expressing tumours* SKOV-3 human ovarian adenocarcima tumour bearing mice were injected intraveneously with the 
vehicle (PBS), or with 100µg TMDIBO1 or Herceptin-TMDIBO 48 h prior to bolus i.v. injection of ~3.7MBq (~100µL) [18F]FEA 
per mouse. The line graphs show the mean relative uptake (%ID per mL) of 18F in each treatment group. *In vivo work was 
carried out by Dr Quang-De Nguyen. 
Although a difference between the treated and non-treated tissue was observed, this 
variance was not significant, suggesting that this observation was not solely to the SPAAC 
reaction occurring in the tumour. This was supported by the fact that a similar pattern was 
also observed in other tissues, as evidenced from the biodistribution studies (Figure 87). 
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Figure 87. Biodistribution experiment* The uptake of 18F in selected organs of SKOV-3 human ovarian adenocarcima 
tumour-bearing mice was measured 1 h after intraveneous injection of a) vehicle (PBS) + ~3.7MBq (~100µL) [18F]FEA (white 
bars); b) 100µg TMDIBO1 + ~3.7MBq (~100µL) [18F]FEA (black bars); c) 100µg Herceptin-TMDIBO + ~3.7MBq (~100µL) 
[18F]FEA (red bars). The bar graphs show the mean relative uptake of 8F after 1 h in each treatment group. *In vivo work was 
carried out by Dr Quang-De Nguyen. 
The biodistribution data indicated a similar increase in uptake in the pretargeted mouse 
across all of the tissue types, with a significant accumulation in the bone joints. This showed 
us that the uptake of 18F in the tumour was not enhanced over the uptake in other tissue, 
suggesting that unfortunately the SPAAC reaction was not occurring in vivo as anticipated, 
or is at least was not specific for the targeted tissue. 
3.3.5 Conclusions  
It was concluded that further optimisation of the reaction was required in order to determine 
whether the SPAAC reaction is achievable in vivo. This could require the use of a different 
cyclooctyne, which would demonstrates a better balance between reactivity in the SPAAC 
reaction with in vivo stability. In addition to the reactivity considerations, it was hypothesised 
that an alternative azide may be required, which also displays better in vivo biodistribution; 
for example using a less volatile compound, which has an improved LogP.  
3.4  Kinetic Evaluation of the SPAAC Reaction  
The results obtained up to this point seem to suggest that the SPAAC reaction is not fast 
enough to occur in vivo. However, in order to corroborate this reaction, it was determined 
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that it should be evaluated in terms of the kinetics, and more specifically, that the effect of 
concentration on the rate of reaction should be considered. Such a study would allow us to 
determine how effective a given SPAAC reaction would be at concentrations relevant to an 
in vivo experiment.  An alternative cyclooctyne was considered at this stage, with the hope 
that this compound could be applied to a similar pretargeting application for future studies.  
3.4.1 Introduction to Aza-Dibenzocyclooctyne (DIBAC) Reagents  
The aza-dibenzocyclooctyne (DIBAC) was developed by Van Delft and co-workers,[129] with 
the intention to combine the favourable reaction kinetics in the cycloaddition reaction 
displayed by dibenzocyclooctyne (DIBO) reagents, developed by Boons et al.[127], and the 
improved hydrophilicity of the aza-dimethoxycyclooctyne (DIMAC) derivatives synthesised 
by Bertozzi and co-workers (Figure 88).[202]  
 
Figure 88. The structures of DIMAC, DIBO and DIBAC 
The nitrogen moiety on DIBAC potentially allows for simple structural modifications to be 
made, providing a useful point of attachment for side-chains, and therefore might be 
anticipated to be easily functionalised for attachment to a biomolecule. These compound 
could additionally be synthesised in 70% overall yield in only five steps, making them 
desirable cyclooctynes for numerous applications, and for this reason a range of these 
reagents are now commercially available.  
These cyclooctynes have been reported to have superior reaction kinetics (k = 0.31 M−1s−1) 
in the SPAAC reaction with benzyl azide in CD3OD, as compared to DIBO (k = 0.17 M−1s−1) 
and DIFO (k = 0.076 M−1s−1) and reacts approximately 100-fold faster than the hydrophilic 
DIMAC system (k = 3×10−3M−1s−1).[55, 127, 129] This may be explained by the increased strain 
accruing from the introduction of two aryl rings adjacent to the alkyne and increased 
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hydrophilicity over the earlier DIBO analogues as the result of incorporation of a nitrogen 
atom into the cyclooctyne ring.[109, 129] Due to the availability of the DIBAC reagents, and the 
fact that these compounds have improved reactivity in the SPAAC reaction, it was 
determined that these reagents might be more suitable than the earlier cyclooctynes 
application to pretargeting. In order to validate these compounds thoroughly in this context, 
the kinetics of these compounds were more extensively evaluated.  
3.4.2 Determining the Rate of Reaction of OCT3 and DIBAC Cyclooctynes 
The direct comparison between a carboxylic acid-derived DIBAC analogue (DIBAC1) and 
OCT3 (a first generation cyclooctyne), was initially carried out, by measuring the reaction 
rates of both of these compounds towards benzyl azide. The kinetics of the reaction between 
OCT3 and benzyl azide 63 has been measured previously by Bertozzi and co-workers using 
1H NMR analysis.[113] This work was repeated in order to validate the method and ensure for 
the reproducibility of the results. OCT3, which was synthesised as described in Chapter 2, 
was reacted using this method; a 1:1 molar ratio of starting materials was employed with a 
concentration of 40 mM (Figure 89).   
 
Figure 89. The reaction of OCT3 with benzyl azide 63 
An NMR tube was treated with a solution containing OCT3, to which another solution 
containing an equimolar amount azide 63 was added. The progress of the reaction was 
monitored using 1H NMR, at a number of time-points up to 16 h. The first time-point 
measured was 15 min, followed by 30 min and 1 h, after which measurement was taken 
every hour up to 8 h after mixing. After 16 h a final 1H NMR was taken, and the relative 
concentration of azide 63 as compared to the initial concentration was measured at each 
time-point (Figure 90). 
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Figure 90. a) Example 1H NMR spectrum of the reaction mixture at 16 h, showing the relative proportion of the starting material 
protons as compared to the triazole product protons b) A stacked plot of the 1H NMR at different time-points showing the 
progress of the reaction over time 
The concentration of benzyl azide 63 remaining in the mixture was calculated based upon 
the relative integration of the benzylic protons at δH ~4.4 ppm in the starting material, as 
compared to those at δH ~ 5.2-5.6 ppm observed in the regioisomeric triazole products 64. 
a) 
b) 
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The calculation was also confirmed using the integration of other reference peaks, such as 
the change in integration of the aromatic protons, which also gave similar results. The rate of 
reaction was calculated using the slope of the line of the graph of 1/[benzyl azide] vs. time 
(Figure 91).  
 
Figure 91. A graph showing time vs. 1/[benzyl azide], which was used to calculate the rate constant for the reaction with OCT3 
These data were collected three times in order to confirm the reproducibility of the results, 
and the graph was plotted based upon the average of the three experiments. The average 
rate of reaction was found to be k = 1.6 x 10-3 M-1s-1, which is comparable to Bertozzi’s value 
of k = 1.3 x 10-3 M-1s-1 for the carboxylic acid analogue of this ester.[113] The same experiment 
was subsequently carried out using DIBAC1, in order to compare a first-generation 
cyclooctyne to the commercially-available, and reportedly more reactive cyclooctyne 
DIBAC1 (Figure 92).[129]  
 
Figure 92.  The reaction of DIBAC1 with benzyl azide 63 in CD3CN, which was monitored by 1H NMR 
The reaction was carried out using identical conditions to those used for the reaction of 
OCT3 with azide 63, and it was found that most of the starting material had reacted to form 
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the triazole regioisomers 65 within 30 min. Therefore, in order to calculate the rate of 
reaction more accurately, the reaction was carried out again, this time monitoring the mixture 
at shorter time-points (every 3 min), up to 49 min. The reaction was carried out in triplicate, 
as with the previous experiment, and the conversion to the triazole products was similarly 
calculated based upon the relative integration of the benzylic protons (δH ~ 4.4 ppm) in the 
azide starting material 63, as compared to the benzylic protons (δH ~ 5.5 - 6.0 ppm) of the 
regioisomeric triazole products 65 (Figure 93). 
 
 
 
 
Figure 93. A stacked plot of the 1H NMR at different time-points showing the progress of the reaction over time  
The rate of reaction was subsequently calculated, as with the previous experiment, by 
plotting a graph of 1/[benzyl azide] against time (Figure 94).  
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Figure 94. A graph showing time vs. 1/[benzyl azide], which was used to calculate the rate constant for the reaction with 
DIBAC1 
Pleasingly, the rate of reaction was calculated to be 0.17 M-1s-1; approximately 100-fold 
faster than OCT3. This value is comparable to, but lower than the reported value of 0.31 M-
1s-1, and the discrepancies may be attributed to the difference in method for calculating the 
rate constant, which were determined by Van Delft et al. using the following equation:[129] 
𝑘𝑡 =    1𝐵 ! − [𝐴]!   × ln 𝐴 !( 𝐵 ! −    𝑃 )( 𝐴 ! − [𝑃]) 𝐵 !  
These initial studies into the kinetics of the SPAAC reaction demonstrate the significant 
difference between the first-generation cyclooctynes as compared to the more recent 
congeners, and that judicious modification of the cyclooctyne structure can have a significant 
positive impact on their rate of reaction with azides.  
These results, however, gave us no indication of how the reaction rates depend upon the 
concentration of the reactants, and consequently whether the reaction will be compatible 
with the very low concentrations required in order for the reaction to occur in vivo. Since we 
wanted to monitor how the reaction performs at much lower concentrations, we envisaged 
that these reactions would need to be evaluated by a more sensitive detection method.  
y = 0.1665x + 315.64 
R² = 0.99344 
0 
200 
400 
600 
800 
1000 
0 500 1000 1500 2000 2500 3000 3500 
1/
[b
en
zy
l a
zi
de
] 
Time (sec) 
Chapter 3 - Evaluating the SPAAC Reaction for Pretargeting 
 
133 
 
3.4.3 Evaluating the Effect of Concentration upon Rate of Reaction 
Due to the relatively impressive reaction kinetics that were demonstrated by DIBAC1 in the 
SPAAC reaction with benzyl azide, it was decided that the rate of reaction should be more 
carefully evaluated in terms of concentration of the cyclooctyne. A maleimide derivative 
(DIBAC2) of this compound was chosen for carrying out these studies, as it would be 
necessary to use such a functional group for attachment to a chosen biomolecule.[129]  
A sugar-derived azide 66 was reacted with DIBAC2 under various conditions, observing the 
effects of modifying the concentration of the cyclooctyne on the rate of reaction within 15 min 
at 40°C (Figure 95)  
 
Figure 95. The reaction of DIBAC2 with a sugar azide 66 in MeCN, which was monitored by HPLC 
Azide 66 was chosen as it contains a suitable amount of functionality, without containing a 
UV chromophore, and would therefore not itself be detected at 254 nm by the UV detector of 
the HPLC instrument. It was planned that the reaction would be monitored at one time-point 
only, and under the optimum conditions for this type of reaction (i.e. using MeCN as solvent 
and at 40°C). 1H NMR analysis of the reaction would not be possible at very low reagent 
concentrations, and for this reason HPLC analysis was chosen in order to observe the 
progress of the reaction. The triazole product 67 could be detected by HPLC, and was 
significantly separated from the DIBAC2 starting material in terms of retention time.  
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The reaction was initially carried out at 90°C, and the two regioisomers of the triazole 
products were observed on the UV trace of the analytical HPLC. The reaction was 
subsequently carried out at 40°C, at four different concentrations of cyclooctyne, and each 
reaction was repeated four times (Figure 96).  
 
 
 
 
 
 
 
  
Some decomposition products were observed in the HPLC trace of the reaction mixture 
when carried out at 90°C, presumably attributable to the high temperatures used. The 
reaction proceeded smoothly at 40°C however, forming a lower number of decomposition 
products. The number of equivalents of azide 66 added in each case was kept constant, and 
the same stock solution of DIBAC2 was used in order to ensure reproducibility. A linear 
dependence on the concentration of DIBAC2 and the area under the curve (AUC) on the UV 
trace (at 254 nm) was demonstrated by injecting known concentrations of the stock solution, 
in order to obtain a calibration curve. 
The conversion to the triazole products 67 was plotted as a function of initial DIBAC2 
concentration, which allowed us to estimate that a concentration of 8.7 M of DIBAC2 would 
be required in order to achieve 100% conversion to the triazole products 67 within 15 min at 
40°C (Figure 97). 
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Figure 96. An example HPLC trace at 254 nm of the reaction mixture after heating to 40°C for 15 min 
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Figure 97. A graph showing initial [DIBAC2] vs. conversion (%) to the triazole products 67 
The maximum conversion to the triazole products 67 within 15 min was observed at the 
highest concentration of DIBAC2 (2.4 M), with only 35% of the cyclooctyne reacting to form 
the triazoles 67. A fairly linear decrease in the reactivity was observed when decreasing the 
concentration of DIBAC2 sequentially by 2-fold for each data point, and only 11.5% of the 
cyclooctyne was reacting by the time the initial concentration was reduced to 0.3 M. 
3.4.4 Conclusions 
The concentrations required in order for the reaction to proceed efficiently are not achievable 
in vivo, and therefore it is unlikely that sufficient reaction will occur within the time-frame of a 
PET experiment for the targeted tissue to show significantly higher uptake than background 
tissue. It should additionally be noted that these studies were carried out in MeCN, as 
DIBAC2 was insoluble in water in the absence of other solvents. However, it could be 
expected that incorporating a more water-soluble side-chain (such as a biomolecule) could 
improve the compatibility of the SPAAC reactions with aqueous media.   
3.5 68Ga-labelled SPAAC Reactions  
3.5.1 Hypothesis for a 68Ga-Labelled SPAAC Reaction  
In order to test the reactivity of DIBAC cyclooctynes further in the context of PET imaging 
applications, we hypothesised that a 68Ga-labelled (DOTA) azide could be synthesised, 
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which could be tested for its reactivity with these cyclooctynes, in a similar manner to the 
study carried out with [18F]FEA. The high volatility of [18F]FEA, coupled with its reasonable, 
but not optimal measured LogP, encouraged us to find a more suitable prosthetic group for 
the radiolabelling of small molecules and peptides using the SPAAC reaction (see section 
3.2). The radiochemical yields that may be achieved using 68Ga chelates such as DOTA are 
usually very reproducible, are frequently superior to those that may be obtained using 18F-
labelling chemistry.[73, 84] In addition, 68Ga is generally produced by a generator containing 
68Ge (see Introduction), and for this reason is a less expensive option than having an on-site 
cyclotron facility.  
For these reasons, we designed a DOTA-containing azide (DOTA-Az), which would be 
readily radiolabelled using standard 68Ga chelation chemistry (Figure 98).  
 
Figure 98. Structure of DOTA-PEG3-azide (DOTA-Az) 
A PEG3 linker was inserted in between the DOTA chelate and the azide moiety, which it was 
anticipated would make the azide more accessible to the SPAAC reaction with cyclooctynes, 
whilst also making the compound more hydrophilic.   
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3.5.2 Synthesis of DOTA-Az  
Two different methods were explored towards the synthesis of the azide DOTA-Az; the first 
involved the synthesis of the tri-tert-butyl protected DOTA, which would have one available 
acid group for amide coupling with the azide-containing amine (Figure 99).[203]  
 
Figure 99. The total synthesis of DOTA-Az from cyclen 68 
The synthesis of the tri-protected DOTA is a literature procedure, and may be achieved in 
three steps from commercially-available 1,4,7,10-tetraazacyclododecane (cyclen) 68.[204, 205] 
The first step of the synthesis involved treating cyclen 68 with three equivalents of tert-butyl 
bromo acetate; this reaction proceeded in 30 h at 70°C, forming the product 69 in a yield of 
60% after recrystallisation. The product 69 was subsequently treated with benzyl 
bromoacetate, in order to introduce an ester onto the remaining position of the cyclen 
structure. This step could be carried out in good conversion, but the purification often 
resulted in the loss of material, and so the product 70 was isolated in yields of just 10% after 
column chromatography. Some of the reported methods for the deprotection of the ethyl 
ester to form the free acid 71 required the use of hydrogenation,[204] but this could be avoided 
by using an alternative method utilising 0.1 M NaOH in dioxane.[205] This reaction proceeded 
in 36 h, and the product 71 could be isolated in 90% yield following work-up.  
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The synthesised DOTA derivative 71 is protected on three of the carboxylic acid groups 
using tert-butyl groups, leaving one available acid for reaction with amine. HBTU was used 
as coupling agent to achieve the amide coupling to form protected form of the azide 72 in 
78% yield. This compound was finally deprotected under acidic conditions to form azide 
DOTA-Az in 68% yield, which has available carboxylic acid groups for chelation to 68Ga.  
Due to the difficulty involved in the second step of the synthesis to form ester 70, and the low 
overall yields that were obtained, an alternative method was employed when repeating the 
synthesis of azide DOTA-Az (Figure 100).  
 
Figure 100. An alternative method for the synthesis of DOTA-Az from DOTA-NHS ester 73 
The second method towards the synthesis relied on the use of commercially-available 
DOTA-N-succinimide ester (DOTA-NHS) 73, which may be directly reacted with the amine 
74 to form azide DOTA-Az in one step under mildly basic conditions.[206] This reaction 
proceeded in good yields, forming the product in up to 70% yield after purification by 
preparative HPLC.  
The purity of azide DOTA-Az was confirmed using 1H NMR, HPLC and HRMS (see 
experimental section). Once synthesised, DOTA-Az could be used for radiolabelling with 
68Ga, and subsequently applied to a 68Ga-labelled SPAAC reaction.  
3.5.3 Radiosynthesis of [68Ga]DOTA-Az 
Once synthesised, the conditions for the radiolabelling of azide DOTA-Az with 68GaCl3 were 
tested and optimised. 68GaCl3 was eluted in 2 mL of a 0.1 M HCl solution, and this eluent 
could be buffered to a higher pH before reaction with the DOTA chelate. DOTA-Az was 
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dissolved in DMSO to a concentration of 1 mg mL-1, and then added to the solution 
containing the buffered 68GaCl3. Two different NaOAc buffers were tested for this particular 
chelation; one at pH 5 and the other at pH 4. The resulting reaction mixture was heated to 
90°C for 10 min, and the progress of the reaction was determined using radio-HPLC (Figure 
101). 
 
Figure 101. Radiosynthesis of [68Ga]DOTA-Az and radio-HPLC trace of  a) [68Ga]DOTA-Az prior to purification, b) 
68Ga]DOTA-Az after purification 
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Although both of these buffers allowed for the formation of the labelled azide [68Ga]DOTA-
Az in >80% conversion from 68GaCl3, the pH 4 buffer provided the optimum pH for this 
reaction, allowing for radiochemical conversions of up to 95%. The radiosynthesis of 68Ga-
labelled azide [68Ga]DOTA-Az, once optimised, are a significant improvement over the 
previously synthesised 18F-labelled azide [18F]FEA. [68Ga]DOTA-Az could be successfully 
purified using a SepPak light C18 cartridge, which allows for the larger compound to be 
retained on the cartridge when washing with water, whilst the smaller molecules, such as 
68GaCl3 are eluted. The purified 68Ga-labelled azide [68Ga]DOTA-Az was then eluted from 
the cartridge using an organic solvent such as EtOH (typically 500 µL). The purity of the 
eluted [68Ga]DOTA-Az fraction was determined using radio-HPLC, which showed that the 
68GaCl3 had been successfully removed from the mixture. [68Ga]DOTA-Az could be 
radiolabelled in isolated yields of up to 65% (n.d.c) after purification, starting with 
approximately 1 mCi of activity, and in >95% radiochemical purity (at least 5 repeats of the 
radiosynthesis were carried out). 
3.5.4 Radiolabelled SPAAC Reactions with [68Ga]DOTA-Az  
The radiolabelled azide [68Ga]DOTA-Az was subsequently used for a series of SPAAC 
reactions with two analogues of commercially-available aza-dibenzocyclooctyne (DIBAC).[127, 
129, 202]  The two cyclooctynes used in this study were DIBAC1 and DIBAC2 (containing a 
carboxylic acid or maleimide functional group, respectively) as the rates of reaction of these 
compounds had previously been evaluated. The progress of the reaction in each case was 
monitored by radio-HPLC, which was used to calculate the conversion from the azide 
[68Ga]DOTA-Az to the regioisomeric triazole products [68Ga]75 and [68Ga]76. In general, the 
results were improved over those demonstrated by the 18F-labelled reaction, which may be 
attributed to the improved reactivity of the DIBAC cyclooctynes over the reagents explored 
earlier (Table 10).  
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a Each reaction carried out using 100 µL of [68Ga]DOTA-Az  (typical activity of ~ 5 MBq); n = 3 in all cases. bRadiochemical 
yield as determined via radio-HPLC showing conversion of [68Ga]DOTA-Az into the summation of the regioisomers. c1% DMSO 
was added to the reaction mixture d10% DMSO was added to the reaction mixture 
Table 10. Radiolabelled SPAAC reactions between DIBAC cyclooctynes and [68Ga]DOTA-Az under different conditions. 
The carboxylic acid analogue DIBAC1 formed the triazole isomers in radiochemical 
conversions of approximately 95% from the radiolabelled azide [68Ga]DOTA-Az at 37°C in 
MeCN within 15 min (Entry 1, Table 10). A higher temperature of 90°C allowed for complete 
conversion to the click products within just 10 min (Entry 2, Table 10). Cyclooctyne DIBAC1 
similarly performed well in the SPAAC reaction with the azide [68Ga]DOTA-Az in water, but 
the addition of 10% DMSO was required in order for the compound to dissolve fully. Low 
conversions of 15% to the triazole products were demonstrated in water at 37°C after 10 min 
(Entry 3, Table 10) but heating to 90°C allowed for the triazoles to be formed in near to 
quantitative yields (Entry 4, Table 10) possibly, at least in part, attributable to the increased 
solubility of the cyclooctyne at higher temperatures.  
The maleimide analogue DIBAC2 demonstrated poor water solubility, even with the addition 
of 10% DMSO, and so the reactivity of this compound in aqueous media was not 
successfully demonstrated (Entry 8, Table 10). Conversely, cyclooctyne DIBAC2 
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demonstrated reasonable reactivity with the azide [68Ga]DOTA-Az in MeCN giving almost 
quantitative conversions to the triazole products at higher temperatures of 90°C (Entry 7, 
Table 10). However, slightly lower conversions of 51.4% and 79.2% were observed at lower 
temperatures of 37°C and 50°C respectively (Entries 5 and 6, Table 10) (Figure 102).  
 
Figure 102. Example radio-HPLC traces of the reaction between [68Ga]DOTA-Az and DIBAC2 at; 50°C in MeCN for 15 min, 
90°C in MeCN for 15 min 
In order to demonstrate the usefulness of the SPAAC reaction when radiolabelling with metal 
chelators, we also decided to compare these results to those obtained using the traditional 
CuAAC radiolabelling method, by reaction of 68Ga-labelled azide [68Ga]DOTA-Az with an 
alkyne under standard CuAAC reaction conditions.[61]  Octreotate analogue 77 was chosen 
for this purpose as this peptide is readily radiolabelled using CuAAC chemistry by reacting 
with previously synthesised azide [18F]FEA. Compound 77 was reacted with [68Ga]DOTA-Az  
under identical reaction conditions to a literature 18F-labeling procedure,[61] but no conversion 
to the triazole product [68Ga]78 resulted (Figure 103).  
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Figure 103. Attempted CuAAC reaction with [68Ga]DOTA-Az and octreotate analogue 77 
This lack of reactivity may be attributed to the deactivation of the copper catalyst in the 
presence of excess DOTA chelate from solid-phase (SP) purification, a problem which is not 
observed in the copper-free version of the reaction. This highlights the utility of the SPAAC 
reaction for labelling biomolecules which cannot tolerate copper catalysts. 
3.5.5 Conclusions 
The radiolabelled azide [68Ga]DOTA-Az has been demonstrated as a useful prosthetic 
group for the radiolabelling of cyclooctyne-containing compounds with 68Ga. The SPAAC 
reaction may be considered as a useful method for labelling biomolecules with 68Ga, due to 
the demonstrated difficulties involved in using the CuAAC in this context. These reactions 
may be particularly useful when aprotic organic solvents can be tolerated (e.g. MeCN), and it 
could be hypothesised that a similar level of reactivity may be achievable in vivo if the 
cyclooctyne were to be attached to a water-soluble biomolecule.  However, the reaction may 
not be fast enough to occur on the time-scales required for a PET experiment (the highest 
Chapter 3 - Evaluating the SPAAC Reaction for Pretargeting 
 
144 
 
radiochemical conversions observed in water were ~15%) and this may be hindered even 
further by the low reactant concentrations that would be found in vivo, as was demonstrated 
in the kinetics studies. 
3.6 Overall Conclusions  
The SPAAC reaction has been described as being bioorthogonal, due to its ability to occur 
quickly and without the need for catalysis.[57, 58, 113] Studying this reaction in more detail, 
however, has enabled us to conclude that the reaction is not optimal within an in vivo setting. 
This was demonstrated initially using an 18F-labelled model reaction between azide 18F[FEA] 
and a series of cyclooctynes, both in a vial and in vivo, which showed that the reaction 
required elevated temperatures or organic solvents in order to proceed efficiently. 
Radiolabelled azide [18F]FEA also displayed less than ideal properties as the radiolabelled 
‘tag’ molecule, as it was shown to be volatile, additionally having relatively low LogP, 
suggesting a less than ideal biocompatibility.[151] The potential binding of cyclooctynes to 
MSA has, in addition, been observed by other groups, significantly lowering the reaction rate 
of the SPAAC reaction in vivo. However, this observation may additionally be attributed to 
accumulation of azides in background tissue.[114, 155] 
The kinetics of the SPAAC reaction could be improved by using the later-generation 
cyclooctynes based on the DIBAC core, which showed enhanced reactivity towards benzyl 
azide 63, and efficient labelling of the alternative azide [68Ga]DOTA-Az could be achieved at 
low temperatures and at short time-points. However, the SPAAC reaction was still 
significantly more efficient in polar aprotic solvents such as MeCN than in water, and high 
temperatures were required in order to achieve quantitative conversions. It was concluded 
from these results that a reaction possessing superior reaction kinetics was required for the 
desired in vivo pretargeting applications.  
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4.1 Synthesis of Tetrazines  
4.1.1 Introduction to Tetrazines for IeDDA Reactions with Strained Alkenes 
As described previously (see chapter 1 – Introduction), the [4+2] cycloaddition reaction 
between tetrazines and strained alkenes has increasingly received attention as an 
alternative bioorthogonal reaction to the SPAAC reaction. This is due to the superior rates of 
reactions that may be obtained, coupled with the vastly increased compatibility with aqueous 
and biological media. In addition to this is the fact that, unlike many other Diels-Alder 
cycloadditions, these reactions are irreversible (due to the elimination of elemental nitrogen); 
an essential feature to achieve biological labelling (Figure 104).[136, 207, 208]  
 
Figure 104. General reaction mechanism for the [4+2] cycloaddition reaction between tetrazines and dienophiles 
A number of tetrazine reagents now exist for application to the inverse electron demand 
Diels-Alder (IeDDA) reactions with alkenes.[209] Modification of the chemical structure can 
help to ‘tune’ the reactivity and the stability of tetrazines by several orders of magnitude, and 
the most appropriate compound for application to pretargeting must be carefully considered, 
to obtain an ideal balance between ease of synthesis, stability and reactivity in the [4+2] 
cycloaddition reaction (Figure 105).  
 
Figure 105. The reaction rates of selected tetrazines with norbornene and trans-cyclooctene (TCO) dienophiles[128] 
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4.1.2 Synthesis of a ‘Symmetrical’ Bipyridyl Tetrazine 
The first tetrazine to be synthesised was a ‘symmetrical’ tetrazine Tz1 with two pyridine 
groups; one of which contained an amine to facilitate subsequent attachment to a radiolabel 
or fluorescent probe (Figure 106).[116, 138, 145] 
 
Figure 106. Tetrazine Tz1 containing two pyridine groups and an amine  
Tetrazine Tz1 reportedly has impressive reaction kinetics in the cycloaddition reaction with 
strained alkenes, and has been applied to a number of applications including pretargeted in 
vivo chemistry using fluorescence.[138] Other tetrazines containing pyridine groups have also 
been used for alternative applications with the IeDDA reaction, such as the post-synthetic 
modifications of DNA, and for the synthesis of a ‘Bio Shuttle’ that helps to transport cargo 
into cells. [210, 211] 
The synthesis of tetrazine Tz1 was reported in two steps from nitriles 79 and 80, and we 
attempted to replicate this synthesis (Figure 107).[116]  
 
Figure 107. Fox’s synthesis of tetrazine Tz1 from nitriles 79 and 80[116] 
The first step was the reaction of 5-amino-2-cyanopyridine 79 and 2-cyanopyridine 80, using 
hydrazine to form the dihydrate 81. This compound was formed in only ~30 % yield after 
column chromatography, which was in accordance with literature protocols.[116] The dihydrate 
81 was then reacted with DDQ via an oxidation to form the dehydrated tetrazine Tz1. 
Obtaining pure desired product was found to be difficult on the first attempts, with a large 
number of impurities making purification challenging. Column chromatography using silica 
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gel deactivated with triethylamine allowed for more successful separation of the desired 
product, forming the product in improved yields of 30%, when compared to previous 
attempts (~10%).  
It was hypothesised that tetrazine Tz1 could be ligated to a side-chain such as DOTA, which 
would serve as a chelate for 68Ga labelling, and this approach was explored. This would 
enable the tetrazine to be radiolabelled using 68Ga, and consequently could allow for a 
radiolabelled IeDDA reaction to be demonstrated, in parallel to the previously demonstrated 
68Ga-labelled SPAAC reaction. This first involved introduction of a suitable linker which 
would serve as a point of attachment to the DOTA chelate (Figure 108).  
 
Figure 108. Introduction of a carboxylic acid side-chain, followed by a PEG2 linker onto tetrazine Tz1 
The first step involved introduction of a carboxylic side chain onto the amine of tetrazine Tz1, 
which would serve as a linker between the tetrazine and PEG2 chain. This reaction was 
carried out according to a literature procedure, but only 10% yields were observed, 
compared to the 40% reported yields for the formation of carboxylic acid analogue 82.[212] 
Attempts were made to improve the yields of this reaction by addition of a catalytic amount 
of DMAP, which it was anticipated, should aid the formation of the amide bond by activation 
of glutaric anhydride. However, the yields for formation of 82 were only marginally improved 
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to 15% using this method. This could be attributed to the poor availability of the amine group 
as a nucleophile, due to localisation of the nitrogen lone pair into the aromatic system. The 
obtained acid 82 was reacted with a Boc-protected PEG2-amine, and almost quantitative 
yields for the formation of the amide coupling product 83 were observed after column 
chromatography, using PyBop as the coupling reagent. The BOC-protected amine  was 
consequently deprotected to the free amine 83 using TFA; this reaction was complete within 
30 min, as determined by TLC, and the crude material was to be used for coupling to the 
DOTA chelate.  
The free amine 83 was reacted with DOTA-NHS 73, forming the desired DOTA-tetrazine 84 
by addition of mild base (Figure 109).  
 
Figure 109. The attempted synthesis of DOTA-tetrazine 84   
The desired product 84 was formed by this method, as was determined by HRMS, but the 
compound was difficult to purify using preparative HPLC. Only trace amounts of the final 
compound were isolated, and attempts to repeat the synthesis of this compound resulted in 
lower overall yields.  For this reason, a different method towards the synthesis of a DOTA-
containing tetrazine was explored.  
In addition to the very low overall yields obtained for this synthesis is that these tetrazines 
have apparently lower water solubility and stability in aqueous media than other 
tetrazines.[145] The strategy employed for the synthesis of this tetrazine, using the addition of 
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hydrazine to aromatic nitriles, as described, is limited to activated nitriles such as 79 and 80, 
and this therefore prohibits access to a diverse range of tetrazines using an analogous 
approach. Alternative methods towards the synthesis of tetrazines, which do not require the 
use of aromatic nitriles, have been recently reported, allowing for the synthesis of a wider 
range of both symmetric and unsymmetrical tetrazines.[144, 145] 
4.1.3 Synthesis of ‘Asymmetric’ Benzylamino Tetrazines 
The methods which allow for the synthesis of asymmetric tetrazines rely upon the use of 
Lewis acid catalysis, presumably in order to activate the nitriles towards addition with 
hydrazine, which allows for even aliphatic nitriles to be used. Tetrazines such as 3-(4-
benzylamino)-1,2,4,5-tetrazine Tz2 were reportedly synthesised in good yield, which have 
greater water solubility and reactivity in aqueous media relative to the diaromatic 
compounds, such as tetrazine Tz1, owing to their slightly reduced lipophilicity (Figure 
110).[115]   
 
Figure 110. Structure of tetrazine Tz2 containing only one aromatic ring  
Tetrazine Tz2 was demonstrated by Hilderbrand et al. as displaying excellent stability in 
PBS, with no decomposition products observed at room temperature after several hours.[115] 
A small amount of decomposition was observed in fetal bovine serum (FBS); however over a 
time-point of 15 h this resulted in only 15% decomposition. This tetrazine demonstrates good 
reaction kinetics with strained alkenes (see section 4.2), and for these reasons have been 
increasingly utilised for numerous applications. 
First attempts towards the synthesis of tetrazine Tz2 relied on repeating the literature 
procedure reported by Hilderbrand et al. whereby 4-(aminomethyl)benzonitrile 85 is reacted 
with formamidine acetate 86 and anhydrous hydrazine in the presence of elemental 
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sulfur.[115] The dihydrotetrazine products formed is subsequently oxidised to the tetrazine Tz2 
using sodium nitrite in acetic acid. Hilderbrand et al. synthesised Tz2 in 20% overall yield, in 
a one-pot procedure, making this method very attractive for the synthesis of these reportedly 
stable and reactive tetrazines (Figure 111). 
 
Figure 111. A) The synthesis of Tz2 as described by Hilderbrand et al; B) The modified method using hydrazine hydrate, which 
resulted in poor conversion to the desired product[115] 
As anhydrous hydrazine is not commercially available in the UK, hydrazine hydrate was 
used as a substitute, using the appropriate number of equivalents. However, this method 
only formed trace amounts of tetrazine Tz2, and attempts to isolate this compound via this 
method were unsuccessful. This was attributed to the use of a lower concentration of 
hydrazine in the mixture, potentially lowering the rate at which the reaction occurred.   
More recently, the Deveraj group developed an alternative method for synthesising this type 
of tetrazine, utilising zinc and nickel salts as catalysts (Figure 112).[144]  
 
Figure 112. Devaraj’s synthesis of 1,2,4,5-tetrazines directly from nitriles catalyzed by Ni(OTf)2 or Zn(OTf)2
[144]
 
19 examples of this type of reaction were demonstrated, allowing for the formation of a 
mixture of symmetric and asymmetric tetrazines. A range of yields was reported, ranging 
from 12% to 95%, and the catalyst used was dependent upon the nitrile substrate selected. 
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It was hypothesised by Devaraj et al. that the metal ion acts as a Lewis acid for the formation 
of the amidrazone intermediate by coordinating to both the nitrile and the hydrazine.[145, 213] 
Alternatively, the metal may coordinate to the nitrile only, still promoting nucleophilic attack 
from the hydrazine (Figure 113).[214] 
 
Figure 113. Hilderbrand’s proposed reaction mechanism for the activation of nitriles by Lewis acid catalysis[144]  
The synthesis of tetrazine Tz2 was described using this method, and first involved the 
protection of the amine side-chain with a Boc group, which could prevent hydrolysis to the 
alcohol; a likely by-product of this reaction (Figure 114).[144]  
 
Figure 114. Devaraj’s synthesis of Boc-protected tetrazine Tz2[144] 
Due to the reportedly improved yields of tetrazine Tz2, attempts were made in order to follow 
the described literature procedure.[144] The protection of nitrile 85 was achieved in 
quantitative yields, and could be carried out on a gram-scale, allowing for formation of large 
quantities of Boc-protected material 87 for further reactions towards tetrazines. The Boc-
protected nitrile 88 was then reacted with formamidine acetate and hydrazine, with zinc 
triflate as the Lewis acid catalyst. DMF was also used as a co-solvent for synthesis of this 
particular tetrazine, owing to the poor solubility of the starting materials in hydrazine.[144]  
First attempts towards the synthesis of tetrazine via this method were carried out in 
hydrazine (1 M) in THF, and using this method the Boc-protected tetrazine 88 was formed in 
approximately 5% conversion after oxidation using sodium nitrite and HCl (1 M). The product 
88 could not be isolated using this method, and the low yields were presumably due to the 
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lower concentration of hydrazine in the mixture as compared to the anhydrous version used 
in the literature procedure. Similar results were obtained using hydrazine hydrate, and it was 
concluded that higher temperatures would be required in order to get the reaction to go to 
completion using this more dilute solution of hydrazine. However, attempts to carry out this 
reaction at 60°C resulted in the formation of unknown by-products, with only trace amounts 
of the desired product being formed.  
The same method was consequently applied to a similar tetrazine Tz3 (1-[4-(6-methyl-
1,2,4,5-tetrazin-3-yl)phenyl]methanamine), containing a methyl group at C3 of the tetrazine 
core. Temperatures of 60°C had been used for the synthesis of this compound following 
Devaraj’s literature procedure (Figure 115).[144] 
 
Figure 115. Structure of Tz3; the methyl group at C3 is expected to enhance stability 
The methyl group is reported by Hilderbrand et al. to increase the stability of the tetrazine 
relative to tetrazine Tz2, which could potentially make the compound easier to synthesise, as 
it is more stable to higher temperatures and harsher reaction conditions (Figure 116).[145] 
 
Figure 116. Hilderbrand’s demonstration of the stability of a series of tetrazines in FBS at 37°C after 10 h, showing the 
significance of introducing a methyl group onto C3[145] 
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This improved stability would also be advantageous when considering using the compound 
for radiolabelling (temperatures of 90°C are required for 68Ga labelling with DOTA), and later 
for in vivo applications. Tetrazine Tz3 was synthesised by reacting the Boc-protected nitrile 
87 with acetonitrile in hydrazine, this time using nickel triflate as the catalyst, with no 
problems associated with the solubility of the starting materials (Figure 117).  
 
Figure 117. Synthesis of tetrazine Tz3 from Boc-protected nitrile 87 
The literature procedure again relies on the use of anhydrous hydrazine, and so initial 
attempts towards the formation of the tetrazine were carried out using a 1 M hydrazine 
solution in THF. However, no product 89 was observed via this method, owing to the use of 
a low concentration of hydrazine solution. The reaction was consequently carried out using 
hydrazine hydrate (55-60%), which formed the Boc-protected tetrazine 89 in ~20% yield 
after oxidation and column chromatography when carried out at 60°C for 24 h. These yields 
could be improved significantly (up to 60%) by increasing the reaction time to 48 h, and by 
carrying out the reaction in a sealed tube. The Boc group in derivative 89 could then be 
removed by simple deprotection in TFA to form tetrazine Tz3 in quantitative yield. Tetrazine 
Tz3 could be obtained in overall yields of up to 59% from nitrile 87 on scales of up to 1g, 
making this a very attractive method for the synthesis of this compound.  
4.2 Evaluating the Reaction Kinetics of the IeDDA Reaction  
Due to the strong concentration dependence on rate of reaction demonstrated with the 
SPAAC reaction (see chapter 3), it was decided that a model IeDDA reaction should be 
evaluated for its concentration dependence. This would enable us to compare the two 
reactions directly, and evaluate their relative merits for use in vivo.   
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4.2.1 Introduction to Norbornenes as Dienopohiles in the IeDDA Reaction 
Norbornenes have been used extensively as the dienophile in the IeDDA reaction with 
tetrazines, due to the overall balance between their reactivity towards tetrazines and their 
general chemical stability. This example of an IeDDA reaction has been applied to a variety 
of in vivo applications for this reason. [115, 145, 211, 215] Additionally, a number of norbornenes 
containing functional handles are commercially available, allowing for straight-forward 
modifications of biological molecules to be made.  
The norbornene functional group demonstrates good reactivity as a dienophile with 
tetrazines, and its reaction with tetrazine Tz2 was evaluated in detail by Hilderbrand et al 
(Figure 118).[115] 
 
Figure 118. Hilderbrand’s demonstration of the reaction between tetrazine Tz2 and a norbornene dienophile 90 
Tetrazine Tz2 displayed a second-order rate constant of 1.9 M-1s-1 in aqueous buffer with 
norbornene analogue 90, which demonstrates the improved water-compatibility of these 
reactions as compared to the SPAAC reactions (rate constants for the SPAAC reactions 
were calculated in either acetonitrile or methanol). A rate constant of 1.6 M-1s-1 could also be 
demonstrated in FBS, further demonstrating the bioorthogonality of these reactions. 
4.2.2 Evaluating the Rate of the IeDDA Reaction at Varying Concentrations  
The incorporation of a methyl group at C3 of the tetrazine core was demonstrated to improve 
their stability in biological media, with marginal compromise to the reaction kinetics.[145] We 
therefore planned to evaluate the kinetics of tetrazine Tz3 in more detail, and in particular to 
focus on the effect of altering the concentration of the tetrazine on the rate of reaction with 
norbornene dienophiles. Unlike symmetrical tetrazine Tz1, tetrazine Tz3 was found to be 
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highly soluble in water; no difficulties were encountered dissolving the compound, even at 
the highest concentrations used. The rate of reaction of tetrazine Tz3 with commercially 
available norbornene analogue 91 was determined at varying concentrations, to evaluate if 
the reaction was likely to occur at concentrations comparable to those expected in vivo. The 
reaction was carried out in aqueous media at 37°C, to demonstrate most effectively the 
applicability of this reaction to biological environments (Figure 119). 
 
 
Figure 119. Reaction of tetrazine Tz3 with norbornene 91, resulting in four dihydropyridazine product regioisomers 
Due to its asymmetric structure, tetrazine Tz3, can react with alkenes via the IeDDA reaction 
to give four isomeric dihydropyridazine products (92a-d). Moreover, when using an 
asymmetric alkene such as norbornene 91, 8 isomeric products can form (the endo and exo 
isomers of products 92a-d). In the event, the reaction between tetrazine Tz3 and the 
norbornene 91 produced the four distinguishable dihydropyridazines (92a-d), which could be 
observed by monitoring the progress of the reaction using the UV detector on a HPLC 
instrument (Figure 120).   
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Tetrazine Tz3 was used as the standard in this reaction, and known concentrations of this 
compound were first injected into the HPLC instrument to confirm that lowering the 
concentration of tetrazine Tz3 decreased the area under the UV peak in a linear fashion, by 
plotting a calibration curve. This was found to be an accurate way to measure the change in 
concentration of the tetrazine, and so the AUC could be used to determine the effective 
change in tetrazine concentration in the reaction mixture.  
The progress of the reaction was subsequently monitored at 4 time-points: 5, 10, 30 and 60 
min, at each of the concentrations used. Due to the formation of multiple products, the 
consumption of the tetrazine Tz3 starting material was calculated. This data was plotted at 
each of the concentrations used (Figure 121). 
 
Figure 121. A plot of time (sec) vs. conversion (%), showing the effect of altering the initial concentration of Tz3 
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Figure 120. Example HPLC trace of the isomeric dihydropyridazine products 92a-d 
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It was concluded from these results that the rate of this IeDDA reaction was only weakly 
dependent on the concentration of the tetrazine Tz3, with the lowest measurable 
concentration (using this HPLC method) of 2.5 x 10-6 M allowing for the formation of the 
product in almost quantitative yields within 60 min. The most significant difference in 
conversion was observed within the first 5 min, but after 10 min the products had formed to 
almost the same extent, independent of the concentration of tetrazine used. Pleasingly, at all 
of the concentrations used, greater than 95% conversions to the dihydropyridazine products 
was achieved within 60 min, which suggests that this reaction may be suitable for an in vivo 
application.  
The lowest concentration measured for the cycloaddition reaction between tetrazine Tz3 and 
norbornene 91 was 10,000 times higher than the lowest concentration measured for the 
SPAAC reaction between cyclooctyne DIBAC1 and a simple azide, as described in chapter 
3. The highest conversion that was measured for the SPAAC reaction within 15 min to the 
triazole regioisomers from cyclooctyne DIBAC1 was 35%, which is almost 3 times lower 
than that which was achieved using this IeDDA reaction. In addition, the IeDDA reaction was 
carried out in aqueous media, whereas the SPAAC reaction was measured in MeCN, owing 
to the poor solubility of the cyclooctyne precursors in water.  
4.2.3 Conclusions 
In general, the cycloaddition reactions between tetrazines and strained alkenes appear to 
display great biocompatibility as compared to those between cyclooctynes and azides, 
combining excellent levels of reactivity at low temperatures and at low concentrations in 
water. The reaction between tetrazine Tz3 and norbornene 91, in particular, appears to be a 
promising bioorthogonal ligation reaction, demonstrating a favourable balance of reaction 
rate and stability in water. For this reason, it was hoped that this reaction could be useful for 
application to a pretargeting. The plan was to first validate this concept using a radiolabelled 
version of this reaction.  
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4.3 Radiolabelled IeDDA Reactions Using [68Ga]DOTA-Tz 
4.3.1 Hypothesis for a 68Ga - Labelled IeDDA Reaction 
Due to the promising results obtained from the concentration dependence studies, it was 
determined that a radiolabelled version of the cycloaddition reaction between tetrazine Tz3 
and norbornenes, and potentially other dienophiles, could be developed. This would initially 
involve the synthesis of a DOTA-tetrazine for labelling with 68Ga, which could then be 
reacted with a series of alkenes in order to demonstrate a radiolabelled IeDDA reaction.  
4.3.1 Synthesis of DOTA-Tz 
It was planned to construct a simple DOTA-tetrazine in which the tetrazine moiety is ligated 
via a free amine residue to one of the available carboxylic acids on DOTA. Thus, DOTA-Tz 
was synthesised by reacting the amine with a commercially available DOTA-NHS 73 (Figure 
122). 
 
Figure 122. Synthesis of DOTA-Tz using tetrazine Tz3 and DOTA-NHS ester 73 
DOTA-Tz could be isolated in much more acceptable yields (60%) than the previously 
synthesised DOTA-tetrazine 84 (cf. Figure 110), and could be isolated in high purity (>95%) 
after purification by preparative HPLC. Due to the enhanced total synthesis of DOTA-Tz as 
compared to the previous compound 84, in addition to the reportedly enhanced stability of 
this type of compound, we decided that this would be the initial construct to take forward to 
radiolabelling reactions, and studies would be carried out into the potential use of this 
compound for pretargeting applications.  
4.3.1 Radiosynthesis of [68Ga]DOTA-Tz 
Initial radiolabelling with tetrazine DOTA-Tz was challenging, resulting in only 40% 
radiochemical conversions from 68GaCl3. This was attributed to some traces of metal 
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impurity in the material as the synthesis of the tetrazine was achieved using Nickel salts, 
which were subsequently removed by carrying out a second purification by preparative 
HPLC.  
A number of different buffers of NaOAc, of varying pH values (ranging from 3.5 - 6.5), were 
evaluated for carrying out the radiolabelling reaction, and the optimum pH was found to be 6. 
Using these conditions, tetrazine DOTA-Tz was radiolabelled in up to 95% radiochemical 
conversions within 10 min at 90°C. The radiolabelled product [68Ga]DOTA-Tz could be 
obtained in >95% purity by use of a SepPak light C18 cartridge, in a similar manner as with 
the purification of labelled azide [68Ga]DOTA-Az (Figure 123).   
 
 
 
 
Figure 123. Radiosynthesis of [68Ga]DOTA-Tz and example HPLC trace of the purified product 
Up to 70% overall radiochemical yields (n.d.c) could be obtained ‘end-of-synthesis’ for this 
reaction, and the synthesis was found to be highly reproducible. The product was eluted in 
0.5 mL of pure ethanol, and could be divided into 100 µL fractions, with up to 2.5 mCi of 
activity being obtained in the most concentrated fractions, and these results were consistent 
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across each experiment (n > 10). The initial 68GaCl3 used in these experiments had an 
activity of 6.6 mCi at the start of the synthesis. The aliquots obtained were sufficient for the 
labelled product to be used for both in vitro and in vivo studies. 
The specific activity of [68Ga]DOTA-Tz was calculated for each of the fractions containing 
the product, in order to determine the relative amount of 68Ga-labelled compound as 
compared to the ‘cold’, non-radiolabelled materials. This is an essential factor when 
considering the use a compound as a potential radiotracer or chemical reporter, for 
application to in vivo pretargeting. This was calculated by injecting known concentrations of 
cold DOTA-Tz, and measuring the AUC at each known concentration. This data was plotted 
as a calibration of the concentration of DOTA-Tz against the AUC in the UV trace (Figure 
124). 
 
Figure 124. A plot of concentration of DOTA-Tz vs. AUC in the UV trace, used to calculate the specific activity 
This plot could be used to determine the concentration of ‘cold’ material in any injected 
sample of the radiolabelled tetrazine [68Ga]DOTA-Tz. This was subsequently used to 
calculate the specific activity of the sample. When starting the synthesis with approximately 
1 mCi of GaCl3, this value was found to be 17 Gbµmol-1.  
[68Ga]DOTA-Tz was additionally tested for its stability in PBS, in order to ascertain whether it 
would be suitable for in vivo applications (Figure 125).  
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Figure 125. A plot demonstrating the stability of [68Ga]DOTA-Tz after 1 and 2 h incubation in PBS, as monitored by the 
permanence of the [68Ga]DOTA-Tz radio-HPLC trace  
Pleasingly, the compound demonstrated good stability after 1 and 2 h incubation in PBS, 
showing no decomposition products within this time-frame. This is significant when 
considering this compound as a potential chemical reporter, as the radiolabelled tetrazine 
must remain stable throughout the pretargeting experiment. Due to these results, it was 
established that the radiolabelled tetrazine [68Ga]DOTA-Tz would be a suitable compound 
for use as a chemical reporter in the hypothesised pretargeting strategy. In order to confirm 
this, it was necessary to demonstrate the reactivity of this compound towards alkenes, and 
show that it displays a good level of biocompatibility. 
4.3.2 Demonstrating the 68Ga - Labelled IeDDA Reaction 
The radiolabelled tetrazine [68Ga]DOTA-Tz was reacted with a series of alkenes in order to 
demonstrate that the IeDDA reaction, could be carried out using this compound, and in order 
to find the most appropriate coupling partner for pretargeting (Table 11).  
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a Each reaction was carried out using 100 µL of [68Ga]DOTA-Tz  (typical activity of ~ 5 MBq); n = 3 in all cases. 
bRadiochemical yield as determined via radio-HPLC showing conversion of [68Ga]DOTA-Tz into the summation of the 
product isomers. cDecomposition of [68Ga]DOTA-Tz  was observed 
Table 11. Radiolabelled IeDDA reactions between a series of alkenes and [68Ga]DOTA-Tz under different conditions 
The reaction was initially carried out using ethyl vinyl ether 93, in order to demonstrate that 
the tetrazine is reactive towards alkenes which do not contain any ring strain, but which are 
electronically activated. Ethyl vinyl ether 93 gave approximately 10% conversion to the 
corresponding dihydropyridazine product from [68Ga]DOTA-Tz at 37°C in 10 min (Entry 1, 
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Table 11), and increasing the temperature to 90°C (Entry 2, Table 11) increased this 
conversion to nearly 30% (Figure 126).   
 
 
 
 
 
 
Figure 126.  Radio-HPLC traces of a) The reaction mixture between [68Ga]DOTA-Tz and 93 at: 37°C in H2O after 10 min, 90°C 
in H2O after 10 min 
Although these results were not very impressive when compared to the strain-promoted 
reactions, and the reaction lacks the same levels of bioorthogonality, this demonstrates the 
possible utility of labelled tetrazines such as [68Ga]DOTA-Tz for a wide range of labelling 
applications. For example, it could be envisaged that these conversions could be greatly 
enhanced by optimisation of the reaction conditions, through use of different co-solvents and 
by increasing the reaction temperatures and time. 
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As mentioned, norbornenes have been shown to react rapidly with tetrazines, due to the 
large amount of strain contained in the alkene. [115, 215] It was not surprising therefore to find 
that radiolabelled tetrazine [68Ga]DOTA-Tz showed high levels of reactivity with this alkene 
(Figure 127). 
 
 
 
Figure 127. Radio-HPLC traces of a) The reaction mixture between [68Ga]DOTA-Tz and 91 at 37°C in H2O after 10 min; b) The 
same reaction mixture after 20 min 
The conversion to the 4 dihydropyridazine products [68Ga]96 was measured using the AUC 
for the starting material [68Ga]DOTA-Tz radio-HPLC peak, as compared to the summation of 
the AUC for the radio-HPLC peaks of the products. When the carboxylic acid functionalised 
norbornene 91 was reacted with [68Ga]DOTA-Tz at 37°C in H2O for 10 min, almost 80% 
radiochemical conversion to the dihydropyridazine isomers was observed within just 10 min 
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(Entry 3, Table 11). Almost quantitative conversion to [68Ga]96 was achieved within 20 min 
under the same conditions (Entry 4, Table 11). 
Due to the impressive yields obtained in the reaction of radiolabelled tetrazine [68Ga]DOTA-
Tz with norbornene 91, a series of modified norbornenes were reacted with [68Ga]DOTA-Tz, 
in order to demonstrate that the tetrazine ligation could be carried out using norbornenes 
containing different side-chains (Entries 6-10, Table 11). 
The effect of altering the side chain on norbornene was demonstrated by reacting the 
radiolabelled tetrazine [68Ga]DOTA-Tz with a number of fluoroaniline derivatives of 
norbornene 91 (100-102). These compounds were synthesised using the amine coupling 
reaction between the carboxylic acid 91 and the respective fluoroanilines 104 and 105 
(Figure 128). 
 
Figure 128. Reaction of norbornene-carboxylic acid 91 with a) 3-fluoroaniline 104 and b) 4-fluoroaniline 105 
The products from these reactions were obtained in good yield (>70%) and were isolated as 
separate endo and exo regioisomers after column chromatography and recrystallisation from 
a mixture of ethyl acetate and hexane. 
Introducing the fluoroaniline side-chain appeared to have a pronounced effect on the 
radiochemical conversion to the dihydropyridazine products within 10 min. This may, at least 
in part, be attributable to their reduced water solubility as compared to compound 91. The 
lower reactivity of radiolabelled tetrazine [68Ga]DOTA-Tz towards these compounds may 
also have been due to the introduction of a slightly larger side-chain, as the most significant 
difference in the rate was observed with the exo isomers 100/102, which formed the 
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respective dihydropyridazine products in ~20-25% conversions in 10 min at 37°C (Entries 6, 
7 and 9, Table 11). The endo 4-fluoroaniline analogue 101 showed the most comparable 
reaction rate to norbornene 91, forming the products in ~50% conversion (vs. 80% for 91) 
within 10 min at 37°C (Entry 10, Table 11) which may reflect the better alignment between 
the tetrazine and the double bond in the transition state for the cycloaddition (Figure 129).  
 
 
Figure 129. Possible transition states for the favoured (exo) orientation between the tetrazine [68Ga]DOTA-Tz and norbornenes 
101 and 102 
In order to demonstrate the biocompatibility of the IeDDA reaction, we also tested the 
reactivity of the tetrazine towards L-tryptophan 103; an “alkene”-containing α-amino acid, 
which is found in high abundance in the human body. Reaction of [68Ga]DOTA-Tz with this 
compound under physiological conditions would hinder the use of this strategy in biological 
applications, such as pretargeted imaging. However, despite containing an alkene, which 
displays enamine type reactivity despite also being part of the aromatic indole ring, 
compound 103 did not show any reactivity towards out tetrazine under these conditions 
(Entry 11, Table 11), eliminating this as a potential problem, and demonstrating further the 
reaction’s utility in biological applications.   
In order to make a direct comparison with the SPAAC reaction, the reaction with the ‘simple’ 
norbornene was also carried out in acetonitrile as solvent. However, rather than observing 
the expected dihydropyridazine products, a different product was formed which had a similar 
retention time to the radiolabelled tetrazine [68Ga]DOTA-Tz. It was proposed that this 
product was formed as a result of a different cycloaddition reaction between the tetrazine 
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and the nitrile moiety of acetonitrile, presumably by a similar mechanism to that proposed for 
the reaction of tetrazines with isonitriles.[216] 
Each of the alkenes used in the radiolabelling experiment was reacted with ‘cold’ tetrazine 
DOTA-Tz, and the products were conjugated with 69Ga using Ga(NO3)3, in order to confirm 
the products formed from the radiolabelling experiment (Figure 130).  
 
 
Figure 130. Synthesis of ‘cold’ labelled dihydropyridazine products 
All of the ‘cold’ labelled compounds were characterised by HRMS and the products 94-99 
obtained from these reactions were additionally used as ‘cold references’ for confirmation of 
the identity of the radiolabelled products (see experimental section for more details).  
4.3.3 Conclusions 
The readily synthesised 68Ga-labelled tetrazine [68Ga]DOTA-Tz was demonstrated as useful 
prosthetic group for radiolabelling of an array of small molecules via bioorthogonal 
chemistry. Norbornenes, in particular, appeared to show impressive reaction rates with the 
radiolabelled tetrazine, and may be considered as a potential chemical handle for the 
pretargeting approach. These reactions could be applied to the labelling of suitably 
functionalised biomolecules, and ultimately could be applied to pretargeted imaging. 
Moreover, it was anticipated that the already impressive rates could be improved, for 
example by use of a more strained dienophile, which would expand further the potential for 
these compounds to be used for a wide range of applications.  
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4.4. Overall Conclusions 
The main advantages of the IeDDA cycloaddition over the SPAAC reaction include the 
improved compatibility with aqueous media, and the ability to achieve reasonable to high 
radiochemical conversions at low temperatures (37°C), and at low concentrations. In 
addition to this was the more achievable synthesis of the tetrazine precursors (which may be 
prepared in just 1 step) as compared to cyclooctynes. Dienophiles such as norbornene are 
commercially available, containing functional groups which enable simple modifications to be 
made, such as ligation to biomolecules.  
For these reasons, radiolabelled tetrazine [68Ga]DOTA-Tz could be used for a number of 
applications, including labelling biomolecules containing strained alkenes such as 
norbornenes or TCO.[217] The radiolabelled tetrazine [68Ga]DOTA-Tz additionally 
demonstrated good stability in PBS within 2 h, complying with a high level of biocompatibility. 
It was therefore imagined that the prosthetic group [68Ga]DOTA-Tz may be considered as a 
potential chemical reporter for the  hypothesised pretargeting strategy, and this idea would 
consequently be explored in more detail.  
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5.1  RGD Cyclic Pentapeptides for an Attempted in vitro IeDDA Reaction  
5.1.1 Hypothesis for Pretargeting Using RGD Cyclic Pentapeptides 
Due to the large size, and ensuing difficulties involved in the characterisation of antibodies, 
we hypothesised that it would be worthwhile validating the IeDDA using smaller 
biomolecules such as peptides. As directly-labelled cyclic RGD peptides are already being 
evaluated as tracers for PET imaging, it would be possible to compare the developed direct 
targeting method, in which the radiolabelled RGD peptide is introduced directly onto high 
αvβ3 integrin expressing cells, with the postulated pretargeting strategy.[218-224]  Based on the 
promising reactivity of norbornene in the IeDDA reaction with the radiolabelled tetrazine 
[68Ga]DOTA-Tz, as discussed in Chapter 4, this strategy would involve ligating the 
norbornene to a cyclic RGD pentapeptide. Accumulation of the modified peptide onto high 
αvβ3 integrin cells would be followed by introduction of the radiolabelled chemical reporter 
[68Ga]DOTA-Tz, with the expectation that the IeDDA reaction would occur on the cell 
surface (Figure 131).  
 
Figure 131. Proposed in vitro pretargeting between RGD cyclic pentapeptides (RGD) ligated with a norbornene functional 
group (NB) and [68Ga]DOTA-Tz 
It was anticipated that this method would help to provide us with proof-of-principle for 
pretargeting using the IeDDA reaction using the tetrazine/norbornene reaction partner.  
5.1.2 Introduction to RGD Cyclopentapeptides for Targeting αvβ3 Integrin 
The integrin family are heterodimers of 19 α- and 8 β- subunits non-covalently imbedded into 
the cell membrane, for which there are 25 known members.[218] The binding of integrins to 
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their respective ligands plays a critical role in processes such as cell attachment, 
proliferation, tumour invasion, angiogenesis and metastasis, as well as a number of other 
significant pathological events. For this reason, integrins have been utilised as targets for 
cancer therapy and imaging, and αvβ3 integrin has been extensively evaluated for its role in 
tumour growth and angiogenesis.  
The αvβ3 receptor ligand has demonstrated good affinity for the RGD (Arg-Gly-Asp) tripeptide 
sequence, as it is the minimum sequence in naturally-occurring ligands that bind the αvβ3 
receptor, and for this reason peptides containing this sequence have often been used as 
targets for the receptor over other integrins. Linear RGD peptides, for example GRGDS (Gly-
Arg-Gly-Asp-Ser), often have lower affinity (IC50 > 100 nM) than cyclised RGD peptides, as 
the fourth amino acid alters the binding specificity and are often susceptible to chemical 
degradation.[225] Structure-activity-relationship (SAR) studies have shown that incorporating 
the RGD sequence into a cyclic pentapeptide framework leads to further selectivity and 
binding affinity for the receptor. The rigidity that is conferred by cyclisation prevents 
degradation, and for this reason, cyclic peptides are more stable, potent and specific for the 
αvβ3 receptor. Additional amino acids are required to build the ring system, and the RGD 
sequence can be placed in a conformation that is specific for the integrin. For example, 
c(RGDfK) is one of such cyclic pentapeptides, whereby an unnatural D-Phe amino acid and a 
lysine (K) residue has been incorporated (Figure 132). 
  
Figure 132. (left) the original straight-chain Arg-Gly-Asp (RGD) tripeptide sequence, (middle) c(RGDfK); an example of a cyclic 
pentapeptide incorporating a D-Phe amino acid and a lysine residue (right) ‘RGD-NB’, the hypothesised modified cyclic 
pentapeptide incorporating a norbornene moiety  
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As a consequence of the high selectivity of RGD cyclic pentapeptides to the αvβ3 receptor 
binding site, these peptides have been evaluated as PET potential tracers for imaging 
angiogenesis in tumours by direct labelling of the peptides, for example through introduction 
of a DOTA or NOTA chelate for 68Ga labelling.[218-224] 
5.1.3 Synthesis of a Norbornene Modified RGD Cyclopentapeptide 
In light of the reactivity of norbornene derivatives in the radiolabelling studies and kinetic 
experiments described in chapter 4, we envisaged synthesis of a norbornene-functionalised 
RGD peptide, which would be reactive towards radiolabelled tetrazine [68Ga]DOTA-Tz. The 
norbornene moiety was introduced onto the lysine residue of the peptide, as it has been 
demonstrated that functionalising this amino acid has little effect on the binding affinity of 
RGD to the αvβ3 receptor.[224] The RGD cyclic pentapeptide was synthesised on a 2-
chlorotrityl resin using a solid-support peptide coupling procedure, which has previously 
been described for the synthesis of this peptide sequence. Introduction of the norbornene 
group was carried out with the peptide still on the solid support, as three additional amino 
acid residues were required to complete the peptide sequence after introduction of this 
group (Figure 133).[43, 224, 225]  
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Figure 133. Synthesis of the RGD cyclic pentapeptide RGD-NB on a 2-chlorotrityl resin.  
Once the amino acid sequence was completed, the fully functionalised peptide was cleaved 
from the resin and the cyclisation reaction was carried out using a mixture of sodium 
bicarbonate and DPPA in DMF. The remaining protecting groups (tert-butyl and Pbf) were 
subsequently removed using a mixture of TFA, TIS and water to give the final crude peptide 
RGD-NB in an overall yield of 15%. The obtained peptide was purified, first by precipitating 
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in diethyl ether to form a white solid, and then using preparative HPLC to obtain the pure 
peptide.  
An alternative method was additionally used for synthesis of the modified peptide RGD-NB, 
which was achieved in 60% overall yield from commercially available protected cyclic RGD 
peptide 104 (Figure 134).  
 
 
Figure 134. An alternative method used for the synthesis of RGD-NB from commercially available protected c(RGDfK) 104 
using NB-NHS  
This method involved coupling a norbornene-NHS ester to the available lysine residue on 
peptide 104. The modified peptide RGD-NB was deprotected under the same deprotection 
conditions as before, using a mixture of TFA, TIS, and water, and the resulting material was 
purified as previously described. All of the obtained peptide products were characterised by 
HRMS and the purity was confirmed using analytical HPLC (see experimental section for 
example spectra and HPLC traces). 
5.1.4 In Vitro Control Experiments by Direct Targeting  
Two control experiments were carried out in order to validate the RGD binding affinity using 
the assay that would be used for the pretargeting strategy. The first of these control 
experiments was carried out using a DOTA-containing RGD-dimer, which is a commercially 
available peptide and is routinely labelled using 68Ga. This peptide has been demonstrated 
to show a higher affinity for the αvβ3 receptor than the monomeric peptide, and so may be 
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considered an alternative structure for modification in the future.[220, 226] The second control 
experiment was carried out using a DOTA-containing RGD-monomer, which is structurally 
more similar to the modified peptide RGD-NB, and was synthesised on the 2-chlorotrityl 
resin as described previously (cf. Figure 133). Both of the control RGD peptides were 
labelled with 68Ga using similar conditions to those described for the radiolabelled DOTA-
tetrazine [68Ga]DOTA-Tz (Figure 135).[224] 
 
Figure 135. Radiosynthesis of [68Ga]RGD-dimer and [68Ga]RGD-monomer  
The two labelled peptides were obtained in good overall radiochemical yields (60% and 70% 
n.d.c at the end of synthesis). The slightly lower than expected yields for [68Ga]RGD-dimer 
were a result of the difficulties in eluting the compound from the C18 cartridge, which 
consequently lead to a portion of the activity being retained on the cartridge. In both cases, 
however, the radiolabelling was achieved in >95% radiochemical conversion from 68GaCl3, 
with >95% radiochemical purity (n = 3 for both reactions), and sufficient material was 
obtained for carrying out the proposed biology experiments.  
Cell lines, each expressing different levels of αvβ3 integrin receptor, were treated directly with 
the radiolabelled RGD peptides. Each experiment was repeated at least three times in order 
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to validate the assay for potential use for the pretargeting approach, which was to be 
demonstrated in ensuing experiments (Figure 136). 
a)  
b)  
Figure 136. Control in vitro experiments using ‘direct’ targeting* Low (M21L) and high (U87.CD4 and M21) αvβ3 integrin 
expressing cell lines were treated with with a) 50 µCi [68Ga]RGD-dimer (white bars), or 1 µM  RGD-dimer for 30 min + 50 µCi 
[68Ga]RGD-dimer (black bars); b) 50 µCi [68Ga]RGD monomer (white bars), or 1 µM  RGD-monomer for 30 min + [68Ga]RGD 
monomer (black bars). The bars represent the mean uptake of 68Ga in each cell line after 30 min incubation. Error bars 
represent the standard errors of the mean. *In vitro work was carried out by Dr Quang-De Nguyen. 
As anticipated, the radiolabelled dimeric peptide [68Ga]RGD-dimer showed the highest 
levels of affinity towards the high αvβ3 integrin expressing cell line (U87.CD4), as evidenced 
by the highest uptake of radioactivity in these cells.[226] Pre-treating these cells with the ‘cold’ 
peptide RGD-dimer showed a marked reduction of the uptake in these cells, presumably 
due to blocking of the αvβ3 integrin receptors.  
The second control experiment was required as it provided a more accurate demonstration 
of the binding affinity of a single molecule of RGD, and gave an indication as to the levels of 
uptake that we might expect to achieve using the pretargeted approach. The smaller peptide 
[68Ga]RGD-monomer expressed similar levels of activity on the high integrin expressing cell 
line (U87.CD4) as the larger dimeric peptide. However, there was no apparent difference 
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between the cell lines which were blocked with ‘cold’ peptide RGD-monomer and those 
which were not pre-treated, suggesting a substantially lower overall affinity for the αvβ3 
integrin receptor than the dimeric peptide. This was later confirmed by blocking the cells with 
the ‘cold’ dimeric peptide RGD-dimer, which showed a more significant decrease in the 
observed activity following treatment with radiolabelled monomeric peptide [68Ga]RGD-
monomer. 
As a consequence of these preliminary studies, it was decided that the dimeric peptide 
RGD-dimer would be used for carrying out the blocking studies for the proposed in vitro 
pretargeting. As this peptide showed the highest overall affinity for the receptor, this would in 
theory allow for the greatest difference in signal between the pre-treated cells and those 
which were not blocked by the peptide to be demonstrated.  
5.1.4 Attempted In Vitro Pretargeting Using Norbornene Modified RGD 
The cell lines used for the previous control experiments were used for application to the 
pretargeting strategy. This first involved incubating the cells with the modified peptide RGD-
NB for 30 min, followed by treatment with approximately 50 µCi of the radiolabelled tetrazine 
[68Ga]DOTA-Tz per well (Figure 137). 
 
Figure 137. Attempted in vitro pretargeting* Low (M21L) and high (U87.CD4 and M21) αvβ3 integrin expressing cell lines 
were treated with a) 1 µM RGD-NB for 30 min + 50 µCi of [68Ga]DOTA-Tz (white bars); b) (1 µM RGD-dimer + 1 µM RGD-NB ) 
for 30 min + 50 µCi of [68Ga]DOTA-Tz (black bars) . The bars represent the mean uptake of 68Ga in each cell line after 30 min 
incubation. Error bars represent the standard errors of the mean. *In vitro work was carried out by Dr Quang-De Nguyen. 
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Unlike with the control experiment with RGD-dimer, the pattern of activity in each cell line 
suggested that non-specific binding was occurring. Specifically, the low uptake pattern in the 
low expressing cell line (M21L) was not substantially different to the higher expressing cell 
lines (M21 and U87.CD4) and none of the observed activity could be successfully blocked by 
the dimeric peptide. This suggested that the observed activity was caused by background 
from the radiolabelled tetrazine [68Ga]DOTA-Tz, rather than been related to the affinity of the 
monomeric peptide, or by the IeDDA reaction occurring on the surface of the cells. This was 
additionally confirmed by treating the cells with the tetrazine [68Ga]DOTA-Tz only, which 
displayed similarly high levels of activity. 
It was concluded from these experiments that either the IeDDA reaction was not occurring 
on the cells, or that the monomeric peptide RGD-monomer did not have high enough affinity 
for the αvβ3 integrin receptor, suggesting that some further optimisation would be required in 
order to achieve significant results in vitro.  
The first strategy explored in order to improve the in vitro reaction was to validate the 
reaction in a vial, using the functionalised peptide, with the intention to improve the reactivity 
of the two cycloaddition partners. Surprisingly, when the reaction between the modified 
peptide RGD-NB and the radiolabelled tetrazine [68Ga]DOTA-Tz was attempted in a vial, no 
product was formed, as determined by monitoring the reaction on the radio-HPLC trace after 
15, 30 or 60 min after incubation in PBS at 37°C. These observations were attributed to the 
reactive site (i.e. the alkene functional group) perhaps having become too hindered by the 
large cyclic pentapeptide structure to allow reaction with the tetrazine. 
Due to these findings, a PEG3 chain was introduced in order to create more distance 
between the RGD structure and the reactive norbornene, with the hope that this would 
enhance the reactivity of the available alkene functional group towards ligation with the 
tetrazine (Figure 138).   
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Figure 138. An alternative RGD peptide, RGD-PEG3-NB  
This compound was synthesised in the same manner as the original modified peptide RGD-
NB (cf. Figure 133). However, even this peptide RGD-PEG3-NB did not show any reaction 
with the radiolabelled tetrazine [68Ga]DOTA-Tz under the conditions used. This result 
suggested that the reason for the lack of reactivity between the tetrazine and the modified 
peptides could be more complex than at first glance. It was concluded that further 
optimisation of the reaction partners would be required in order to validate the IeDDA 
reaction in vitro.  
5.1.6 Conclusions 
None of the norbornene-modified RGD cyclic pentapeptides developed so far had 
demonstrated the expected reactivity with radiolabelled tetrazine [68Ga]DOTA-Tz in a vial or 
in vitro. However, cyclic RGD peptides have previously been used for carrying out ‘click’-type 
reactions with 18F-labelled prosthetic groups, and so these results may be considered 
unexpected, especially considering the reactivity of norbornenes towards the radiolabelled 
tetrazine [68Ga]DOTA-Tz in previous experiments.[63] It was concluded, therefore, that further 
modifications needed to be made in order for the IeDDA reaction to be demonstrated for the 
required pretargeting approach.  
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5.2  An Alternative DOTA-Tetrazine for 68Ga Radiolabelling 
5.2.1 Synthesis of DOTA-GA-Tz 
Due to the observed lack of reactivity of our radiolabelled tetrazine [68Ga]DOTA-Tz towards 
the norbornene-modified RGD peptides, an alternative method towards improving the 
reactivity was explored. It was hypothesised that the introduction of a linker between the 
DOTA chelate and the tetrazine moiety might improve the availability of the tetrazine for 
cycloaddition with alkenes containing bulky side-chains, such as biomolecules. An 
alternative DOTA-ligated tetrazine DOTA-GA-Tz was therefore synthesised from tetrazine 
Tz3. The synthesis of this compound involved introduction of a carboxylic acid side-chain 
onto tetrazine Tz3, initially by reaction of the amine residue with glutaric anhydride. Unlike 
when the same reaction was carried out with symmetrical tetrazine Tz1 (cf. section 4.1), this 
reaction proceeded efficiently, affording the acid product 105 in almost quantitative yields 
after purification by column chromatography (Figure 139).  
 
Figure 139. Synthesis of DOTA-GA-Tz from Tz3 
Chapter 5 - Application of the IeDDA reaction to pretargeting 
 
182 
 
A simple reaction of the carboxylic acid 105 with NHS allowed for the formation of a 
succinimide ester activated acid derivative 106, which could subsequently be reacted with 
the free amine on the DOTA-derivative 107 in the presence of a mild base. The final DOTA 
analogue DOTA-GA-Tz could be purified by preparative HPLC, and was isolated in 40% 
yield. The lower than expected yield for this final step was a consequence of problems 
during purification; the multiple protonation states in the product resulted in the product 
eluting from the HPLC at different retention times. This situation could be moderately 
improved by dissolving the crude material in acidic media prior to purification.  
5.2.2 Radiosynthesis of [68Ga]DOTA-GA-Tz 
The structurally modified DOTA chelate containing the tetrazine moiety DOTA-GA-Tz was 
radiolabelled under the same conditions as the original compound DOTA-Tz, and up to 95% 
conversions to the labelled product were observed from 68GaCl3 when the reaction was 
carried out in pH6 NaOAc buffer. The crude material could be purified by passing through a 
Sep-Pak light C18 cartridge, as was described for the radiosynthesis of previously labelled 
[68Ga]DOTA-Tz (see section 4.3), forming the radiolabelled product in >95 % radiochemical 
purity (Figure 140). 
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Figure 140. Radiosynthesis of [68Ga]DOTA-GA-Tz from DOTA-GA-Tz, and radio-HPLC trace of purified [68Ga]DOTA-GA-Tz 
The 68Ga-labelled product was obtained by treating the conditioned C18 cartridge with the 
crude material, and subsequently washing with 500 µL of water, before eluting the product in 
five 100 µL fractions of ethanol. When starting the reaction with 6.8 mCi of 68GaCl3, a 
maximum of 2.5 mCi of the product could be eluted in the most concentrated fraction, with a 
total of  4.7 mCi of the product being obtained ‘end-of-synthesis’; equivalent to a 
radiochemical yield of 70% (n.d.c).  
The specific activity of the obtained fractions of radiolabelled tetrazine [68Ga]DOTA-GA-Tz 
was calculated in a similar manner to the previously purified compound [68Ga]DOTA-Tz (cf. 
section 4.3). Known concentrations of ‘cold’ compound were injected, and the AUC was 
measured at each of the known concentrations, providing a linear plot, which could be used 
to calculate the concentration of the non-labelled compound in the sample (Figure 141).  
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Figure 141. A graph showing [DOTA-GA-Tz3] vs. the measured AUC from the UV trace, used to measure the specific activity 
of [68Ga]DOTA-GA-Tz3 
Initially, the specific activity of the labelled compound was calculated at 162 µCi µmol-1, as 
determined from the synthesis starting with approximately 900 µCi of 68GaCl3. This specific 
activity was obtained using 50 µL of a 1 mgmL-1 solution of the DOTA-GA-Tz (equivalent to 
0.06 µmol) at the start of the synthesis. Using 6.5 mCi of 68GaCl3 at the start of the 
synthesis, the specific activity could be improved to 540 µCi µmol-1 (using a new 68Ga 
generator), using the same amount of precursor DOTA-GA-Tz. This could be significantly 
enhanced by using only 25 µL of the stock solution of DOTA-GA-Tz (0.03 µmol). Using 
these parameters, the purified compound could be obtained with a specific activity of up 
to1.5 Ci µmol-1, and this value was calculated for each of the radiolabelling experiments that 
were carried out, and was found to be consistent across each subsequent experiment (n > 
10).  
In order to demonstrate the biocompatibility of this compound further, the stability of this 
compound was tested, by incubating ~100 µCi of conjugate [68Ga]DOTA-GA-Tz in PBS. The 
radio-HPLC of the solution was taken after 1 and 2 h after incubation at 40°C, and the 
experiment was repeated at least 3 times in order to ensure reproducibility (Figure 142). 
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Figure 142.  A graph demonstrating the stability of [68Ga]DOTA-GA-Tz in PBS buffer after 1 and 2 h 
As was observed when carrying out the same experiment with the original radiolabelled 
tetrazine [68Ga]DOTA-Tz, no decomposition of the radiolabelled product was observed at the 
time-points measured, suggesting that this compound would be similarly stable in a 
biological environment, and importantly, in vivo.  
Due to the high purity, and good specific activity of the radiolabelled tetrazine [68Ga]DOTA-
GA-Tz, we hypothesised that this compound could be used as an alternative to the 
previously radiolabelled tetrazine [68Ga]DOTA-Tz as a chemical reporter in the pretargeting 
strategy, with the hope that introduction of the linker would make the tetrazine more 
available for reaction with highly substituted dienophiles, such as the norbornene 
functionalised RGD peptides.  
5.2.3 Testing the IeDDA Reaction with [68Ga]DOTA-GA-Tz  
Unfortunately, attempted reaction between the radiolabelled tetrazine [68Ga]DOTA-GA-Tz 
and the modified peptides RGD-NB and RGD-PEG3-NB, were unsuccessful (Figure 143).  
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Figure 143. Attempted reaction between [68Ga]DOTA-GA-Tz and a) RGD-NB and b) RGD-PEG3-NB  
The lack of reactivity of the modified radiolabelled tetrazine [68Ga]DOTA-GA-Tz towards 
both of the RGD cyclic pentapeptides, suggests that the cyclic peptide was in some way 
hindering the reactivity of the dienophile towards reaction with the tetrazine. One possible 
explanation for this observation is that the chain containing the strained alkene adopted a 
folded conformation inside the structure of the cyclic RGD, and subsequently blocked the 
alkene functional group from being available for reaction. Future work could therefore be to 
synthesise a linear RGD peptide in order to test this hypothesis. It should be noted however, 
that the linear structure does not have the same binding affinity for the αvβ3 integrin receptor 
as the cyclic peptide, and so it would not enable us to fully demonstrate the proof-of-principle 
concept for pretargeting by direct comparison to the direct targeting approach.[225] A  similar 
reaction, however, was demonstrated by Conti and co-workers between an 18F-labelled TCO 
and a tetrazine-modified cyclic RGD peptide, suggesting the problems in reactivity that we 
observed may instead have been caused by the lower reaction rate of the norbornene 
moiety as compared to TCO towards IeDDA reactions with tetrazines.[227] 
5.2.4 Conclusions  
As a result of these observations, it was concluded that more detailed characterisation of the 
structure of the RGD peptides would be required in order to fully understand the negative 
results obtained. As was observed with the radiolabelling studies between the radiolabelled 
tetrazine [68Ga]DOTA-Tz and norbornenes (see chapter 4), the addition of even a small a 
side-chain can have a significant effect on the reactivity of an appended dienophile towards 
tetrazines. An alternative strategy would be to introduce a greater number of norbornene 
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functional groups per biomolecule, which would be difficult to achieve using relatively small 
biomolecules such as the RGD peptides, without significantly altering the binding affinity. An 
alternative biomolecule would be preferable for validating the pretargeting strategy, which 
would allow for the addition of multiple dienophiles, and would moreover increase the 
probability of the reaction occurring. It was additionally considered that a more reactive 
dienophile would circumvent the problems observed with the reactivity of the modified 
biomolecules, as the increased rate of the cycloaddition must outweigh any steric problems 
that may prevent the reaction from occurring.  
5.3  In Vitro Pretargeting Using TCO Modified Cetuximab   
5.3.1 Hypothesis for Pretargeting Using Cetuximab-TCO  
Monoclonal antibodies, as discussed previously, are particularly amenable to pretargeting 
due to the balance between high affinity and specificity for their receptors, coupled with slow 
physiological half-lives, circulation time and clearance.[139, 143, 228, 229]  Due to the apparently 
high reactivity of the TCO dienophile towards tetrazines, it was hypothesised that this could 
be ligated to the Cetuximab (C225) monoclonal antibody for subsequent application to a 
pretargeting strategy, using radiolabelled tetrazine [68Ga]DOTA-GA-Tz as the chemical 
reporter (Figure 144). 
 
Figure 144. Proposed in vitro pretargeting between Cetuximab (C225) ligated with a TCO functional group  
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5.3.2 Introduction to Cetuximab as an Antibody for EGFR 
Cetuximab (Erbitux/C225) is a monoclonal antibody that is used for treatment of colorectal 
cancer and head and neck cancer, by inhibiting the epidermal growth factor receptor 
(EGFR).[230] Growth factors bind to their respective receptors on the surface of the cell, which 
causes the receptors to produce a signal, ultimately leading to cell division.[231, 232] Mutated 
receptors may lead to the production of a signal which causes the cells to divide without the 
use of a growth factor, and hence cause uncontrolled proliferation, which may ultimately lead 
to cancer. The inhibition of these receptors, for example using the C225 antibody, 
subsequently prevents the uncontrolled growth of cells in EGFR mutated cancers.  
It was anticipated that this monoclonal antibody could be used for the pretargeting strategy, 
as it has high affinity for the EGFR receptor, and could be used to target cells over-
expressing EGFR, prior to introduction of the radiolabelled chemical reporter. Significantly, 
C225 would not be readily internalised into the cell, which is an important consideration in 
order to achieve pretargeting, especially when using a non-cell penetrating chemical 
reporter.  
5.3.3 Introduction to trans-Cyclooctenes (TCOs) as Dienophiles 
As was observed during the radiolabelling experiments between tetrazine [68Ga]DOTA-Tz 
and the series of alkenes that altering the side-chain of the norbornene can have a 
significant effect on the rate of reaction with the tetrazine (see section 4.3). When large 
cyclic peptides such as the RGD cyclopentapeptide are used as the side-chain, it may be 
expected that this effect will be even more significant. We therefore decided to explore the 
use of a more reactive alkene in place of the norbornene. The hope was that the improved 
reaction kinetics of the small molecule with tetrazines would out-weigh any steric problems 
that may be caused by the peptide.  
Trans-cyclooctenes (TCOs) have received increasing attention as the dienophile in the 
IeDDA reaction with tetrazines.[116, 136, 140, 147, 217, 233-240] These highly strained alkenes 
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demonstrate superior reaction kinetics with tetrazines over norbornenes, due to the 
increased strain that is imposed on the double bond; Weissleider and co-workers measured 
second order rate constants of 6000 ± 200  M−1  s−1 at 37°C for TCO, as compared to 
previously measured rate constants of 1.6  M−1  s−1 at 20°C for norbornene using the same 
tetrazine.[115, 140, 207] The mechanism of the reaction is similar to that described for the IeDDA 
reaction with norbornenes (see chapter 4), and in the presence of protic solvents the 
intermediate dihydropyridizine rearranges to form isomeric dihydropyridazines products 
(Figure 145).[116] 
 
 
Figure 145. The IeDDA reaction between tetrazines and TCO to form dihydropyridazines, showing the mechanism of the 
cycloaddition and the intermediate dihydropyridizine formed 
However, this increase in reactivity is balanced by a slightly lower in vivo stability due to the 
spontaneous trans/cis isomerism which may occur over time.[138, 241] The synthesis of trans 
cyclooctenes requires photochemical irradiation of the corresponding cis isomers,[217] but 
fortunately the increasing interest in the IeDDA reaction means that a number of these 
compounds are now commercially available, containing a range of functional side-chains, 
suitable for attaching to biomolecules (Figure 146).[138, 141, 242] 
 
Figure 146. The structure of TCO-PEG4-NHS 108 
Due to the availability of the TCO functional handle, coupled with its promising kinetic profile 
with tetrazines, the IeDDA reaction between these two reaction partners has become the 
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most utilised bioorthogonal ligation for use in vivo, and has started to be utilised for 
pretargeted PET imaging applications, as well as for pretargeted RIT.[139, 143, 228, 229]  
5.3.3 Synthesis of TCO Modified Cetuximab  
A number of procedures have been reported for the ligation of norbornenes and TCOs to 
antibodies, all of which involve the reaction of the available lysine residues on the antibody 
with an NHS ester group.[140-143] The use of the NHS ester rather than an alternative 
activating group towards amide couplings (for example PyBOP or HBTU) is desirable in this 
case, as only mildly basic conditions are required in order for the reaction to proceed, and 
NHS is the only major by-product formed (Figure 147).  
 
Figure 147. Ligation of Cetuximab (C225) with TCO-PEG4-NHS to form TCO-modified antibody (C225-TCO) 
Commercially available TCO containing a PEG4 linker 108, was used so that a linker 
between the antibody and the TCO functional group would be introduced, in the same 
manner as with the RGD peptides. This would help to ensure that the strained alkene 
functional group was still available for reaction with the tetrazine.  
A large excess of TCO-PEG4-NHS ester 108 (100 molar equivalents) was used for the 
ligation reaction, in order to ensure that a sufficient number of TCO molecules would be 
introduced. The reaction was carried out at 4°C for 16 h, following gentle agitation, after 
which time the crude mixture (containing both the modified antibody and a significant amount 
of unreacted TCO small molecule) was purified using centrifugal filtration, using Amicon 
Ultra® Centrifugal filters. This purification method utilises the difference in size of the 
antibody and small molecules, by using filters which retain molecules of a certain size (in this 
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case 30 kDa), letting any molecules of a smaller size pass through. As a result, any antibody 
molecules (both modified and unmodified) are separated from any small molecules in the 
mixture.  
The amount of time required in order to achieve successful separation was optimised, and 
the removal of the small molecule was monitored using size-exclusion column (SEC) HPLC, 
requiring approximately 40 min of spin time in order to obtain pure modified antibody. This 
method also relies on the separation of molecules by size, but in this case molecules of a 
larger size are eluted first, with small molecules eluting later. A sample of unmodified 
antibody (C225) was initially injected onto the SEC column, and the retention time of the 
compound was observed to be ~6 min, which was confirmed by injecting the compound 
multiple times (n = 3). It was anticipated, based on the theory of SEC, that the unmodified 
and modified antibodies would have similar, if not identical, retention times, as it is unlikely 
that either of these can fit into even the largest pores in the column. This was found to be the 
case, and any unreacted small molecule was observed significantly later in the UV trace 
(Figure 148). 
a)   
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b)  
Figure 148. HPLC traces of the modified antibody after a) 20 min of purification b) 40 min of purification (at 215 nm). The UV 
peak corresponding to the antibody has a retention time of 6 min. 
After 40 min of filtration, the small molecule had been removed successfully, as evidenced 
by the UV trace at both 215 nm and 254 nm. The collected waste from the centrifugal 
filtration was additionally retained, and a sample was injected into the SEC column, in order 
to check for any traces of antibody. This showed that none of the modified antibody had 
passed through the filter, implying that at least 95% of the antibody was in the purified 
fraction. The purified fractions were made up to an estimated concentration of 5 mgmL-1 in 
PBS (pH 7.4), and the actually concentrations were measured using a bicinchroninic acid 
(BSA) assay and this confirmed a relatively consistent concentration of approximately 5 
mgmL-1 across each batch of antibody. 
After successful optimisation of the purification method, it was determined that an average of 
17 molecules of TCO had been added to each molecule of antibody (using MALDI mass 
spectrometry), by calculating the difference in mass between the unmodified antibody and 
the average mass of the modified antibody C225-TCO (see experimental section for details 
and spectra). 
The immunoreactivity of the modified antibody C225-TCO was confirmed by carrying out a 
western-blot (Figure 149).  
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Figure 149. Immunoreactivity assessment of C225-TCO* High and low EGFR expressing cell lines (human epidermoid 
carcinoma A431 cells and human colon carcinoma HCT116 cells, respectively) were incubated in the absence or presence of 
EGF (100 ng/mL) for 15 min, prior to incubation with C225-TCO (50 µg/mL) or C225 (50 µg/mL) for a 24 h. Whole cell lysates 
were prepared and 30µg processed for immunoblot analysis using primary antibodies against phosphorylated-EGFR (p-EGFR), 
total EGFR (EGFR), and alpha-tubulin. *Immunoreactivity assessment was carried out by Dr Quang-De Nguyen. 
The western blot generally showed that the modified antibody still maintained its 
immunoreactivity towards the EGFR receptor. On the high EGFR expressing cell-line 
(A431), a similar level of expression of phosporolated EGFR was observed for both the 
unmodified (Cetuximab) and the modified antibody. The same was not observed in the low 
EGFR expressing cell-line (HCT116), demonstrating selectivity of the antibody for the 
receptor. The level of immunoreactivity is important, as the antibody must maintain its 
specificity for EGFR in order to demonstrate the pretargeting strategy in vitro and in vivo. 
5.3.4 In vitro IeDDA Reactions Using TCO Modified Cetuximab 
In order to demonstrate that the IeDDA reaction could be carried out using the modified 
antibody C225-TCO, it was first necessary to validate the reaction in a vial, by incubating 
C225-TCO with the radiolabelled tetrazine [68Ga]DOTA-GA-Tz in PBS, and observing the 
progress of the reaction by SEC HPLC (Figure 150). 
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Figure 150. General scheme for the reaction of [68Ga]DOTA-GA-Tz with C225-TCO. The number of [68Ga]DOTA-GA 
molecules introduced per antibody is unknown, but is based on an average of 17 TCO molecules in the original antibody  
Prior to carrying out the reaction with the modified antibody, a sample of tetrazine 
[68Ga]DOTA-GA-Tz was injected onto the SEC column, in order to determine the retention 
time of the starting material, and to ensure that sufficient separation from the antibody could 
be achieved. The peak obtained for the tetrazine was very broad, lying between 10 and 14 
min (see experimental section for example spectra), which may be expected considering the 
principles of size-exclusion chromatography. However, sufficient separation was achieved 
from the labelled antibody in order for the conversion to the radiolabelled antibody 
[68Ga]C225 be quantified, which was expected to have a retention time of 6 min, based upon 
the UV trace obtained from the cold material (cf. Figure 148).  
A series of reactions were carried out with the radiolabelled tetrazine [68Ga]DOTA-GA-Tz, 
and each experiment was carried out twice times using the initial batch of antibody. The 
reaction was carried out using 2 initial volumes of the modified antibody C225-TCO, and the 
progress of the reaction was monitored by injection of a portion of the reaction mixture onto 
the SEC column and observing the resultant radio-HPLC trace. The conversion to the 
radiolabelled antibody was measured using the relative AUC of the radio-peak estimated as 
corresponding to the antibody as compared to the AUC of the radio-peak corresponding to 
the tetrazine (Figure 151).  
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Figure 151. Radio-HPLC traces of The reaction between C225-TCO and [68Ga]DOTA-GA-Tz in PBS after; immediate injection, 
the same reaction mixture after 20 min incubation at 37°C 
Using 10 µL of a 2 mgmL-1 solution (2 µg) of this batch of modified antibody C225-TCO 
(diluted to 1 mgmL-1 using 10 µL PBS for the reaction), and ~50 µCi of tetrazine 
[68Ga]DOTA-GA-Tz, the reaction formed ~10% of the radiolabelled antibody after injection of 
the reaction mixture as soon as the two components were incubated (Figure 152). 
 
Figure 152. The conversion to the radiolabelled antibody measured as a percentage from the radiolabelled tetrazine radio-
HPLC trace, using 2 different volumes (2 and 10 µg) of C225-TCO  
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The reaction did not appear to proceed significantly over a time-point of 40 min, showing 
only a small increase in the conversion to the product after this time (~12%). A second 
experiment was carried out using a larger initial volume of C225-TCO of 50 µL, equivalent to 
10 µg, diluted to the same concentration as with the first experiment. In this case, a 
significant increase in the formation of the radiolabelled product was observed, and 50% 
conversion was observed when injected immediately after incubation. This could be 
increased to 70% after incubating the reaction mixture at 37°C for 20 min, and a maximum 
conversion of 75% to radiolabelled C225 was observed after 40 min incubation, suggesting 
that the reaction had reached a plateau. These results suggested that the reaction of 
modified antibody C225-TCO with the radiolabelled tetrazine [68Ga]DOTA-GA-Tz was 
dependent on the concentration of antibody used. This was considered to be significant for 
carrying out subsequent in vitro and in vivo experiments, due to the requirement for the 
amount of the modified antibody used to be controlled. However, in general the results 
obtained from this experiment were promising, and the ability to radiolabel antibodies via a 
two-step labelling procedure was demonstrated. Sufficient labelling of the modified antibody 
could be achieved within 40 min, and this result was considered extremely important in the 
context of pretargeting as the reaction must be achievable within the half-life of 68Ga (68 
min) in order to attain sufficient accumulation of 68Ga in the targeted tissue. 
Due to the ability to demonstrate reaction between the modified antibody C225-TCO and 
radiolabelled tetrazine [68Ga]DOTA-GA-Tz in a vial, the reaction was next carried out in 
vitro. This was demonstrated by using two cell lines (A431 and HCT116) which each 
expressed different levels (high and low, respectively) of EGFR. The first experiment was 
carried out using the same batch of modified antibody C225-TCO as was used in the initial 
radiolabelling experiments. The cells were initially incubated either with 100 µgmL-1 of 
unmodified C225 (as a control experiment), or with C225-TCO at varying concentrations (5, 
10 and 20 µgmL-1 respectively). After a 15 min incubation, ~50 µCi of tetrazine [68Ga]DOTA-
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GA-Tz was introduced to each well, and the cells were incubated for a further 45 min, after 
which time the uptake of activity in each cell line was measured (Figure 153). 
 
Figure 153. In vitro pretargeting was successfully demonstrated on high EGFR expressing cells* High (A431) and Low 
(HCT116) and EGFR expressing cell lines were treated with 50 µCi of [68Ga]DOTA-GA-Tz, following either: no treatment (white 
bars), treatment with 5, 10, or 20 µg/mL C225-TCO for 15 min, or with 100 µg/mL C225-TCO for 5 min + 20 µg/mL C225-TCO 
for 15 min (black bars). The bars represent the mean uptake of 68Ga in each cell line after 45 min incubation. Error bars 
represent the standard errors of the mean. *In vitro work was carried out by Dr Quang-De Nguyen. 
It was generally observed in the high EGFR expressing cells (A431) that significantly higher 
uptake was measured in the pretargeted cells vs. the cells which had not been treated, as 
well as those which had been pre-treated with the unmodified antibody, which demonstrated 
blocking of the receptor. This observation was further validated using the negative cell line 
(HCT116), which pleasingly did not show the same increase in uptake in the pretargeted 
cells. It was concluded from these results that the pretargeting strategy could be 
demonstrated using this approach, and that the IeDDA reaction was occurring on the high 
EGFR expressing cells.  
For future application of this method towards an in vivo setting, it was determined that the 
optimum concentration of the modified antibody C225-TCO required in order for the reaction 
to occur in vitro would be calculated. As could be observed from the initial experiment, a 
slight decrease in uptake was observed when lowering the concentration of C225-TCO from 
20 µgmL-1 to 10 µgmL-1, and subsequently to 5 µgmL-1, however these differences were not 
significant. A second experiment was carried out using the same batch of antibody and the 
concentration of the modified C225-TCO antibody used was consequently lowered 
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successively by 10-fold, so that the cells were incubated with pretargeted concentrations of 
0.2, 2 and 20 µgmL-1  of C225-TCO respectively (Figure 154). 
 
Figure 154. In vitro pretargeting on high EGFR expressing cells was dependent upon the concentration of C225-TCO 
used* High (A431) EGFR expressing cell lines were treated with 50 µCi of [68Ga]DOTA-GA-Tz, following either: no treatment 
(white bars), treatment with 0.2, 2, or 20 µg/mL C225-TCO for 15 min, or with 100 µg/mL C225-TCO for 5 min + 20 µg/mL 
C225-TCO for 15 min (black bars). The bars represent the mean uptake of 68Ga in each cell line after 45 min incubation. Error 
bars represent the standard errors of the mean. *In vitro work was carried out by Dr Quang-De Nguyen. 
This experiment showed us that there was a dependence on concentration of the modified 
antibody C225-TCO used upon the reaction occurring within the time-frame of the 
experiment (45 min), which was supported by the observations found from the radiolabelling 
experiments (see section 5.3.3). The optimum concentration of C225-TCO for carrying out 
the in vitro experiments was found to lie between 2 and 20 µgmL-1, with only a minimal 
observed difference in uptake between the two experiments. Decreasing the concentration 
to 0.2 µgmL-1 had a much more pronounced effect, lowering the measured uptake 
significantly, suggesting that careful consideration must be taken when considering the 
concentration that would be required for achieving the reaction in vivo.    
Due to the results obtained to this point, it was determined that a second batch of antibody 
would be required in order to carry out further in vitro and in vivo experiments. The second 
batch was synthesised using the same method as described, other than that the modification 
was carried out using a stock solution of TCO-PEG4-NHS ester 108, which had been stored 
in the freezer for 1 month. Using this batch of modified antibody (Batch 2), as well as with 
the initial batch (Batch 1), a repeat of the described radiolabelling experiment was carried 
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out in a vial. A single experiment was carried out using 10 µg of the initial stock solution of 
each batch of modified antibody, injecting the reaction mixture 0, 15 and 30 min after 
incubation in PBS (Figure 155).  
 
Figure 155. The conversion to the radiolabelled antibody measured as a percentage from the radiolabelled tetrazine radio-
HPLC trace, using 3 batches of C225-TCO  
From this experiment it was observed that a maximum of only 25% conversion to the 
radiolabelled antibody could be achieved using Batch 2 after 30 min incubation in PBS 
showing only a minimal increase in labelling following the initial injection (~12% conversion). 
The rate of reaction appeared to be increasing linearly, but at a considerably slower rate 
than Batch 1. The first batch however, performed in a similar manner to when the reaction 
was carried out previously, showing a range of conversions to the radiolabelled product 
between 40 and 75% within the 30 min time-frame (cf. Figure 152). The rate of reaction of 
Batch 1 appeared to be increasing linearly, and the reaction had yet to reach the plateau 
that was observed after the 40 min time-point in the previous experiments. 
A third batch of the modified antibody C225-TCO was synthesised in light of these 
experiments, whereby the modification reaction was carried out using a fresh batch of the 
NHS ester 108. As can be seen from the graph, this batch of antibody gave impressive 
radiochemical conversions to the labelled antibody within 30 min, with 75% of the activity 
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being associated with the antibody upon initial injection of the reaction mixture. Almost 
quantitative conversions to the radiolabelled product were observed after 30 min, with only a 
minimal increase as compared to the 15 min time-point, which was suggestive of saturation 
of the reactive TCO functional groups. It was hypothesised that these observations were 
mostly a result of the introduction of a range of TCO molecules per C225 molecule, and this 
theory was confirmed by obtaining the MALDI mass spectra for Batches 2 and 3 (a sufficient 
signal was not obtained from Batch 1) of the modified antibody (Figure 156).  
 
  
It was found that the Batch 2 had an average molecular weight of 153460, indicating the 
addition of an average of only 1 TCO molecule per antibody, by calculating the difference in 
average mass from the unmodified antibody C225. In contrast, Batch 3 was found to have 
an average molecular weight of 160811, indicative of 17 additions of TCO onto the antibody. 
This explained the observed difference in the ability to radiolabel the respective antibodies, 
and highlighted the importance of using a consistent method for the modification step. It may 
be imagined that this observation is a result of the use of an older stock solution of TCO-
a) b) c) 
Average MW = 153073  Average MW = 153460  Average MW = 160811 
Figure 156. The MALDI mass spectra for a) Unmodified C225 antibody and modified C225-TCO antibodies b) Batch 2 
(approximately 1 TCO molecule), c) Batch 3 (approximately 17 TCO molecules) 
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NHS ester 108; the instability of the NHS group towards hydrolysis lowered the reactivity of 
the compound towards free lysine residues on the antibody.  
In order to validate these findings further, the in vitro experiment was carried out with each of 
the 3 batches of antibody (Figure 157).  
 
Figure 157. In vitro pretargeting was demonstrated on high EGFR expressing cells using 3 different batches of C225-
TCO* High (A431) EGFR expressing cell lines were treated with 50 µCi of [68Ga]DOTA-GA-Tz, following either: no treatment, 
treatment with 20 µg/mL C225-TCO for 15 min, or with 100 µg/mL C225-TCO for 5 min + 20 µg/mL C225-TCO for 15 min. The 
bars represent the mean uptake of 68Ga in each cell line after 45 min incubation. Error bars represent the standard errors of the 
mean. *In vitro work was carried out by Dr Quang-De Nguyen. 
When the in vitro experiments were repeated with the second batch of C225-TCO (Batch 2), 
it was found that the uptake (in the high EGFR expressing cells), which was observed using 
the first batch was not achieved, showing an uptake in the pretargeted cells that was not 
significantly greater than the non targeted or blocked cells. These observations were in 
accordance with the experiments that were carried out in a vial, and it was seen by the mass 
spectra that the second batch did not contain enough TCO molecules for successful reaction 
with the radiolabelled tetrazine under these conditions.  
This observation was further supported by repeating the experiment with Batch 3, which 
showed a greater than 30-fold increase in uptake in the pretargeted cells as compared to 
Batch 1, and almost 200-fold increase as compared to Batch 2. The observed difference 
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between batches of the modified antibody C225-TCO was found to be more significant in 
vitro than in a vial, possibly due to the more quantitative nature of the results obtained. This 
highlights the importance of carrying out full characterisation of the antibody post-
modification, as small discrepancies in the method for carrying out the ligation reaction can 
lead to significantly different levels of reactivity.  
This was attributed to the significantly increased probability of the IeDDA reaction occurring 
in the presence of a greater number of TCO groups. It was deduced, therefore, that Batch 3 
would be used for each subsequent experiment so as to ensure reliable results, and would 
be used for carrying out future work into in vivo pretargeting with the radiolabelled tetrazine 
[68Ga]DOTA-GA-Tz.  
5.3.5 Conclusions 
The in vitro data obtained for the reaction between the modified antibody C225-TCO and the 
radiolabelled tetrazine [68Ga]DOTA-GA-Tz provided some very promising results, 
suggesting the potential for use of this model reaction for in vivo pretargeting. The 
successful labelling of the C225 antibody was demonstrated, suggesting that a similar 
method may be used for labelling alternative antibodies for both direct targeting and 
pretargeting approaches.  
Using the first batch of modified antibody C225-TCO, the observed increase in uptake in the 
pretargeted A431 cells vs. the non-targeted cells was significant, and implied a selective 
IeDDA reaction was occurring on the cells. This was supported by the reactivity of the two 
species in a vial, which enabled for the C225 antibody to be radiolabelled with 68Ga via the 
IeDDA reaction, in 70% radiochemical conversions at 37°C within 20 min. These initial 
results suggested a potential for the IeDDA reaction for performing in vivo pretargeting, and 
therefore successive batches of the modified antibody were synthesised. However, 
considerable differences in reactivity were observed between the different batches of 
modified antibody, with the most significant difference observed in the in vitro experiments. 
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The third batch of the modified antibody C225-TCO confirmed that an average of 17 copies 
of TCO could be added to each antibody molecule, and extremely promising reactivity of this 
modified antibody towards the radiolabelled tetrazine in a vial and in vitro were 
demonstrated.  
The most significant variable to consider when applying the strategy in vivo is the amount of 
the modified antibody C225-TCO (and initial injected concentration) used, which must be 
high enough for the reaction to occur at the low concentrations in vivo, but not too high as to 
exceed the recommended injected dose. Future work will therefore be to adapt these initial 
positive in vitro results, and to translate them into a small animal in vivo model.  
5.4 Overall Conclusions 
It was observed that the IeDDA reaction between tetrazines and strained alkenes displays 
superior reaction kinetics to the SPAAC reaction between cyclooctynes and azides, and for 
this reason has been utilised for a number of in vivo applications, including pretargeted 
imaging and therapy. The reaction between radiolabelled tetrazine [68Ga]DOTA-Tz and a 
series of norbornene analogues, as described in Chapter 4, encouraged us to apply this 
bioorthogonal ligation to our proposed pretargeting strategy.  
When functionalised with a cyclic RGD peptide, the norbornene group appeared to show 
none of the expected reactivity with radiolabelled tetrazine [68Ga]DOTA-Tz in a vial or in 
vitro, suggesting further revisions of the strategy were required. Introducing a linker between 
RGD and the norbornene had no impact on the reactivity with the radiolabelled tetrazine. 
Similar results were observed by introducing a linker between the DOTA chelate and the 
tetrazine moiety, towards an alternative radiolabelled tetrazine [68Ga]DOTA-GA-Tz.  
Therefore, an alternative strategy was explored towards the pretargeting application. A C225 
monoclonal antibody was instead modified with the more reactive TCO functional group, and 
approximately 17 copies of this functional handle could be introduced to each molecule of 
C225, increasing the probability of reaction with labelled tetrazine [68Ga]DOTA-GA-Tz. 
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Pleasingly, the modified C225-TCO antibody showed much more promising reactivity with 
our labelled tetrazine, which could be translated to an in vitro setting. This suggests that the 
IeDDA reaction between TCO and our tetrazine demonstrates appropriate kinetics for 
application to the envisaged pretargeting strategy in vivo. Our radiolabelled tetrazine 
[68Ga]DOTA-GA-Tz may be considered an attractive chemical reporter due to its ease of 
synthesis, and demonstrated stability in PBS, and consequently this strategy may enable us 
to demonstrate the use of short-lived isotopes, in combination with antibodies, for 
pretargeted PET imaging. 
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6.1 Final Conclusions 
The aim of this project was to evaluate the strain-promoted, copper-free azide-alkyne [3+2] 
cycloaddition (SPAAC) reaction, and the Inverse-electron Demand Diels-Alder (IeDDA) 
reaction, as a potential tools for carrying out pretargeted in vivo PET imaging.   
This first involved the synthesis of a library of literature cyclooctyne precursors for 
application to the SPAAC reaction (Chapter 2), which could then be used to evaluate the 
reaction in the context of pretargeting. It was observed that these compounds are 
challenging to synthesise, with the final ‘elimination’ step to form the alkyne functional group 
often being the lowest yielding. For this reason, an alternative method towards the synthesis 
of symmetrical cyclooctynes was explored through use of Sonogashira couplings, but further 
work on this approach is still required, as initial attempts have been unsuccessful. 
The kinetics of the SPAAC reaction using the synthesised cyclooctynes was examined by 
reacting with both ‘cold’ and radiolabelled (18F and 68Ga) azides (Chapter 3), which 
demonstrated that the precise structure of the chosen cyclooctyne has a significant effect on 
the rate of the reaction. These experiments also gave us an indication that the SPAAC 
reaction is more suited to organic solvents than water, and may not be achievable at very 
low concentrations, particularly in an environment that replicates close to physiological 
conditions. For this reason, the effect of reaction concentration was considered in more 
detail, and it was concluded that this reaction is not achievable at the low concentrations that 
would be found in vivo. This observation was supported by the initial in vivo experiments 
using antibody (Herceptin) ligated cyclooctynes and the 18F-labelled azide ([18F]FEA),  which 
indicated that the SPAAC reaction was not occurring under these conditions.   
For these reasons, the IeDDA reaction was considered as an alternative bioorthogonal 
reaction for pretargeting. After a minimal amount of optimisation, the tetrazine precursors 
required for these reactions could be synthesised in a one-pot procedure (Chapter 4). The 
most suitable tetrazine was tested for its reactivity with a strained alkene (norbornene) at 
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various concentrations, demonstrating that the rate of the IeDDA reaction is only minimally 
affected by the concentration of the tetrazine. A 68Ga-labelled tetrazine ([68Ga]DOTA-Tz) 
was reacted with a series of norbornene analogues, demonstrating superior reaction kinetics 
and enhanced biocompatibility when compared to the SPAAC reaction.  
For this reason, it was deduced that the IeDDA reaction would be more suitable than the 
SPAAC reaction for application to pretargeting. It was initially imagined that RGD cyclic 
pentapeptides could be used as an alternative biomolecule to antibodies, to provide a proof-
of-concept for the pretargeting strategy (Chapter 5). The RGD peptides were therefore 
ligated with norbornene functional groups, and were tested for their reactivity with the 68Ga-
labelled tetrazine, both in a vial and in vitro. However, these experiments indicated that the 
IeDDA reaction was not occurring as expected, which may be a result of the introduction of a 
bulky peptide side-chain onto the norbornene moiety.  
We therefore decided to return to the antibody model, which would allow for the introduction 
of a greater number of alkene molecules per biomolecule, increasing the probability of the 
reaction with the radiolabelled tetrazine. Cetuximab ligated trans-cyclooctenes (TCOs), 
which show enhanced reaction kinetics with tetrazines as compared to norbornenes, were 
synthesised. The IeDDA reaction with our modified 68Ga-labelled tetrazine ([68Ga]DOTA-GA-
Tz) was successfully demonstrated in a vial, and these results were supported by the 
validation of in vitro pretargeting on high EGFR expressing cells.   
6.2 Summary and Future Work 
Although the SPAAC reaction has not demonstrated fast enough reaction kinetics for 
application to pretargeting, the reaction was shown to be useful for a number of other 
chemical reporter applications, showing sufficient reactivity on the surface of cells. 
Therefore, it may be considered that further optimisation of the cyclooctyne precursors could 
be carried out, in order to enhance the reaction kinetics and biocompatibility of this reaction 
further. The synthesis of cyclooctynes may be improved, for example by use of metal-
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catalysed procedures, and these could negate the need to the final, and often challenging 
elimination step. Further optimisation of these metal-catalysed reactions needs to be carried 
out, as the introduction of an alkyne into a strained ring is still difficult to achieve. For 
example, a Ring-Closing Metathesis (RCM) reaction may be considered as an alternative to 
achieve such a transformation.   
The IeDDA reaction demonstrates much more favourable reaction kinetics for use as the 
bioorthogonal reaction for pretargeted PET imaging using short-lived isotopes such as 68Ga. 
The use of radiolabelled tetrazine [68Ga]DOTA-GA-Tz has been demonstrated as a suitable 
chemical reporter, due to its impressive reaction kinetics with the modified C225-TCO 
antibody, and good stability in PBS over a period of 2 h. This has been supported by 
successful validation of the reaction in a vial and in vitro. Future work will therefore be to 
validate this reaction in an in vivo setting, using a small animal model, with the hope that the 
pretargeting strategy will be equally successful in this environment. It is anticipated that 
sufficient accumulation of the 68Ga label will be achieved within the targeted tissue, for there 
to be enhanced signal over background tissues. Successful validation of this system would 
be in accordance with work currently being carried out by other research groups.[116, 136, 140, 147, 
217, 233-240]  
Moreover, it could be envisaged that a library of tetrazines could be synthesised, in order to 
determine which compound demonstrates the most favourable reaction kinetics and stability 
under biological conditions. This may involve further optimisation of the synthetic procedure 
towards these compounds, with the existing metal-catalysed method currently being the 
most appropriate for the synthesis of large compound libraries. Alternative chelates for 68Ga 
labelling, such as NOTA may also be considered, which may demonstrate different levels of 
stability in vivo. 
It may additionally be possible to synthesise an 18F-labelled tetrazine, for a comparative 
pretargeting reaction to be demonstrated; this removes the need for incorporation of 
chelating groups. For example, it could be imagined that a tetrazine containing an amine 
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moiety, such as Tz3, might be reacted with [18F]fluorobenzaldehyde via reductive amination 
to form an 18F-labelled analogue. This type of chemical reporter could be preferred over 
68Ga-labelled compounds due to its anticipated smaller size and enhanced cell permeability. 
This may well be necessary if the strategy is to be applied to intracellular targets in which the 
biomolecule is internalised prior to introduction of the chemical reporter. 
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7.1 General Experimental Procedures, Materials and Instrumentation  
All reactions were performed under anhydrous conditions and an atmosphere of nitrogen in 
flame-dried glassware unless otherwise stated. Yields refer to chromatographically and 
spectroscopically (1H NMR) homogenous materials. 
Solvents and reagents: All solvents were purified and dried according to standard methods 
prior to use. All chemicals were handled in accordance with COSHH regulations. All 
reagents were used as commercially supplied. 
Flash chromatography (FC) was always performed on silica gel (Merck ASTM 60 F254 230-
400 mesh) according to the method of W. C. Still, unless otherwise stated.[243] Thin Layer 
Chromatography (TLC) was performed on Merck aluminium-backed plated pre-coated with 
silica (0.2 mm, 60 F254) which were visualised either by quenching of ultraviolet fluorescence 
(λ = 254 and 366 nm) or by charring with 10% KMnO4 in 1M H2SO4, unless otherwise stated. 
1H NMR spectra: These were recorded at 400 MHz on a Bruker AV-400 instrument. 
Chemical shifts (δH) are quoted in parts per million (ppm), referenced to the appropriate 
residual solvent peak. Coupling constants (J) are reported to the nearest 0.5 Hz. 13C NMR 
spectra: These were recorded at 100 MHz on a Bruker AV-400 instrument. Chemical shifts 
(δC) are quoted in ppm, referenced to the appropriate residual solvent peak. 19F NMR: These 
were recorded at 400 MHz on Bruker DRX-400 instrument. Chemical shifts (δF) are quoted 
in ppm, referenced to fluorobenzene at -113.5 ppm. Mass spectra: Low resolution mass 
spectra (m/z) and High resolution mass spectra (m/z) were recorded on either a VG platform 
II or VG AutoSpec spectrometers, with only molecular ions (M+, MH+, MNa+, MK+, MNH4+) 
and major peaks being reported.  
Analytical reverse-phase HPLC was carried out on an Agilent 1100 series HPLC system 
(Agilent Technologies, Stockport, UK) equipped with a UV detector (254 nm) and a LabLogic 
Flow-Count radio-detector, using a Phenomenex Gemini C18 column (150 mm x 4.6 mm) at 
a flow rate of 1 mLmin-1. Radio-HPLC was carried out on an Agilent 1100 series HPLC 
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system (Agilent Technologies, Stockport, UK) equipped with a γ-RAM Model 3 gamma-
detector (IN/US Systems Inc., Florida, USA) and Laura 3 software (LabLogic, Sheffield, UK). 
One of the following gradients was used: Gradient A; (0-95% B over 15 min) Buffer A = 
MeCN (0.1% TFA), Buffer B = H2O (0.1% TFA). Gradient B; (0-95% B over 15 min,) Buffer A 
= MeCN (10% H2O, 0.1% TFA), Buffer B = H2O (0.1% TFA). Gradient C; (20-80% B over 15 
min) Buffer A = MeCN (0.1% TFA), Buffer B = H2O (0.1% TFA). Semi-preparative reverse-
phase HPLC was carried out on a Waters 600E system equipped with a UV detector (254 
nm), using a Phenomenex Luna C18 column (100 mm x 10 mm) on either Gradient A or 
Gradient B, at a flow rate of 10 mLmin-1. Size-exclusion HPLC was carried out on either an 
Agilent 1100 series HPLC system (Agilent Technologies, Stockport, UK) equipped with UV 
detector (215 nm) or on a Waters 600E system equipped with UV detector (215 nm) using a 
Phenomenex BioSep-SEC-S column (300 x 7.80 mm) on Gradient D; (100% A) Buffer A = 
sodium phosphate (pH 6.5) at a flow rate of 1 mLmin-1. Laura 3 software was used for 
processing all analytical HPLC chromatograms.  
[18F]Fluoride was produced by a cyclotron (GE PETrace) using the 18O(p,n)18F nuclear 
reaction with 16.4 MeV proton irradiation of an enriched [18O]H2O target. 68GaCl3 was 
produced using an Eckert & Ziegler IGG100 68Ge/68Ga-Generator using a fully-automated 
Modular-Lab system. 68GaCl3 was eluted in 2 mL of a 0.1M HCl solution, which was 
subsequently buffered for direct use in radiolabelling experiments.    
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7.2 Experimental for Chapter 2 
Synthesis of cyclooct-1-yn-3-glycolic acid (OCT2)[113, 149, 150] 
 
8,8-Dibromobicyclo[5.0.1]octane (2)[113, 149] 
Potassium tert-butoxide (10.8 g, 145.6 mmol) was stirred in pentane (20 mL) at room 
temperature for 15 min. Cycloheptene 1 (8.4 mL, 72.8 mmol) was added and the mixture 
was cooled to -10°C. Bromoform (9.4 mL, 109.2 mmol) was added dropwise over ~20 min 
and the mixture turned pale brown. The reaction was allowed to warm to room temperature 
once the addition was complete and was stirred for 16 h, after which time H2O (100 mL) was 
added, and the mixture was acidified using HCl (1M, 200 mL). The product was extracted 
with pentane (2 x 100 mL) and the combined organic layers were washed with H2O (2 x 50 
mL), dried over MgSO4 and concentrated in vacuo to give crude material as an orange oil. 
The crude material was purified by column chromatography, eluting with 5% EtOAc in 
petroleum ether, to yield pure product 2 (16.7 g, 58.7 mmol, 80% yield) as a colourless oil. 
δH (400 MHz, CDCl3) 1.14-1.27 (m, 3H); 1.34-1.45 (m, 2H); 1.69-1.77 (m, 2H); 1.82-1.93 (m, 
3H); 2.25-2.31 (m, 2H). δC (100 MHz, CDCl3) 28.0; 28.9; 32.2; 34.7; 40.7. m/z (EI+) calcd. for 
C8H1379Br2 ([M+H]+) 266.9 found: 265.9, 267.9 (1:1). 
 
Methyl 2-bromocyclooct-1-en-3-glycolate (3)[113, 149] 
Silver perchlorate (667 mg, 3.2 mmol) was added portionwise to a stirred solution of 8,8-
dibromobicyclo[5.0.1]octane 2  (467 mg, 1.6 mmol) and methyl glycolate (1.09 mL, 14.4 
mmol) in anhydrous toluene (1 mL). The reaction vessel was protected from light by use of 
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aluminium foil, and the mixture was stirred at room temperature for 1.5 h, after which time 
the silver salts were removed by filtration and the residue was purified straight away by 
column chromatography on Alumina eluting with 5-10% EtOAc/pet. ether to afford 3 as a 
pale yellow oil (260 mg, 0.9 mmol, 59% yield). δH (400 MHz, CDCl3) 0.75-0.93 (m, 1H); 1.27-
1.89 (m, 7H); 2.13-2.30 (m, 2H); 3.75 (s, 3H); 3.95 (d, J = 16.5 Hz, 1H); 4.10 (dd, J = 5.0 Hz, 
10.0 Hz, 1H); 4.23 (d, J = 16.5 Hz, 1H); 6.35 (dd, J = 11.5 Hz, 4.0 Hz, 1H). δC (100 MHz, 
CDCl3) 23.6; 27.0; 29.2; 30.3; 33.7; 51.8; 53.5; 65.6; 84.6; 126.3; 135.9; 170.7. m/z (EI+) 
calcd. for C11H1879BrO3 ([M+H]+) 277.0 found: 276.0, 278.0 (1:1). 
 
Cyclooct-1-yn-3-glycolic acid (OCT2)[113, 149] 
To a solution of NaOMe in MeOH (0.5M, 13 mL) and dry DMSO (0.65 mL) was added 
methyl 2-bromocyclooct-1-en-3-glycolate 3 (260 mg, 0.94 mmol) and the resultant mixture 
was stirred at room temperature for 12 hs. The solvent was evaporated in vacuo to yield an 
orange gel-like solid. CH2Cl2 (10 mL) was added and the mixture was acidified to pH ~ 2 by 
cautious addition of 1M HCl (150 mL). The product was extracted with CH2Cl2 (3 x 15 mL), 
and the combined organic layers were washed with H2O (10 mL), dried over MgSO4 and 
concentrated in vacuo to obtain crude material as a yellow oil. The crude material was 
purified by column chromatography eluting first with 2% MeOH/CH2Cl2, then with 5% MeOH/ 
CH2Cl2, to obtain pure OCT2 as a pale yellow solid (14 mg, 0.08 mmol, 8% yield). δH (400 
MHz, CDCl3) 1.3-2.3 (m, 10H); 4.32-4.45 (m, 1H); 4.45 (d, J = 17.0 Hz, 1H); 4.58 (d, J = 17.0 
Hz, 1H); 8.12 (s, 1H). δC (100 MHz, CDCl3) 20.5; 26.0; 29.3; 33.7; 41.8; 65.5; 72.6; 91.2; 
101.6; 173.5. m/z (CI+) calcd. for C10H15O31 ([M+H]+) 183.2 found: 183.2. 
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2-(Cyclooct-2-yn-1-yloxy)-N-(4-methoxybenzyl)acetamide (OCT4)[151] 
To a stirred solution of cyclooct-1-yn-3-glycolic acid (OCT2) (12.5 mg, 0.07 mmol) in 
anhydrous DMF (1 mL) was added DIPEA (13.4 µL, 0.014 mmol) and HBTU (53 mg, 0.014 
mmol). The resultant mixture was stirred at room temperature for 30 min, after which time 4-
methoxy benzylamine 4 (121.0 µL, 0.084 mmol) was added and the mixture was stirred at 
room temperature for 16 h. TLC (1:1 EtOAC/pet. ether) indicated that the reaction had gone 
to completion. The reaction was stopped and the product was extracted with CH2Cl2 (2 x 10 
mL) and washed with brine (2 x 10 mL). The combined organic layers were dried over 
MgSO4 and the solvent was evaporated in vacuo to yield crude material as an orange oil. 
The crude material was purified by column chromatography eluting with 50-70% EtOAc/pet. 
ether to yield OCT4 as a colourless oil (16 mg, 0.05 mmol, 74% yield). δH (400 MHz, CDCl3) 
1.30-2.11 (m, 10H); 3.69 (s, 3H); 3.89 (d, J = 15.0 Hz, 1H); 4.03 (d, J = 15.0 Hz, 1H); 4.33-
4.43 (m, 3H); 6.84 (d, J = 8.5 Hz, 2H); 6.93 (bs, 1H); 7.20 (d, J = 8.5 Hz, 2H). δC (100 MHz, 
CDCl3) 23.5; 27.0; 29.2; 31.4; 33.7; 42.3; 55.3; 68.3; 114.0; 129.0; 130.2; 135.6. m/z (EI+) 
calcd. for C18H23NO3 ([M+H]+) 302.1756, found: 302.1760. 
Synthesis of Cyclooctane-1,3-dione (5)[156] 
 
(Z)-1,2-Bis(trimethylsiloxy)cycloheptene (9)[156] 
To a flame-dried reaction vessel under nitrogen gas was added anhydrous toluene (70 mL), 
followed by sodium (2.93 g, 128 mmol) in pieces, cut under pentane. The solution was 
refluxed (110°C) and stirred for 2 h to produce a sodium dispersion. The addition funnel was 
charged with toluene (25 mL), diethyl pimelate 8 (5.82 g, 27 mmol), and trimethylsilyl 
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chloride (13.5 g, 15.8 mmol) and the solution was mixed by bubbling under N2(g). The 
solution was added to the refluxing reaction mixture dropwise over 2-3 h, with stirring. The 
reaction mixture turned deep purple upon addition, after which stirring was continued for 16 
h. The mixture was then allowed to cool to room temperature, and was filtered first through 
glass wool, and then through 1cm of Celite® on a glass frit to remove residual sodium, 
washing with toluene. The solvent was evaporated in vacuo to give pure product 9 as a 
yellow oil (6.2 g, 22.6 mmol, 84% yield). δH (400 MHz, CDCl3) 0.13 (s, 18H); 1.57 (m, 6H); 
2.14 (t, 4H). m/z (EI+) calcd. for C13H29O2Si2 ([M+ H]+) 273.1628, found: 273.1642. 
 
1,7-Bis(trimethylsiloxy)bicycle[5.1.0]octane (10)[156] 
To a three-neck, flame-dried flask was added 1,2-bis(trimethylsiloxy)cycloheptene (4.74 g, 
16.6 mmol), followed by diiodomethane (3.8 mL, 47.2 mmol) in toluene (25 mL) and the 
resultant mixture was cooled to -20°C under a N2(g) atmosphere. To this was added 
diethylzinc in toluene (1.1M, 43.6 mL, 48.0 mmol) over a period of 30 min. The mixture was 
stirred for 1 h at this temperature and then at room temperature for 16 h. The mixture was 
quenched by pouring onto sat. aq. NH4Cl and the product was extracted with toluene (3 x 50 
mL). The combined organic layers were washed with H2O (50 mL) and brine (50 mL), dried 
over MgSO4, filtered and concentrated in vacuo to yield 2 as a yellow liquid (3.2 g,11.1 
mmol, 81% yield). δH (400 MHz, CDCl3) 0.20 (s, 18H); 0.75 (d, J = 7.0 Hz, 1H); 0.90 (d, J = 
7.0 Hz, 1H) 1.20-1.80 (m, 6H) 2.00-2.40 (m, 4H). 
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Cyclooctane-1,3-dione (5)[156]  
Method 1 
Anhydrous FeCl3, (1.0 g, 6.2 mmol) was transferred quickly to a round-bottom flask under 
N2(g). Since anhydrous FeCl3 dissolves exothermically, dry DMF (1 mL) was added slowly 
with mechanical stirring to the ice cooled flask. A solution of 1,7-
bis(trimethylsiloxy)bicyclo[5.1.0]octane 10 (420 mg, 1.5 mmol) in dry DMF (0.5 mL) was 
added to the mixture, and the dark brown suspension was stirred at 60°C for 16 h. After 
cooling, the mixture was poured into cold 10% aqueous HCl (25 mL) and the product was 
extracted with CHCl3 (4 x 25 mL). The combined organic layers were washed with 10% HCl 
(2 x 20 mL) and brine (20 mL), dried over MgSO4 and concentrated in vacuo to give crude 
material as a brown oil. which was Kugelrohr distilled to give product 3 as a pale yellow oil 
(634 mg, 4.5 mmol, 73% yield), bp 86°C (3 Torr). δH (400 MHz, CDCl3) 1.5-1.9 (m, 6H); 2.3-
2.6 (m, 4H); 3.5 (s, 2H). δC (100 MHz, CDCl3) 24.1; 27.3; 44.0; 58.9; 206.3.  
Method 2 
A solution of periodic acid (1.56 g, 6.8 mmol) in absolute ethanol (12 mL) was cooled to -
10°C. To this was added a solution of 1,7-bis(trimethylsiloxy)bicyclo-[5.1.0]octane (1.89 g, 
6.64 mmol) 10 in ethanol (12 mL). An orange colour formed immediately. The reaction was 
stirred at -10°C for 30 min, by which time the colour had discharged. Following dilution with 
30 mL of chloroform (30 mL), the solution was washed with H2O (20 mL), 5% aq. Na2SO3 (20 
mL), and brine (20 mL). The organic layers were dried over MgSO4, filtered and 
concentrated in vacuo to give a yellow oil as crude, which was Kugelrohr distilled to give 
product 3 as a pale yellow oil (770 mg, 5.5 mmol, 81% yield), bp 86°C (3 Torr).  
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Synthesis of α-iodocyclooctanone (17)[174] 
 
α-Iodo cycloocatnone (17)[174] 
Cyclooctanone 23 (630 mg, 5.0 mmol) was added to a stirred solution of NaI (0.77 g, 5.15 
mmol) in H2O (15 mL). The flask was cooled in an ice-water bath and H2SO4 (1.06 mL, 20 
mmol) and H2O2, 30% soln (3.3 mL, 30 mmol) were sequentially added. The resultant 
mixture was heated to 40°C for 3 h. The reaction mixture was allowed to cool, and the 
product was extracted with CH2Cl2 (3 x 25 mL). The combined organic layers were washed 
with H2O (2 x 50 mL) and Na2S2O3, 5% solution in water (2 x 50 mL), dried over MgSO4, 
filtered and concentrated in vacuo to afford ketone 17 as a yellow oil (1.1 g, 4.5 mmol, 90% 
yield). δH (400 MHz, CDCl3) 1.04 (m, 1H); 1.29 (m, 1H); 1.51 (m, 3H), 1.69 (m, 2H), 1.87 (m, 
1H), 2.29 (m, 2H), 2.46 (m, 1H), 2.94 (td, J = 12.0 Hz, 12.0 Hz, 3.5 Hz, 1H), 4.40 (dd, J = 
12.5 Hz, 3.5 Hz, 1H). δC (100 MHz, CDCl3) 23.7; 25.4; 29.5; 29.7; 34.1; 35.0; 53.5; 209.8. 
m/z (EI+) calcd. for C8H14OI ([M+H]+)  253.0089, found: 253.0096. 
Synthesis of methyl 4-(cyclooct-2-yn-1-ylmethyl)benzoate (OCT3)[113] 
 
Methyl 4-[(2-oxocyclooctyl)methyl]benzoate (24)[113] 
A solution of LDA, 1.8M in heptane/THF/ethylbenzene (8.54 mL, 15.4 mmol) was added 
drowise to a stirred solution of cyclooctanone 23 (1.76 g, 14.0 mmol) in THF (30 mL) at -
78°C, and the resultant mixture was stirred at this temperature for 1 h. After this time, a 
solution of methyl 4-bromomethylbenzoate 18 (3.53 g, 15.4 mmol) in THF (10 mL) was 
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added, and the mixture was allowed to warm to rt. After 30 min, the reaction was quenched 
by addition of H2O (10 Ml), and the THF was evaporated in vacuo.  The residue was diluted 
with EtOAc (100 mL), washed with H2O (3 x 100 mL) and brine (50 mL), dried over MgSO4, 
filtered and concentrated in vacuo to afford the crude material as a yellow oil. The product 
was purified by column chromatography, eluting with 10% EtOAc/pet ether, to yield ketone 
24 as a colourless oil (2.8 g, 9.9 mmol, 65% yield). Rf = 0.4 (10% EtOAc/pet ether). δH (400 
MHz, CDCl3) δ = 1.10-1.29 (m, 1H); 1.29-1.49 (m, 1H); 1.49-1.82 (m, 6H); 1.93-2.04 (m, 1H); 
2.06 (ddd, J = 14.0 Hz, 7.5 Hz, 3.0 Hz, 1H); 2.18-2.25 (m, 1H); 2.57 (dd, J = 13.0 Hz, 6.0 Hz, 
1H); 2.94 (m, 2H); 3.89 (s, 3H); 7.13 (d, J = 8.5 Hz, 2H); 7.86 (d, J = 8.5 Hz, 2H). δC (100 
MHz, CDCl3) 24.5; 24.6; 25.1; 27.7; 32.9; 38.1; 43.1; 51.5; 51.9; 128.0; 128.9; 129.5; 129.6; 
145.5; 166.9; 218.7. m/z (CI+) calcd. for C17H23O3 ([M+H]+)  275.1647, found: 275.1628. 
 
Methyl 4-{[(2E)-2-{[(trifluoromethyl)sulfonyl]oxy}cyclooct-2-en-1-yl]methyl}benzoate 
(26)[113] 
To a stirred solution of methyl 4-[(2-oxocyclooctyl)methyl]benzoate 24 (500 mg, 1.8 mmol) in 
THF (100 mL) at -78°C was added KHMDS, 0.5M solution in toluene (3.95 mL, 2.0 mmol). 
After 1 h, a solution of Tf2NPh (707 mg, 2.0 mmol) was added and the resultant mixture was 
allowed to warm to rt. After 30 min, the solvent was evaporated in vacuo to give crude 
material as a yellow oil. The product was purified by column chromatography, eluting with 
5% EtOAc/pet ether to yield triflate 26 as a colourless oil (460 mg, 1.1 mmol, 62% yield). Rf 
= 0.3 (5% EtOAc/pet ether). δH (400 MHz, CDCl3) 1.25-1.38 (m, 1H); 1.52-1.71 (m, 4H); 
1.71-1.85 (m, 3H); 1.98-2.11 (m, 1H); 2.15-2.25 (m, 1H); 2.70 (dd, J = 14.0 Hz, 7.0 Hz, 1H); 
2.95 (dd, J = 14.0 Hz, 8.0 Hz, 1H); 3.10 (m, 1H); 3.87 (s, 3H); 5.72 (t, J = 8.5 Hz, 8.5 Hz, 
1H); 7.24 (d, J = 8.0 Hz, 2H); 7.94 (dd, J = 8.5 Hz, 1.5 Hz, 2H). δC (100 MHz, CDCl3) 25.2, 
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25.9, 26.5, 29.8, 33.4, 37.5, 39.8, 116.8, 116.8, 119.9, 120.0, 121.3, 128.4, 128.8, 129.8, 
151.1, 167.0. δF (376 MHz, CDCl3) -74.7. m/z (CI+) calcd. for C18H22O5F3S ([M+H]+) 
407.1140, found: 407.1112. 
 
Methyl 4-(cyclooct-2-yn-1-ylmethyl)benzoate (OCT3)[113] 
To a stirred solution of methyl 4-{[(2E)-2-{[(trifluoromethyl)sulfonyl]oxy}cyclooct-2-en-1-
yl]methyl}benzoate 26 (200 mg, 0.5 mmol) in THF (3 mL) at 0°C was dropwise added LDA, , 
1.8M in heptane/THF/ethyl benzene (0.32 mL, 0.5 mmol) over 1 h. The reaction was 
quenched by addition of H2O (10 mL) and the THF was evaporated in vacuo. The residue 
was diluted with EtOAc (20 mL), and the organic layer was washed with H2O (3 x 10 mL) 
and brine (50 mL), dried over MgSO4, filtered and concentrated in vacuo to give crude 
material as a yellow oil. The product was purified by column chromatography, eluting with a 
gradient of 0-20% EtOAc/pet ether to yield OCT3 as a colourless oil (15 mg, 0.05 mmol, 
11% yield). Rf = 0.2 (5% EtOAc/pet ether). δH (400 MHz, CDCl3) 1.40 (m, 1H); 1.60 (m, 1H), 
1.72-1.98 (m, 4H); 2.01-2.08 (m, 1H); 2.12-2.22 (m, 2H); 2.64-2.78 (m, 3H); 3.89 (s, 3H); 
7.28 (m, 2H); 7.95 (m, 2H). δC (100 MHz, CDCl3) 20.9; 28.5; 30.0; 34.8; 36.5; 40.3; 41.7; 
51.9; 95.0; 96.2; 128.1; 128.9; 129.6; 145.7; 167.1. m/z (CI+) calcd. for C17H21O2 ([M+H]+) 
257.1542, found: 257.1539. 
Synthesis of carbonic acid-2’,3’,2”,3”-tetramethoxy-7,8-didehydro-1,2:5,6-
dibenzocyclocta-1,5,7-triene-3-yl 4-nitrophenyl ester (TMDIBO1)[178, 244] 
 
(3,4-dimethoxyphenyl)acetaldehyde (28)[178, 244] 
Chapter 7 - Experimental 
 
221 
 
To a stirred solution of 2-(3,4-dimethoxyphenyl)ethanol 27 (7.7 g, 42.1 mmol) in methylene 
chloride (50 mL) was added portionwise Dess-Martin periodinane (25 g, 58.9 mmol). The 
resultant mixture was stirred at room temperature for 1 h, after which time TLC in 50% 
EtOAc/hexane indicated that the reaction had gone to completion. The solvent was 
evaporated in vacuo to yield crude material as an orange oil. Column chromatography 
eluting with 30-40% EtOAc/hexane yielded (3,4-dimethoxyphenyl)acetaldehyde 28 as a pale 
yellow liquid (6.1 g, 33.7 mmol, 80% yield). δH (400 MHz, CDCl3) 3.64 (d, J = 2.5 Hz, 2H); 
3.89 (s, 6H); 6.72-6.89 (m, 3H). δC (100 MHz, CDCl3) 50.1; 55.8; 55.9; 111.6; 112.9; 121.9; 
124.1; 148.4; 149.3; 199.6. m/z (EI+) calcd. for C10H13O3 ([M+H]+) 181.08 found: 181.1. 
 
2’,3’,2”,3”-Tetramethoxy-2,3:6,7-dibenzo-9-oxabicyclo[3.3.l]nona-2,6-diene (29)[178, 244] 
To a stirred solution of (3,4-dimethoxyphenyl)acetaldehyde 28 (1.5 g, 8.7 mmol) in CH2Cl2 
(10 mL) at -78°C was dropwise added iodo(trimethyl)silane (1.5 mL, 10.9 mmol). The 
solution was stirred at -78°C for 2 h, after which time it was slowly allowed to warm to room 
temperature. After the solution had fully warmed to room temperature, it was quenched by 
addition of aqueous sodium thiosulfate. The product was extracted with CH2Cl2 (2 x 20 mL), 
and the organic layer washed with H2O (2 x 10 mL). The combined organic layers were dried 
over MgSO4, filtered, and the solvent evaporated in vacuo to give crude material as a brown 
solid. The product was recrystallised from MeOH to give 29 as an off-white powder (1.7 g, 
5.0 mmol, 60% yield). δH (400 MHz, CDCl3) 2.66 (dd, J = 9.5 Hz, 16.0 Hz, 2H); 3.45 (dd, J = 
6.0 Hz, 16.0 Hz, 2H); 3.85 (d, J = 23.0 Hz, 12H); 5.23 (d, J = 6.0 Hz, 2H); 6.47 (s, 2H); 6.57 
(s, 2H). δC (100 MHz, CDCl3) 35.5; 55.7; 56.0; 108.0; 110.8; 111.5; 123.4; 129.5; 147.4; 
148.0. m/z (EI+) calcd. for C20H23O5 ([M+H]+) 343.15 found: 343.2. 
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3-Hydroxy-2’,3’,2”,3”-tetramethoxy-1,2:5,6-dibenzocycloocta-1,5,7-triene (30)[178, 244] 
To a stirred solution of ether 29 (200 mg, 0.58 mmol) in dry THF (6 mL) was added dropwise 
n-butyllithium (1.4M, 0.86 mL, 1.17 mmol) at room temperature. The resultant mixture was 
stirred at room temperature under nitrogen for 4 h. The reaction was stopped and H2O (10 
mL) was added with caution. The product was extracted with CH2Cl2 (2 x 10 mL) and the 
combined organic phases were washed with brine (10 mL), dried over MgSO4 and 
concentrated in vacuo to give crude alcohol 30 as a yellow oil. The product was purified by 
column chromatography eluting with 100% EtOAc to give alcohol 17 as a pale yellow solid 
(114 mg, 0.3 mmol, 57% yield). δH (400 MHz, CDCl3) 3.30 (m, 2H); 3.81-3.88 (m, 12H); 5.20 
(m, 1H); 6.59-7.00 (m, 6H). δC (100 MHz, CDCl3) 41.6; 55.9; 76.8; 111.3; 111.4; 112,4; 
112.9; 125.9; 129.4; 129.8; 131.9; 146.6; 147.4. m/z (EI+) calcd. for C20H23O5 ([M+H]+) 
343.15 found: 343.2. 
 
3-tert-Butyldimethylsilyloxy-2’,3’,2”,3”-tetramethoxy-1,2:5,6-dibenzocyclocta-1,5,7-
triene (31)[178] 
tert-Butyldimethylsilyl chloride (440 mg, 2.9 mmol) was added to a stirred solution of 3-
hydroxy-2’,3’,2”,3”-tetramethoxy-1,2:5,6-dibenzocycloocta-1,5,7-triene 30 (400 mg, 1.2 
mmol) in pyridine (5.6 mL, 6.9 mmol) and CH2Cl2 (20 mL) and the resultant mixture was 
stirred at room temperature for 16 h. The mixture was diluted by addition of H2O (20 mL) and 
extracted with CH2Cl2 (3 x 20 mL), washed with brine and dried over MgSO4. The solvent 
was evaporated in vacuo to yield crude material as a yellow oil. The product was purified by 
column chromatography eluting with 40% EtOAc/pet ether to give silyl ether 31 as a 
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colourless oil (1.1 g, 2.3 mmol, 80% yield). Rf = 0.5 (50% EtOAc/pet ether). δH (400 MHz, 
CDCl3) -0.05 (s, 3H); 0.00 (s, 3H); 0.88 (s, 9H); 3.11 (dd, J = 15.5 Hz, 10.0 Hz, 1H); 3.40 (dd 
J = 15.5 Hz, 5.5 Hz, 1H); 3.80-3.88 (m, 12H); 5.39 (dd, J = 10.0 Hz, 5.5 Hz, 1H); 6.54-7.10 
(m, 6H). δC (100 MHz, CDCl3) -4.7; -4.6; 18.5; 25.9; 26.0; 46.6; 55.8; 55.9; 71.8; 109.2; 
111.0; 113.4; 113.6; 126.9; 128.2; 128.8; 129.2; 132.6; 136.4; 146.7; 147.2; 147.7; 148.4. 
m/z (EI+) calcd. for C26H36O5SiNa ([M+Na]+)  479.2 found: 479.2. 
 
3-Hydroxy-2’,3’,2”,3”-tetramethoxy-7,8-didehydro-1,2:5,6-dibenzocyclocta-1,5,7-triene 
(34)[178] 
Bromine (22.6 µL, 0.44 mmol) was dropwise added to a stirred solution of 3-tert-
Butyldimethylsilyloxy-2’,3’,2”,3”-tetramethoxy-1,2:5,6-dibenzocyclocta-1,5,7-triene 31 (200 
mg, 0.44 mmol) in CH2Cl2 (4 mL) and the resultant mixture was stirred at -40°C until the 
brown colour persisted. The mixture was concentrated in vacuo and the residue was 
dissolved in THF (4 mL). N-methylpiperazine (0.66 g, 6.6 mmol) was added, followed by 
KOtBu (198 mg, 1.8 mmol). The resulting suspension was stirred overnight, after which time 
it was poured over an ice/water bath, and the product was extracted with EtOAc (2 x 20 mL). 
The combined organic layers were concentrated in vacuo and the residue was dissolved in 
THF (4 mL). TBAF (1M in THF, 0.58 mL, 0.58 mmol) was dropwise added to the mixture at 
0°C. The mixture was allowed to warm to room temperature and was stirred for an additional 
30 min, after which time the reaction was quenched with NaHCO3 (aq.), and the product was 
extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 
20 mL), dried over MgSO4, filtered and concentrated slowly in vacuo to afford crystallisation 
of the product. The crystals were filtered off to afford 34 as an off-white solid (102 mg, 0.3 
mmol, 70% yield). Rf = 0.3 (50% EtOAc/pet ether). δH (400 MHz, CDCl3) 2.64 (dd, J = 14.0 
Hz, 3.5 Hz, 1H); 3.07 (dd, J = 14.0 Hz, 2.0 Hz, 1H); 3.81 (s, 6H); 3.87 (s, 6H); 4.28 (app dd, 
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J = 5.0 Hz, 2.0 Hz, 1H); 6.95 (s, 1H); 6.96 (s, 1H); 7.14 (s, 1H); 7.38 (s, 1H). δC (100 MHz, 
CDCl3) 49.6; 55.8; 55.9; 56.2; 56.3; 74.6; 109.5; 109.5; 109.6; 110.5; 112.1; 112.3; 114.6; 
115.1; 145.7; 147.4; 147.7; 148.8; 149.1; 151.1. m/z (EI+) calcd. for C20H31O5 ([M+H]+) 341.1 
found: 341.1. 
 
Carbonic acid-2’,3’,2”,3”-tetramethoxy-7,8-didehydro-1,2:5,6-dibenzocyclocta-1,5,7-
triene-3-yl 4-nitrophenyl ester (TMDIBO1)[178] 
3-Hydroxy-2’,3’,2”,3”-tetramethoxy-7,8-didehydro-1,2:5,6-dibenzocyclocta-1,5,7-triene 
(34) (50 mg, 0.15 mmol) was dissolved in CH2Cl2 (4.9 mL), and pyridine (0.059 mL, 0.73 
mmol) and 4-nitrophenyl chloroformate (59.2 mg, 0.294 mmol) were added. The resultant 
mixture was stirred at room temperature for 2 h. The mixture was diluted by addition of 
CH2Cl2 (20 mL), washed with brine (2 x 10 mL) and dried over MgSO4. The organic layers 
were filtered, and the solvent was evaporated in vacuo to yield crude material as an off-white 
solid. The product was recrystallised from EtOAc to give carbonate TMDIBO1 as a white 
solid (72 mg, 0.14 mmol, 95% yield). Rf = 0.25 (2.5% Et2O/CH2Cl2). δH (400 MHz, CDCl3) 
major rotamer: 2.97 (dd, J = 15.5 Hz, 4.0 Hz, 1H); 3.23 (dd, J = 15.5 Hz, 4.0 Hz, 1H); 3.89 
(s, 3H); 3.90 (s, 3H); 3.91 (s, 3H); 3.95 (s, 3H); 5.51 (dd, J = 4.0 Hz, 2.0 Hz, 1H); 6.83 (s, 
1H); 6.86 (s, 1H); 6.90 (s, 1H); 7.13 (s, 1H); 7.42 (d, J = 9.5 Hz, 2H); 8.28 (d, J = 9.5 Hz, 
2H). minor rotamer: 2.90 (dd, J = 14.0 Hz, 2.0 Hz, 1H); 3.72 (dd, J = 14.0 Hz, 10.0 Hz, 1H); 
3.88 (s, 3H); 3.91(s, 3H); 3.93 (s, 3H); 3.94 (s, 3H); 6.14 (dd, J = 10.0 Hz, 2.0 Hz, 1H); 6.84 
(s, 1H); 6.87 (d, J = 9.0 Hz, 2H); 6.88 (s, 1H); 6.90 (s, 1H); 7.13 (s, 1H); 8.14 (d, J = 9.0 Hz, 
1H). δC (100 MHz, CDCl3) major+minor rotamer 39.3; 46.2; 56.1; 56.1; 56.1; 56.1; 78.5; 
82.1; 107.7; 108.2; 108.7; 108.8; 109.2; 109.3; 109.5; 110.4; 112.7; 113.2; 113.9; 115.3; 
115.6; 115.6; 115.6; 118.2; 121.5; 121.8; 125.1; 125.3; 139.4; 140.3; 143.0; 143.5; 145.3; 
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145.4; 148.1; 148.1; 148.2; 148.9; 149.2; 149.6; 151.5; 152.1; 155.3; 155.4. m/z (EI+) calc. 
for C27H24NO9 ([M+H]+) 506.1451, found: 506.1462. 
Synthesis of sym-dibenzo-1,5-cyclooctadiene-3,7-diyne (DIBOD)[182] 
 
ortho-(Phenylsulfonylmethyl)benzonitrile (39)[182] 
To a stirred solution of α-bromotolunitrile 38 (1 g, 5.2 mmol) in anhydrous DMF (10 mL) was 
added benzenesulfinic acid sodium salt dihydrate (1.01 g, 6.2 mmol). After the mixture had 
been stirred at 80ºC for 2 h, it was cooled to room temperature. The reaction mixture was 
extracted with H2O (50 mL) and EtOAc (3 x 50 mL), dried over MgSO4 and the solvent was 
evaporated in vacuo. The crude residue was purified via recrystallisation from EtOAc/hexane 
to give ortho-(phenylsulfonylmethyl)benzonitrile 39 as colourless needles (1.1 g, 4.2 mmol, 
82% yield). δH (400 MHz, CDCl3) 4.57 (s, 2H); 7.42 (m, 4H); 7.67 (m, 5H); δc (100 MHz, 
CDCl3) 60.5; 114.4; 116.6; 128.7; 129.3; 129.4; 131.6; 132.2; 132.8; 133.0; 134.3; 137.5. 
m/z (EI+) calcd. for C14H12NO2S ([M+H]+) 258.1 found: 258.1.  
 
ortho-(Phenylsulfonylmethyl)benzaldehyde (40)[182] 
To a stirred solution of ortho-(phenylsulfonylmethyl)benzonitrile 39 (1.03 g, 4.0 mmol) in 
CH2Cl2 (13 mL), was added DIBAL-H (1M in hexane, 9.3 mL, 9.3 mmol) at -78°C. After the 
reaction had been stirred at this temperature for 2 h, NH4Cl (aq.) (30 mL) was poured into 
the mixture. The reaction mixture was extracted with 1M HCl (2 x 25 mL) and CH2Cl2 (2 x 25 
mL), dried over MgSO4 and the solvent was evaporated in vacuo. The crude residue was 
filtered and subsequently purified via recrystallisation from CH2Cl2/hexane gave ortho-
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(phenylsulfonylmethyl)benzaldehyde 40 as colourless needles (493.5 mg, 1.9 mmol, 48% 
yield). δH (400 MHz, CDCl3) 5.03 (s, 2H); 7.46 (m, 3H); 7.59 (m, 3H); 7.72 (m, 3H); 9.83 (s, 
1H). δC (100 MHz, CDCl3) 57.7; 128.7; 128.8; 129.5; 133.6; 133.8; 133.9; 134.5; 134.6; 
138.2; 192.0. m/z (EI+) calcd. for C14H13O3S ([M+H]+) 261.1, found: 261.1.  
 
sym-Dibenzo-1,5-cyclooctadiene-3,7-diyne (DIBOD)[182] 
To a stirred solution of ortho-(phenylsulfonylmethyl)benzaldehyde 40 (442 mg, 1.7 mmol), 
ClP(O)(OEt)2  (0.3 mL, 2.0 mmol) in anhydrous THF (50 mL), was added LiHMDS (1M in 
THF, 3.4 mL, 3.4 mmol) at -78˚C. After the mixture had been stirred at -78 ˚C for 30 min, and 
then at room temperature for 1.5 h, LDA, 1.8M in THF/heptane (4.7 mL, 8.5 mmol) was 
added dropwise at -78˚C. The reaction mixture was stirred at this temperature for 2 h, and 
then NH4Cl (aq.) (25 mL) was poured into the mixture. The product was extracted with 
EtOAc (2 x 25 mL) and washed with H2O (2 x 25mL). The combined organic layers were 
dried over MgSO4 and the solvent evaporated in vacuo to yield crude material as a brown 
oil. The crude material was purified by column chromatography, eluting with CH2Cl2 to yield 
DIBOD as a yellow solid (51.2 mg, 0.26 mmol, 15% yield). δH (400 MHz, CDCl3) 6.71-6.77 
(m, 4H); 6.90-6.95 (m, 4H). δC (100 MHz, CDCl3) 110.1; 128.5; 129.1; 132.8. m/z (EI+) calcd. 
for C16H9 ([M+H]+) 201.1, found: 201.2. 
Synthesis of precursors for ‘Dual’ Sonogashira reactions[186] 
 
1,2-Bis((trimethylsilyl)ethynyl)benzene (44) and 1-[2-(Trimethylsilyl)ethynyl]-2-
iodobenzene (45)[186] 
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Trimethylsilylacetylene (1.1 mL, 7.5 mmol) was added in one portion to a degassed solution 
of 1,2-diiodobenzene  41 (1.0 g, 3.05 mmol), Pd(PPh3)4 (0.18 g, 0.15 mmol) and CuI (0.5 g, 
2.5 mmol) in Et3N/THF (2:1, 15 mL) at room temperature. The mixture was sitrred under 
nitrogen at 60°C for 20 h. The reaction was cooled to room temperature, and was quenched 
by addition of NH4Cl (aq) (10 mL). The product was extracted with CH2Cl2 (3 x 50 mL) and 
the combined organic layers were washed with H2O (20 mL) and brine (20 mL) dried over 
MgSO4 and concentrated in vacuo to give crude material as a brown oil. The crude material 
was purified by column chromatography eluting with 100% pet. ether to yield a mixture of 44 
(430 mg, 52% yield) and 45 (190 mg, 21% yield) as pale yellow oils.  
1,2-Bis((trimethylsilyl)ethynyl)benzene (44)[186] 
δH (400 MHz, CDCl3) 0.29 (s, 18H); 7.24-7.28 (m, 2H); 7.25-7.50 (m, 2H). δC (100 MHz, 
CDCl3) 0.1; 98.5; 103.2; 125.8; 128.1; 132.3. 
1-[2-(Trimethylsilyl)ethynyl]-2-iodobenzene (45)[186] 
δH (400 MHz, CDCl3) 0.28 (s, 9H); 6.97 (td, J = 1.5 Hz, 1H); 7.24-7.28 (m, 1H); 7.45 (dd, J = 
1.5 Hz, 7.5 Hz, 1H); 7.81 (dd, J = 0.7 Hz, 8.2 Hz, 1H). δC (100 MHz, CDCl3) 0.0; 98.8; 101.3; 
106.5; 127.7; 129.2; 129.6; 132.7; 138.7.  
 
1,2-Diethynylbenzene (42)[186] 
To a stirred solution of 1,2-Bis((trimethylsilyl)ethynyl)benzene 44 (310 mg, 1.5 mmol) in 
MeOH/THF (1:1, 100 mL) was added K2CO3 (800 mg, 6.0 mmol) and the resultant mixture 
was stirred at room temperature for 1 h. The mixture was diluted with diethyl ether (300 mL) 
and washed with NH4Cl (aq) (2 x 200 mL) and H2O (2 x 200 mL). The organic layer was 
dried over MgSO4, filtered and concentrated in vacuo to afford 42 (115 mg, 0.9 mmol, 60% 
yield) as a yellow oil. The crude material was used for further reactions without purification. 
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δH (400 MHz, CDCl3) 3.34 (s, 2H); 7.31 (dd, J = 3.5 Hz, 6.0 Hz, 2H); 7.51 (dd, J = 3.5 Hz, 5.5 
Hz, 2H). δC (100 MHz, CDCl3) 81.2; 81.8; 125.0; 128.5; 132.7. m/z (EI+) calcd. for 
C10H7([M+H]+) 128.0626, found: 128.0625. 
 
1-Ethynyl-2-iodobenzene (43)[187] 
To a stirred solution of 1-[2-(trimethylsilyl)ethynyl]-2-iodobenzene 45 (370 mg, 1.2 mmol) in 
MeOH/CH2Cl2 (2:1, 6 mL) was added KOH (138 mg, 2.5 mmol) and the resultant mixture 
was stirred at room temperature over night. The reaction was quenched by addition of H2O 
(10 mL) and the product was extracted with CH2Cl2 (3 x 10 mL) and the organic layers were 
washed with H2O (10 mL) and brine (10 mL), filtered and concentrated in vacuo to afford 43 
(213 mg, 72% yield) as a pale yellow oil. The crude material was used for further reactions 
without purification. δH (400 MHz, CDCl3) 3.40 (s, 1H); 7.04 (m, 1H); 7.31 (td, J = 1.0 Hz, 
1H); 7.51 (dd, J = 1.5 Hz, 7.5 Hz, 1H); 7.85 (dd, J = 1.0 Hz, 8.0 Hz, 1H). δC (100 MHz, 
CDCl3) 81.0; 85.2; 100.5; 127.82; 128.75; 130.0; 133.5; 138.8. m/z (EI+) calcd. for C8H6I 
([M+H]+) 229.9593, found: 229.9597. 
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7.3 Experimental for Chapter 3 
Synthesis of 2-flouroethylazide (FEA)[151] 
 
2-Fluoroethyl tosylate (56) 
To a stirred solution of 2-fluoroethanol 55  (0.55 mL, 7.8 mmol) in CH2Cl2 (15 mL) was added 
tosylchloride (2.23 g, 11.7 mmol) and DIPEA (1.52 mL, 15.8 mmol) and the resultant mixture 
was stirred at room temperature under nitrogen for 16 h. CH2Cl2 (30 mL) was added and 
was washed with H2O (2 x 10 mL). The solvent was evaporated in vacuo to yield crude 2-
fluoroethyl tosylate 56 (1.83 g), which was carried through to the next step without further 
purification.  
 
2-Fluoroethyl azide (FEA) 
To a stirred solution of 2-fluoroethyl tosylate 56 (200mg, 0.92 mmol) in DMF (5 mL) was 
added sodium azide (178.6 mg, 2.75 mmol) and the resultant mixture was stirred at room 
temperature under nitrogen for 48 h, at which point TLC (1:1 EtOAc/Hex.) showed complete 
consumption of the starting material. The reaction mixture was then filtered to remove the 
white precipitate, and the filtrate was used for the next step without work-up or purification. 
δF (400 MHz, CDCl3) -224. 
General method for the copper-free ‘click’ reaction with cyclooctynes[151] 
2-Fluoroethyl azide (FEA) (0.02 mmol) was added to a stirred solution of cyclooctyne 
(0.005 mmol) in CDCl3 (0.6 mL). The resultant mixture was stirred at 40°C for 2 h. When 
complete, the reaction was stopped and the solvent evaporated in vacuo. The crude material 
was re-dissolved in CDCl3 and the 19F, 1H and 13C NMR spetra were taken. These crude 
compounds, as mixtures of regioisomers, were used as references only. The ratio of 
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regioisomers was determined using a combination of 18F HPLC traces of the radiolabelled 
compounds, and by the 19F NMR spectra (see appendix 2). The characterisation of these 
compounds is detailed below.  
Characterisation of triazole products 
 
{[1-(2-Fluoroethyl)-4,5,6,7,8,9-hexahydro-1H-cycloocta[d][1,2,3]triazol-4-yl]oxyacetic 
acid (49) as a mixture of regioisomers in ratio 2:1. 
δH (400 MHz, CDCl3) 1.25-2.46 (m, 15H); 3.30-3.40 (m, 4.5H); 4.28 (dd, J = 27.0 Hz, 4.0 Hz, 
3H); 4.56 (d, J = 47.0 Hz, 3H); 8.06 (s, 1H). δF (400 MHz, CDCl3) -224.5 (1); -222.4 (2). m/z 
(EI+) ([M+ H]+) calcd. for 272.1405, found: 272.1405.  
 
{[1-(2-Fluoroethyl)-4,5,6,7,8,9-hexahydro-1H-cycloocta[d][1,2,3]triazol-4-yl]oxy} N-(4-
methoxybenzyl)acetamide (50) as a mixture of regioisomers in ratio 2:1. 
δH (400 MHz, CDCl3) 1.15-2.04 (m, 13.5H); 2.80-2.64 (m, 3H); 3.31-3.53 (m, 8H); 4.13-4.31 
(m, 3H); 7.13-7.19 (m, 1H); 7.53 (dd, J = 5.5 Hz, 3.5 Hz, 1.5H); 7.70 (dd, J = 5.5 Hz, 3.5 Hz); 
7.78 (d, J = 8.0 Hz, 1H). δc (100 MHz, CDCl3) 19.9; 23.0; 23.7; 24.2; 27.0; 29.1; 30.4; 33.3; 
38.7; 48.6; 49.3 (d, JCF = 25.0 Hz); 48.6; 54.3; 68.2; 81.6 (d, JCF = 168.0 Hz); 125.9; 228.8; 
131.0; 132.5; 165.6; 167.8. δF (400 MHz, CDCl3) -222.5 (2); -225.5 (1). m/z (EI+) ([M+K]+) 
calcd. for 429.1699, found: 429.1701.  
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1-(2-Fluoroethyl)-carbonicacid-2’,3’,2”,3”-tetramethoxy-7,8-didehydro-1,2:5,6-
dibenzocyclocta-1,5,7-triene-[1,2 ,3]triazolyl 4-nitrophenyl ester (51) as a mixture of 
regioisomers in ratio 2:1. 
δH (400 MHz, CDCl3) 2.89 (app s, 1H); 2.96 (app s, 1H); 3.10 (app s, 0.5H); 3.21 (app s, 
0.5H); 3.70- 4.01 (m, 18H); 4.53-4.79 (m, 6H); 5.34-5.72 (m, 1H); 6.57-6.63 (m, 1H); 6.68-
6.72 (m, 1H); 6.81-6.83 (m, 1H); 6.91 (d, J = 9.0 Hz, 2H); 6.99-7.01 (m, 1H); 7.07-7.10 (m, 
1H); 8.07 (d, J = 9.0 Hz, 1H); 8.14 (d, J = 9.0 Hz, 2H). δc (100 MHz, CDCl3) 41.0; 45.6; 50.8 
(d, JCF = 24.0 Hz) 55.9; 55.9;, 56.0; 56.0; 81.9 (d, JCF = 171.0 Hz); 107.4; 107.2; 109.3; 
111.7; 113.0; 113.7; 114.7; 115.5; 115.7; 124.8; 125.9; 141.1; 142.5; 143.3; 146.5; 148.6; 
149.7; 150.2; 150.7; 152.8; 154.3. δF (400 MHz, CDCl3) -222.3 (1); -222.4 (2). m/z (EI+) ([M+ 
2H]2+) calcd. for 298.0954, found: 298.1001. 
 
1-(2-Fluoroethyl)-carbonicacid-2’,3’,2”,3”-tetramethoxy-7,8-didehydro-1,2:5,6-
dibenzocyclocta-1,5,7-triene-[1,2,3]triazolyl N-(2-aminoethyl)maleimide (52) as a 
mixture of regioisomers in ratio 7:1. 
δH (400 MHz, CDCl3). 2.44 (s, 1H); 2.60 (s, 1H); 2.72 (s, 1H); 2.80 (s, 1H); 3.00 (s, 1H); 3.07 
(s, 1H); 4.16-4.23 (m, 12H); 4.25 (dm, J = 27.0 Hz, 2H); 4.56 (dm, J =  47.0 Hz, 2H); 5.28-
5.61 (m, 1H); 7.33 (s, 1H); 7.35 (s, 1H); 7.50-7.52 (m, 2H); 7.67-7.69 (m, 2H). δc (100 MHz, 
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CDCl3) . 28.9; 29.7; 30.4; 36.5; 40.3; 46.1; 56.0; 67.1 (d, JCF = 26.5 Hz); 68.1; 80.6 (d, JCF = 
174.5 Hz); 107.8; 108.7; 109.5; 112.0; 113.7; 114.1; 115.5; 128.0; 128.8; 130.8; 132.5; 
145.1; 147.8; 148.5; 150.6; 151.1; 161.0; 162,6; 167.8. δF (400 MHz, CDCl3) -225.2. m/z 
(EI+) ([(M-maleimide)+H]+) calcd. for 430.1773, found: 430.1775.  
 
4,4-Difluoro-1-(2-fluoroethyl)-4,5,6,7,8,9-hexahydro-1H-cycloocta[d][1,2,3]triazol-5-yl 4-
nitrophenyl carbonate (53) as a mixture of regioisomers in ratio 2:1. 
δH (400 MHz, CDCl3) 1.18-1.37 (m, 1.5H); 1.73-1.86 (m, 1.5H); 2.30-2.39 (m, 6H); 2.43-2.47 
(m, 3H); 4.57 (dm, J = 22.5 Hz, 3H);  4.92 (dm, J = 26.0 Hz, 3H); 5.35-5.38 (m, 1.5H); 7.19 
(d, J = 8.0 Hz, 2H); 7.83 (d, J = 8.0 Hz, 2H). δc (100 MHz, CDCl3) 19.7; 24.1; 29.1; 29.7; 
32.6; 50.6 (d, JCF = 20.0 Hz); 80.4 (d, JCF = 176.0 Hz); 82.0; 85.1; 111.8; 112.4; 113.1; 113.7; 
115.6; 121.8; 126.0; 128.6. δF (400 MHz, CDCl3) -223.7 (2); -223.5 (1); -107.8; -107.5; -
104.9; -101.3; -100.5; -93.7. m/z (EI+) ([M+H]+) calcd. for 415.1224, found: 415.1220 
Radiosynthesis of [18F]FEA 
Radiosynthesis of [18F]2-fluoroethylazide ([18F]FEA) was carried out using the method 
described by Glaser et al.[62] Briefly, a mixture of Kryptofix 222 (5 mg, 13.3 µmol), K2CO3 (1 
mg, 7.2 µmol, in 50 µL H2O), and CH3CN (1 mL) was added to [18F]fluoride (74−370 MBq) in 
H2O (1 mL). The solvent was removed by heating at 80°C under a stream of N2 (g) (100 mL 
min-1). Afterward, CH3CN (0.5 mL) was added, and the distillation was continued. This 
procedure was repeated twice. After cooling to room temperature, a solution of 2-azidoethyl-
4-toluenesulfonate (1.5 µL, 7.5 µmol) in anhydrous CH3CN (0.2 mL) was added. The 
reaction mixture was stirred for 15 min at 80°C. After addition of CH3CN (0.3 mL), [18F]FEA 
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was distilled at 130°C under a flow of N2 (g)  (15 mL min-1) into a trapping vial containing 
CH3CN (0.1 mL). [18F]FEA was collected with a radiochemical yield of 54% (decay-
corrected) and 63% distillation efficiency. 
 
Figure SI 1. Radio-HPLC trace of [18F]FEA using gradient A 
Synthesis of maleimide-substituted cyclooctynes 
 
Carbamate-2’,3’,2”,3”-tetramethoxy-7,8-didehydro-1,2:5,6-dibenzocyclocta-1,5,7-
triene-3-yl N-(2-Aminoethyl)maleimide (TMDIBO2) 
To a stirred solution of carbonic acid-2’,3’,2”,3”-tetramethoxy-7,8-didehydro-1,2:5,6-
dibenzocyclocta-1,5,7-triene-3-yl 4-nitrophenyl ester (TMDIBO1) (5.0 mg, 0.01 mmol) in 
DMF (1 mL) was added DIPEA (2.1 µL, 0.01 mmol). The resultant mixture was stirred at 
room temperature for 15 min, after which time N-(2-aminoethyl)maleimide 57 (5.1 mg, 0.02 
mmol) was added and the mixture was stirred at room temperature for 16 h. The product 
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was extracted with EtOAc (2 x 10 mL) and washed with H2O (2 x 10 mL). The combined 
organic layers were dried over MgSO4 and the solvent was evaporated in vacuo to yield 
crude material as a yellow oil. The product was purified by column chromatography, eluting 
with 50-70% EtOAc/pet. ether to yield TMDIBO2 as a yellow powder (5 mg, 0.01 mmol, 99% 
yield). δH (400 MHz, CDCl3) 2.92 (s, 2H); 2.99 (s, 2H); 3.07-3.11 (m, 1H); 3.45-3.48 (m, 1H); 
3.82-3.98 (m, 12H); 5.44 (m, 1H); 6.83-6.85 (d, J = 6.0 Hz, 2H); 6.92-6.94 (d, J = 9.0 Hz, 
2H); 7.03-7.06 (d, J = 12.0 Hz, 2H). δC (100 MHz, CDCl3) 30.9; 31.5; 36.5; 40.3; 46.7; 56.1; 
68.2; 108.2; 108.7; 109.1; 112.5; 114.1; 115.6; 126.2; 128.8; 130.9; 134.2; 145.2; 147.8; 
148.8; 150.2; 161.7; 162.4; 207.0. m/z (EI+) calcd. for C20H21O5 ([(M-mal)+H]+) 341.1384, 
found: 341.1390.  
 
2-(Cyclooct-2-yn-1-yloxy)-N-(2-Aminoethyl)maleimide (OCT5) 
To a stirred solution of cyclooct-1-yn-3-glycolic acid OCT5 (25 mg, 0.14 mmol) in DMF (3 
mL) was added DIPEA (50 µL, 0.30 mmol). The resultant mixture was stirred at room 
temperature for 15 min, after which time N-(2-aminoethyl)maleimide 57 (42.7 mg, 0.17 
mmol) was added and the mixture was stirred at room temperature for 16 h. TLC (1:1 
EtOAC/pet. ether) indicated that the reaction had gone to completion. The reaction was 
stopped and the product was extracted with EtOAc (2 x 25 mL) and washed with H2O (2 x 25 
mL). The combined organic layers were dried over MgSO4 and the solvent was evaporated 
in vacuo to yield crude material as a yellow oil. The product was purified by column 
chromatography, eluting with 60-80% EtOAc/pet.ether to yield OCT5 as a yellow solid (15 
mg, 0.05 mmol, 35% yield). δH (400 MHz, CDCl3) 1.3-2.3 (m, 10H); 3.44-2.61 (m, 2H); 3.75 
(t, 2H); 3.97 (dd, J = 75.0 Hz, 15.0 Hz, 2H); 4.22-4.28 (m, 1H); 6.75-6.86 (m, 2H). m/z (EI+) 
calcd. for  C16H21N2O4 ([(M+H]+) 305.14, found: 305.14.  
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Cell viability assay using TMDIBO1* 
A sulforhodamine B cell viability assay was carried out in order to assess the toxicity of the 
cyclooctyne TMDIBO1. On day one HCT116 colon cancer cells were seeded in a 96-well 
plate at a density of 2,000 cells per well in a volume of 150 µl of RPMI supplemented with 1 
% penicillin/streptomycin and 10% FBS. On day two cells were treated by addition of 50 µL 
of TMDIBO1 at a range of concentrations between 0 and 20 µM. After 72 h, cells were fixed 
by addition of 50% trichloroacetic acid and stained with a 0.4% solution of sulforhodamine B 
in 1% acetic acid. Finally, 10 mM tris base buffer was used to solubilise the stained protein 
and absorbance was measured at 540 nm.  
The cell viability versus compound concentration curve was plotted as a percentage of non-
treated control cells. The experiment was carried out on three separate occasions with n=6 
replicates for each concentration. 
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*The cell viability assay was carried out by Dr Quang-De Nguyen 
Figure SI 2. Growth inhibition of HCT116 cells after 72 h incubation with an increasing concentration of TMDIBO1. 
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Conjugation of Herceptin to cyclooctynes 
Thiol-substituted Herceptin/IgG1 (61/62) 
Herceptin/IgG1 (21 mgmL-1, 700 µL) 59/60 was stirred at room temperature with 2-imino 
thiolane 58 (3 µmol, 0.4 mg) for 1 h and the resultant solution was used for direct 
conjugation to the cyclooctyne.  
OCT-Herceptin/IgG1 
OCT5 (0.25 mg, 0.6 µmol) was dissolved in a 1:1 DMF/DMA solution (0.25 mL) and the 
resultant mixture was added dropwise to the solution of 59/60. The mixture was agitated in 
the dark for 1 h. 0.5 mL of the reaction mixture was loaded onto a NAPTM-5 column and the 
ligated antibody was eluted with 0.25 M sodium acetate buffer (1.0 mL). 
TMDIBO-Herceptin/IgG1 
TMDIBO2 (0.25 mg, 0.6 µmol) was dissolved in a 1:1 DMF/DMA solution (0.25 mL) and the 
resultant mixture was added dropwise to the solution of 59/60. The mixture was agitated in 
the dark for 1 h. 0.5 mL of the reaction mixture was loaded onto a NAPTM-5 column and the 
ligated antibody was eluted with 0.25 M sodium acetate buffer (1.0 mL). 
Characterisation of Herceptin-conjugated cyclooctynes 
In order to determine the number of cyclooctynes attached to the Herceptin antibody, the 
mass spectra was determined first of the antibody alone, and then with the antibody 
conjugated to the cyclooctyne. Mass spectral analysis of the Herceptin conjugates was 
carried out by the DCMR facility in Ecole Polytechnique, France. For example, the mass of 
OCT-Herceptin was determined as described below.  The molecular masses measured for 
Herceptin were found to be 148 063, 148 219 and 148 379. These probably correspond to 
three isoforms differing in the number of hexoses (162 Da). 
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Figure SI 3. MALDI MS of unmodified Herceptin 
The molecular mass measured for OCT-Herceptin was calculated at approximately 149 
060. The difference between both can be calculated as 148 380 (to take the average mass 
of the pattern) - 149 060 = 680 Da. This mass corresponds probably to two molecules of 
OCT5. Then 337*2-2= 672 which is close to 680 and would indicate the presence of 2 OCT 
molecules (as an average). The spectrum indicates that we probably have a mixture of 1, 2 
and 3 OCT, with 2 being the major isoform.  
	  
Figure SI 4. MALDI MS of OCT-Herceptin 
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[18F]FEA small animal PET imaging and tissue biodistribution.* 
BALB/c mice (n=3, Harlan, UK) were scanned on a dedicated small animal PET scanner 
(Siemens Multimodality Inveon, Siemens Molecular Imaging Inc., Knoxville, USA) following a 
bolus i.v. injection of ~3.7 MBq of [18F]FEA. All animal experiments were done in 
accordance with the United Kingdom Home Office Guidance on the Operation of the Animal 
(Scientific Procedures) Act 1986 (HMSO, London, United Kingdom, 1990) and within 
guidelines set out by the United Kingdom National Cancer Research Institute Committee on 
Welfare of Animals in Cancer Research.[10] Dynamic emission scans were acquired in list-
mode format over 60 min. The acquired data were then sorted into 0.5 mm sinogram bins 
and 19 time frames for image reconstruction, which was done by filtered back projection. 
Direct [18F]FEA tissue biodistribution was assessed subsequent to the PET scan. For this, 
blood was taken by cardiac puncture from the animals and tissues were excised. The tissues 
were weighted and immediately counted for fluorine-18 radioactivity. Data were expressed 
as percentage injected dose per gram (%ID/ g). 
 
Figure SI 5. [18F]FEA tissue biodistribution in BALB/c mice* in vivo work was carried out by Dr Quang-De Nguyen 
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Synthesis of 2,2′,2″-(11-Azido-3,6,9-trioxaundecan-1-amino)-2-oxoethyl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (DOTA-Az)[203] 
1,4,7-Tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane-10-acetic acid (71) 
was synthesised in accordance with the literature procedure. [204, 205] DOTA-NHS ester 72 
was purchased from Macrocyclics, Inc. (Dallas, TX). 
 
2,2′,2″-(11-Azido-3,6,9-trioxaundecan-1-amino)-2-oxoethyl)- 1,4,7-tris(tert-
butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane (72)[203] 
To a stirred solution of 71 (400 mg, 0.7 mmol) in DMF (8 mL) was added HBTU (530 mg, 1.4 
mmol) and DIPEA (134 µL, 1.4 mmol) and the resultant mixture was stirred at room 
temperature for 30 min. After this time, 11-azido-3,6,9-trioxaundecan-1-amine (200 µL, 0.85 
mmol) was added and the resultant mixture was stirred at 40°C for 16 h. The mixture was 
allowed to cool to room temperature, and the product was extracted with CH2Cl2 (3 x 10 mL). 
The combined organic layers were washed with H2O (2 x 10 mL) and brine (10 mL), dried 
over MgSO4, filtered, and concentrated in vacuo to yield the crude material as an orange oil. 
The product was purified by column chromatography, eluting with 5% MeOH/CH2Cl2, to give 
pure product 72 as an off-white oil (421 mg, 78% yield). m/z (ES+) calcd for: C36H69N8O10 
([(M+H]+) 773.5137, found: 773.5148.   
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2,2′,2″-(11-Azido-3,6,9-trioxaundecan-1-amino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid (DOTA-Az)[203] 
Method 1: 
To a stirred solution of 72 (400 mg, 0.52 mmol) in CH2Cl2 (22.5 mL) was added TFA (30 mL) 
and the resultant mixture was stirred at room temperature for 2 h. The mixture was  
concentrated in vacuo and azeotroped 3 times with chloroform (3 x 25 mL). The residue was 
dissolved in acetone (5 mL) and the solution was added to diethyl ether (25 mL). The 
resulting precipitate was filtered off, and the supernatant was evaporated in vacuo to yield 
the crude material as a yellow oil. The product was purified by HPLC to yield DOTA-Az as a 
yellow oil (213 mg, 69% yield).  δH (400 MHz, DMSO-d6) 3.00-3.30 (m, 18H), 3.38-3.48 (m, 
8H), 3.50-3.61 (m, 14H). m/z (ES+) calcd for: C24H45N8O10 605.3259 ([(M+H]+), found: 
605.3251 
Method 2: 
11-Azido-3,6,9-trioxaundecan-1-amine 74 (13.5 mg, 0.07 mmol) was dissolved in DMF (1 
mL) and DOTA-NHS ester 73 (48.5 mg, 0.063 mmol) and triethylamine (105 µL, 0.7 mmol) 
were added, and the resultant mixture was stirred at room temperature for 2 h. The mixture 
was concentrated in vacuo, to give a yellow oil as crude. A portion of the crude material was 
purified by preparative HPLC to yield DOTA-Az as a yellow oil (29 mg, 69% yield)..  
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General procedure for Ga-labelling DOTA compounds (synthesis of ‘cold’ 
reference compounds) 
To a stirred solution of DOTA-compound (1.5 µmol) in NaOAc buffer (0.2 M, pH 6) was 
added Ga(NO3)2 (15 µmol) and the resultant mixture was stirred at 80°C for 30 min. The 
mixture was cooled to room temperature, before being applied to a pre-conditioned (5 mL 
EtOH, followed by 5 mL H2O) Sep-pak light C18 cartridge. The cartridge was washed with 
H2O (5 mL), and the compound was eluted in EtOH (0.5 mL). The EtOH was evaporated in 
vacuo, and the compound re-dissolved in H2O, before being freeze-dried to give the 69Ga-
labelled cold reference compound.  
 
 [69Ga]2,2′,2″-(11-Azido-3,6,9-trioxaundecan-1-amino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid ([Ga]DOTA-Az) 
[Ga]DOTA-Az was synthesised from DOTA-Az, in accordance with the general procedure. 
m/z (ES) calcd for C24H42N8O1069Ga, 671.2280 ([(M+H]+), found 671.2297 
General procedure for the SPAAC reaction between [Ga]DOTA-Az and DBCO 
cyclooctynes  
DOTA-Az (50.0 µmol) was dissolved EtOH/DMSO (5:1, 500 mL), and cyclooctyne (55.0 
µmol, 1.1 eq.) was added. The mixture was stirred at 50°C for 4 h. The mixture was purified 
by preparative HPLC, to form the triazole products as white solids. The triazole products 
were labelled with 69Ga, as described in the general procedure. 
 
 
Chapter 7 - Experimental 
 
242 
 
Characterisation of triazole products 
 
Triazole 75: m/z (ES) calcd for C45H64N9O13, 938.4624 (M+), found 938.4664. [Ga]75: m/z 
(ES) calcd for C45H61N9O1369Ga ([M+H]+), 1004.3645, found 1004.3627 
 
Triazole 76: m/z (ES) calcd for C49H65N11O14, 1032.47 (M+), found 1032.4581; 515.735 (M2+), 
found 516.7386. [Ga]76: m/z (ES) calcd for C49H60N11O1469Ga ([M+H]2+) 549.8743 found 
549.8743 
Radiosynthesis of [68Ga]DOTA-Az  
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A solution of DOTA-Az (50 µL, 1 mgmL-1 in DMSO) was diluted with NaOAc buffer solution 
(pH 4), and the 68GaCl3 was eluted directly into the reaction vial (~1.5 mCi). The 
radiosynthesis of [68Ga]DOTA-Az was achieved in 10 min at 90°C, in >95% radiochemical 
conversion, and the product was obtained in >95% radiochemical purity, and in 60% isolated 
RCY (n.d.c) by passing through a Sepak light C18 cartridge, eluting in 100% EtOH. The 
mixture was then diluted with water or acetonitrile for application to the 68Ga-labeled click 
reactions.  
 
Figure SI 6. Radio-HPLC trace of [68Ga]DOTA-Az using gradient A 
 
General procedure for 68Ga-labeled SPAAC reactions between [68Ga]DOTA-Az 
and DIBAC cyclooctynes 
To a 10 mg mL-1 solution of cyclooctyne (DIBAC1/DIBAC2) (50 µL) in either H2O (10 % 
DMSO) or MeCN, was added [68Ga]DOTA-Az (100 µL), and the mixture was heated to 
either 37°C or 90°C for the given time-point, without stirring. The progress of the reaction 
was monitored by radio-HPLC.  
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7.4 Experimental for Chapter 4 
Synthesis of 6-(6-(Pyridin-2-yl)-1,2,4,5-tetrazine-3-yl)pyridine-3-amine (Tz1)[116] 
 
6-(6-Pyridin-2-yl-1,4-dihydro-1,2,4,5-tetrazin-3-yl)-pyridin-3-ylamine (81)[116] 
A dry round-bottomed flask was charged with 5-amino-2-cyanopyridine 79 (572 mg, 4.8 
mmol), 2-cyanopyridine 80 (500 mg, 4.8 mmol) and hydrazine hydrate (50-60 %, 1.2 mL, 
19.2 mmol). The flask was fitted with a reflux condenser, and the mixture was stirred at 90°C 
for 12 h. The mixture was cooled to room temperature, and the orange precipitate formed 
was isolated by filtration and was washed with H2O (3 x 10 mL). The orange solid 81 (1.03 g, 
4.0 mmol, 85% yield) obtained was used for the next step without further purification. δH (400 
MHz, DMSO-d6) 5.88 (s, 2H) 6.98 (dd, J = 2.5 Hz, 8.5 Hz, 1H); 7.50 (m, 1H); 7.63 (d, J = 8.5 
Hz, 1H); 7.92 (m, 3H); 8.61 (m, 1H); 8.65 (s, 1H); 8.70 (s, 1H). δC (100 MHz, DMSO-d6) 
120.8; 121.3; 122.3; 125.7; 134.5; 134.6; 137.8; 146.7; 147.1; 147.1; 147.3; 149.0. HRMS 
(ESI) m/z calcd for C12H12N7 ([M+H]+) 254.1154, found 254.1147. 
 
6-(6-(Pyridin-2-yl)-1,2,4,5-tetrazine-3-yl)pyridine-3-amine (Tz1)[116] 
To a stirred solution of 6-(6-Pyridin-2-yl-1,4-dihydro-[1,2,4,5]tetrazin-3-yl)-pyridin-3-ylamine 
81 (1.0 g, 3.95 mmol) in toluene (25 mL) was added DDQ (1.8 g, 7.9 mmol) and the resultant 
mixture was stirred under reflux for 16 h. The crude product was concentrated in vacuo onto 
silica deactivated with triethylamine (5% in hexane), and was purified by column 
chromatography eluting with 20-100% acetone in hexane. Tz1 (eluted in 100% acetone) was 
isolated as a brown/purple solid (735 mg, 2.9 mmol, 75% yield). δH (400 MHz, DMSO-d6) 
6.38 (s, 1H); 7.13 (dd, J = 8.7, 2.8, 1H); 7.69 (ddd, J = 7.5 Hz, 4.5 Hz, 1.0 Hz, 1H); 8.12 (td, 
J = 8.0 Hz, 2.0 Hz, 1H); 8.24 (d, J = 3.0 Hz, 1H); 8.36 (d, J = 8.5 Hz, 1H); 8.53 (d, J = 8.0 Hz, 
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1H); 8.89-8.91 (m, 1H). δC (100 MHz, DMSO-d6) 119.4; 124.2; 126.2; 126.7; 136.5; 137.7; 
138.2; 148.5; 150.9; 163.0; 163.4. HRMS (ESI) m/z calcd for C12H10N7 ([M+H]+) 252.0098, 
found 252.1002. 
Synthesis of 4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzylamine (Tz3)[144] 
 
tert-Butyl [4-(Boc-aminomethyl)benzonitrile] (87)[144] 
4-(Aminomethyl)benzonitrile·HCl 85 (5.0 g, 30.0 mmol) was azeotroped with toluene (3 x 20 
mL) and dissolved in CH2Cl2 (4.0 mL). Triethylamine (11.0 mL, 75.0 mmol) and Boc2O (7.4 
g, 33.0 mmol) were added and the resultant mixture was stirred at room temperature for 16 
h. The mixture was concentrated in vacuo to yield a white solid, which was recrystallised 
from EtOAc/pet ether, to yield tert-butyl (4-(aminomethyl)benzocarbamate) 87 (6.0 g, 25.8 
mmol, 87% yield) as a white powder. δH (400 MHz, CDCl3) 1.43 (s, 9H); 4.33 (d, J = 6.0 Hz, 
2H); 5.10 (bs, 1H); 7.36 (d, J = 8.5 Hz, 2H); 7.58 (d, J = 8.5 Hz, 2H). δC (100 MHz, CDCl3) 
28.3; 44.1; 79.9; 111.0; 118.7; 127.7; 132.3; 144.7; 155.8. m/z (ES+) calcd for: C13H17N2O 
([M+H]+)  233.1290, found: 233.1294. 
 
tert-Butyl 4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzylcarbamate (89)[144] 
A high pressure reaction tube was treated with 4-(boc-aminomethyl)benzonitrile 87 (232 mg, 
1.0 mmol), MeCN (525 µL, 10.0 mmol), Ni(OTf)2 (178 mg, 0.5 mmol) and hydrazine hydrate 
(50-60% NH2NH2) (3.1 mL, 50.0 mmol). The tube was sealed and heated to 60°C for 24 h, 
after which time the mixture had turned deep purple in colour. NaNO2 (1.4 g, 20.0 mmol) in 
H2O (5 mL), was added to the mixture, followed by dropwise addition of HCl (1M), until the 
pH reached 3 and gases stopped evolving, at which point the mixture had turned bright red. 
The product was extracted with EtOAc (3 x 20 mL), and the combined organic layers were 
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washed with H2O (2 x 10 mL) and brine (10 mL), dried over MgSO4, filtered, and 
concentrated in vacuo to yield a bright pink oil as crude. The product was purified by column 
chromatography, eluting with 0-3% diethyl ether/CH2Cl2, to give tert-butyl 4-(6-methyl-
1,2,4,5-tetrazin-3-yl)benzylcarbamate 89 (74 mg, 0.3 mmol, 60% yield) as a bright pink solid. 
Rf = 0.35 (2% diethyl ether/CH2Cl2). δH (400 MHz, CDCl3) 1.47 (s, 9H); 3.08 (s, 3H); 4.42 (d, 
J = 4.5 Hz, 2H); 5.04 (bs, 1H); 7.48 (d, J = 7.5 Hz, 2H); 8.53 (d, J = 7.5 Hz, 2H). δC (100 
MHz, CDCl3) 20.5; 27.8; 43.7; 79.2; 127.5 (d, J = 14.0 Hz); 130.1; 143.3; 155.3; 163.3; 
166.6. m/z (ES+) calcd for: C11H11N5O2  ([M-tBu]+) 246.0991 found: 246.0983. 
 
4-(6-Methyl-1,2,4,5-tetrazin-3-yl)benzylamine (Tz3)[144] 
tert-Butyl 4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzylcarbamate 89 (45.0 mg, 0.15 mmol) was 
treated with TFA/CH2Cl2 (1/1, v/v, 4 mL) for 1 h. The resultant mixture was concentrated in 
vacuo to yield 4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzylamine Tz3 as a bright pink solid (30 
mg, 0.14 mmol, >95% yield).  δH (400 MHz, DMSO-d6) 3.01 (s, 3H); 4.18 (bs, 2H); 7.73 (d, J 
= 8.5 Hz, 2H); 8.26 (bs, 2H); 8.52 (d, J = 8.5 Hz, 2H). δC (100 MHz, DMSO-d6) 27.8; 41.9; 
127.5; (d, J = 14.0 Hz); 129.7; 131.9; 138.2; 162.9; 167.2. m/z (CI) calcd for C10H12N5 
202.1093 (M+), found 202.1096. m/z (CI) calcd for  C10H12N5  ([M+H]+) 202.1093, found 
202.1096.  
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2,2′,2″-(10-(2-((4-(6-methyl-1,2,4,5-Tetrazin-3-yl)benzyl)amino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid (DOTA-Tz) 
4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzylamine Tz3 (13.5 mg, 0.07 mmol) was dissolved in 
DMF (1 mL) and DOTA-NHS ester 73 (48.5 mg, 0.06 mmol) and triethylamine (105 µL, 0.7 
mmol) were added, and the resultant mixture was stirred at room temperature for 2 h. The 
mixture was concentrated in vacuo, to give a pink oil as crude. The crude material was 
purified by preparative HPLC to yield DOTA-Tz as a pink solid (25 mg, 0.04 mmol, 60% 
yield). δH (400 MHz, DMSO-d6) 3.00 (s, 3H); 3.06-3.17 (m, 8H); 3.19-3.35 (m, 8H); 3.60-3.70 
(m, 4H); 3.85-4.02 (m, 4H); 4.48 (d, J = 5.5 Hz, 2H); 7.59 (d, J = 8.5 Hz, 2H); 8.46 (d, J = 8.5 
Hz, 2H); 9.00 (bs, 1H). m/z (ES+) calcd. for C26H38N9O7 ([M+H]+) 588.2894, found 588.2870. 
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Figure SI 7. HPLC (UV) trace of DOTA-Tz at 254 nm using gradient B 
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General procedure for the synthesis of norbornene analogues 
 
5-Norbornene-2-carboxylic acid (mixture of endo and exo, predominantly endo) (91) (130.2 
mg, 1.0 mmol) was dissolved in CH2Cl2 (10 mL), and EDCI (230 mg, 1.2 mmol), DMAP (30.5 
mg, 0.25 mmol) and triethylamine (167 µL, 1.2 mmol) were added, and the mixture was 
stirred at room temperature for 30 min. Fluoro-aniline (1.2 mmol) was added, and the 
resultant mixture was stirred at room temperature for 4 h. The mixture was partitioned 
between CH2Cl2 (20 mL) and NaHCO3 (20 mL, sat. aq.), and the organic layer was washed 
with H2O (2 x 20 mL) and brine (2 x 20 mL), dried over MgSO4, filtered and concentrated in 
vacuo. The crude material was purified by column chromatography eluting with 100% 
CH2Cl2, and the solid was recrystallised from EtOAc/hexane to yield the product  
 
 (1S,4S)-N-(3-Fluorophenyl)bicyclo[2.2.1]hept-5-ene-2-carboxamide (exo) (100) 
Using the general procedure, 3-fluoroaniline provided amide 100 as a white powder (162 
mg, 0.7 mmol, 70% yield). δH (400 MHz, CDCl3) 1.16 (m, 1H); 1.31 (m, 2H); 1.81 (ddd, J = 
3.5 Hz, 9.5 Hz, 11.5 Hz, 1H); 2.83 (m, 2H); 3.05 (s, 1H); 5.85 (dd, J = 3.0 Hz, 5.5 Hz, 1H); 
6.12 (dd, J = 3.0 Hz, 5.5 Hz, 1H); 6.59 (ddt, J = 0.5 Hz, 2.5 Hz, 8.5 Hz, 1H); 6.93 (dd, J = 1.0 
Hz, 8.0 Hz, 1H); 7.06 (m, 1H); 7.29 (m, 1H). δC (101 MHz, CDCl3) 29.6; 42.6; 45.6; 46.3; 
50.0; 106.8; 110.2; 114.6; 129.7 (d, JCF = 9.5 Hz); 131.6; 137.9; 139.3; 161.5; 172.6. δF (376 
MHz, CDCl3) -111.62 (m). m/z (ES) calcd for C14H15NOF ([M+H]+) 232.1138, found 
232.1149. 
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 (1S,4S)-N-(4-Fluorophenyl)bicyclo[2.2.1]hept-5-ene-2-carboxamide (endo) (101) 
Using the general procedure, 4-fluoroaniline provided amide 101 as a white powder (111 
mg, 0.5 mmol 50% yield). δH (400 MHz, CDCl3) 1.40 (m, 2H); 1.76 (d, J = 8.5 Hz, 1H); 2.02 
(td, J = 4.0 Hz, 11.5 Hz, 1H); 2.14 (dd, J = 4.5 Hz, 10.0 Hz, 1H); 3.00 (d, J = 30.5 Hz, 2H); 
6.16 (ddd, J = 3.0 Hz, 5.5 Hz, 22.0 Hz, 2H); 7.00 (t, J = 8.5 Hz, 2H); 7.48 (dd, J = 5.0 Hz, 9.0 
Hz, 2H). δC (100 MHz, CDCl3) 30.3; 41.3; 45.4; 46.0; 47.0; 115.1; 115.3; 121.2 (d, JCF = 8.0 
Hz), 133.9; 135.5; 138.2; 157.7; 160.1; 173.6. δF (376 MHz, CDCl3) -118.41 (m). m/z (ES) 
calcd for C14H15NOF ([M+H]+) 232.1138, found 232.1145. 
 
 (1S,4S)-N-(4-Fluorophenyl)bicyclo[2.2.1]hept-5-ene-2-carboxamide (exo) (102) 
Using the general procedure, 4-fluoroaniline provided amide 102 as a white powder (74 mg, 
0.32 mmol, 30% yield). δH (400 MHz, CDCl3) 1.34 (d, J = 8.0 Hz, 1H); 1.48 (m, 2H); 2.01 (m, 
1H); 2.98 (m, 2H); 3.22 (s, 1H); 6.04 (dd, J = 3.0 Hz, 5.5 Hz, 1H); 6.30 (dd, J = 3.0 Hz, 5.5 
Hz, 1H); 6.98 (t, J = 8.5 Hz, 2H), 7.15 (bs, 1H), 7.42 (m, 1H). δC (101 MHz, CDCl3) 30.0; 
42.9; 45.8; 46.5; 50.2; 115.4; 115.6; 121.5 (d, JCF = 8.0 Hz); 132.0; 134.0; 138.1; 158.0; 
160.4; 172.5. δF (376 MHz, CDCl3) -118.52 (m). m/z (ES) calcd for C14H15NOF  ([M+H]+) 
232.1138, found 232.1133. 
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General procedure for the IeDDA reaction between DOTA-Tz and alkenes 
 
[Ga]DOTA-Tz was synthesised from DOTA-Tz as described in the general procedure for 
69Ga-labelling. m/z (ES) calcd for C26H35N9O769Ga, ([M+H]+) 654.1915, found 654.1927 
Synthesis of dihydropyridazine products (‘cold’ reference compounds) 
DOTA-Tz3 (5.0 µmol) was dissolved in H2O/10% MeOH (1 mL), and alkene (5.5 µmol, 1.1 
eq.) was added. The mixture was stirred at 50°C for 2-4 h. Completion of reaction was 
indicated by the colour change of solution from pink to colourless. The mixture was purified 
by preparative HPLC, to form the dihydropyridazine products as white solids. The obtained 
dihydropyridazine products were labelled with Ga using the general procedure.   
Characterisation of dihydropyridazine products 
 
Dihydropyridazine 95: m/z (ES+) calcd. for: C34H47N7O9, ([M+H]+) 698.34, found: 698.4279; 
[Ga]95: m/z (ES) calcd. for: C34H47N7O9Ga, ([M+H]+) 764.2535, found: 764.2502 
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Figure SI 8. ES m/z for [Ga]95 
 
 
Dihydropyridazine 96: m/z (ES) calcd for C40H52N8O8F ([M+H]+) 791.3892, found 791.3884; 
[Ga]96: m/z (ES) calcd for: C40H49N8O8FGa ([M+H]+) 857.2913, found: 857.2924 
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Figure SI 9. ES m/z for [Ga]96 
 
 
Dihydropyridazine 97: m/z (ES) calcd for C40H52N8O8F ([M+H]+) 791.3892, found 791.3909; 
[Ga]97: m/z (ES) calcd for C40H49N8O8FGa ([M+H]+) 857.2903, found 857.2893 
Dihydropyridazine 98: m/z (ES) calcd for C40H52N8O8F ([M+H]+) 791.3892, found 793.3568; 
[Ga]98: m/z (ES) calcd for C40H48N8O8FNaGa ([M+H]+) 855.2508, found 855.2477. 
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Figure SI 10. ES m/z for [Ga]98 
 
Radiosynthesis of [68Ga]DOTA-Tz  
 
A solution of DOTA-Tz (25 µL, 1 mgmL-1 in DMSO) was diluted with NaOAc buffer solution 
(pH 6), and the 68GaCl3 was eluted directly into the reaction vial (~ 6.0 mCi). The 
radiosynthesis of [68Ga]DOTA-Tz was achieved in 10 min at 90°C, in >95 % radiochemical 
conversion, and the product was obtained in >95% radiochemical purity, and in 60-70% 
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isolated RCY (n.d.c) by passing through a Sepak light C18 cartridge, eluting in 100% EtOH. 
The mixture was then diluted with water or acetonitrile for application to the 68Ga-labeled 
IeDDA reactions.  
 
Figure SI 11. Radio-HPLC trace of [68Ga]DOTA-Tz using gradient B 
 
General procedure for 68Ga-labeled IeDDA reactions between [68Ga]DOTA-Tz 
and alkenes 
To a 10 mgmL-1 solution of alkene (50 µL) in either H2O or MeCN was added [68Ga]DOTA-
Tz (100 µL), and the mixture was heated to 37°C for the given time-point, without stirring. 
The progress of the reaction was monitored by radio-HPLC.  
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7.5 Experimental for Chapter 5 
General Procedure for the Synthesis of RGD Cyclic Pentapeptides 
Synthesis of RGD cyclic pentapeptides were carried out according to standard Fmoc 
coupling procedures[225] or from RGDfK(NH2), which was purchased from FutureChem.  
Characterisation of RGD Cyclic Pentapeptides 
 
C35H50N9O8 
MALDI calc for: 724.37, found: 724.4 
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Figure SI 12. MALDI m/z for RGD-NB 
Figure SI 13. HPLC (UV) trace of RGD-NB at 254 nm using gradient A 
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C44H67N10O1 
MALDI calc for: 926.49, found 927.6 
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Figure SI 14. MALDI m/z for RGD-PEG3-NB 
 
Figure SI 15. HPLC (UV) trace of RGD-PEG3-NB at 254 nm using gradient A 
 
Chapter 7 - Experimental 
 
257 
 
 
 
 
C43H68N13O14 
MALDI calc for: 990.49, found 990.8 
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Figure SI 17. HPLC (UV) trace of RGD-monomer at 254 nm using gradient A 
Figure SI 16. . MALDI m/z for RGD-monomer 
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Radiosynthesis of [68Ga]RGD-monomer 
A solution of RGD-monomer (50 µL, 1 mgmL-1 in DMSO) was diluted with NaOAc buffer 
solution (pH 6), and the 68GaCl3 was eluted directly into the reaction vial (~ 1.2 mCi).   The 
radiosynthesis of [68Ga]RGD-monomer was achieved in 10 min at 100°C, in >90% 
radiochemical conversion, and the product was obtained in >95% radiochemical purity, and 
in 75% isolated RCY (n.d.c) by passing through a Sepak light C18 cartridge, eluting in 100% 
EtOH (500µL total volume).  
 
Figure SI 18. Radio-HPLC trace of [68Ga]RGD-monomer using gradient A 
 
Radiosynthesis of [68Ga]RGD-dimer 
A solution of RGD-dimer (50 µL, 1 mgmL-1 in DMSO) was diluted with NaOAc buffer solution 
(pH 6), and the 68GaCl3 was eluted directly into the reaction vial (~ 1.2 mCi).   The 
radiosynthesis of [68Ga]RGD-dimer was achieved in 10 min at 100°C, in >90% 
radiochemical conversion, and the product was obtained in >95 % radiochemical purity, and 
in 55% isolated rcy (n.d.c) by passing through a Sepak light C18 cartridge, eluting in 100% 
EtOH (500µL total volume).  
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Figure SI 19. Radio-HPLC trace of [68Ga]RGD-dimer using gradient A 
 
Synthesis of DOTA-GA-Tz 
 
5-{[4-(6-Methyl-1,2,4,5-tetrazin-3-yl)benzyl]amino}-5-oxopentanoic acid (105) 
A dry flask was treated with Tz3 (66.4 mg, 0.33 mmol), glutaric anhydride (188 mg, 1.65 
mmol) and THF (10 mL), and the resultant mixture was heated to 70°C for 4 h. The mixture 
was cooled to 50°C, and was stirred at this temperature for a further 16 h. The solvent was 
evaporated in vacuo, to give the crude material as a pink oil. The product was purified by 
column chromatography eluting with a gradient of 0-5% MeOH/CH2Cl2 to give 105 as a red 
solid (100 mg, 0.32 mmol, >95% yield). Rf = 0.3 (5% MeOH/ CH2Cl2). δH (400 MHz, DMSO-
d6) 2.24 (m, 6H); 2.99 (s, 3H); 3.36 (bs, 1H); 4.38 (d, J = 6.0 Hz, 2H); 7.52 (d, J = 8.5 Hz, 
2H); 8.42 (d, J = 8.5 Hz, 2H); 12.08 (bs, 1H). δC (100 MHz, DMSO-d6) 21.2; 21.3; 33.2; 33.5; 
34.8; 42.3; 127.9; 128.5; 130.8; 145.0; 163.6; 167.5; 172.3; 174.6; 174.6. m/z (ES+) calcd for  
C15H18N5O3 316.1410 (M+), found 316.1409. 
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5-[(2,5-Dioxopyrrolidin-1-yl)oxy]-N-[4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl]-5-
oxopentanamide (106) 
To a stirred solution of 105 (63.1 mg, 0.2 mmol) in dichloroethane (2 mL), was added N-
hydroxysuccinimide (92.1 mg, 0.8 mmol) and EDCI·HCl (153.4 mg, 0.8 mmol) and the 
resultant mixture was stirred for 16 h at rt. The mixture was diluted with CH2Cl2, and the 
organic layer was washed with HCl (1M, 2 x 40 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give a fushia-coloured solid (82.0 mg, 0.2 mmol, >95% yield). Rf = 
0.3 (2% MeOH/CH2Cl2). The product was used for the next step without purification. m/z 
(ES+) calcd for  C19H21N6O5 413.1573 (M+), found 413.1586.  
 
2,2',2''-(10-(1-Carboxy-4-((4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)amino)-4-oxobutyl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (DOTA-GA-Tz) 
To a stirred solution of 106 (38.1 mg, 0.08 mmol) in DMF (5 mL), was added DOTA-GA-NH2 
(number) and triethylamine (290 µL), and the resultant mixture was stirred at rt for 4 h. The 
solvent was evaporated in vacuo to give a pink oil as crude. The product was purified by 
preparative HPLC, to yield DOTA-GA-Tz as a pink oil. m/z (ES+) calcd for C36H54N11O11 
816.4004 (M+), found 816.4001 . 
Chapter 7 - Experimental 
 
261 
 
 
 
 
 
 
 
Radiosynthesis of [68Ga]DOTA-GA-Tz 
A solution of DOTA-GA-Tz (25 µL, 1 mgmL-1 in DMSO) was diluted with NaOAc buffer 
solution (pH 6), and the 68GaCl3 was eluted directly into the reaction vial (~ 6.0 mCi).   The 
radiosynthesis of [68Ga]DOTA-Tz was achieved in 10 min at 90°C, in >95% radiochemical 
conversion, and the product was obtained in >95% radiochemical purity, and in 60-70% 
isolated RCY (n.d.c) by passing through a Sepak light C18 cartridge, eluting in 100% EtOH 
(500µL total volume).  
 
Figure SI 21. Radio-HPLC trace of [68Ga]DOTA-Tz using gradient A 
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Figure SI 20. HPLC (UV) trace of DOTA-GA-Tz at 254 nm using gradient A 
 
0:00 10:00 20:00 30:00 mm:ss 
0.0 
200.0 
400.0 
600.0 
800.0 
1000.0 
1200.0 
1400.0 
mAU 
Chapter 7 - Experimental 
 
262 
 
Procedure for modification of Cetuximab (C225) with TCO 
A 5 mgmL-1 stock solution of C225 (3 mL, 15 mg, 1.02 x 10-4 mmol) was concentrated down to a 
final concentration of 7 mgmL-1 (2.14 mL) by buffer exchange into NaHCO3 (pH 8.5) via 
centrifugal filtration using Amicon Ultra® Centrifual filters (0.5 mL) with a 30K MW cut-off. TCO-
PEG4-NHS (purchased from Jena bioscience) 108 (257 µL, 1.02 x 10-2 mmol, 40 mM solution in 
DMF) was added to the C225 solution, and the mixture was sonicated for 60 sec, followed by 
incubation at 4°C for 16 h. The modified antibody was purified from unconjugated TCO by 
centrifugal filtration using Amicon Ultra® Centrifual filters (30K MW cut-off), for a total spin-time 
of 40 min. Complete removal of unmodified TCO from the antibody mixture was confirmed by 
SEC HPLC. C225-TCO was re-dissolved in PBS (pH 7.4) to a final concentration of 5 mgmL-1. 
MALDI MS confirmed an average of ~17 additions of TCO-PEG4 per C225 molecule (see 
appendix 2). MALDI MS of all Cetuximab antibody conjugates was carried out by the EPSRC 
National Mass Spectrometry Facility, at the College of Medicine in Swansea. 
 
Radiolabelling C225-TCO with [68Ga]DOTA-GA-Tz 
[68Ga]DOTA-GA-Tz (~50 µCi) was added to a solution of C225-TCO (50 µL, diluted to 1 
mgmL-1 in PBS). Progress of the reaction was monitored by radio-HPLC (see appendix 1 for 
example HPLC traces). 
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8.1 Publications and Presentations Associated with this Work  
Publications 
1. Copper-free click - a promising tool for pre-targeted PET imaging  
 Helen L. Evans, Rozanna L. Slade, Laurence Carroll, Graham Smith, Quang-De 
 Nguyen, Lisa Iddon, Nazila Kamaly, Henning Stöckmann, Finian J. Leeper, Eric O. 
 Aboagye and Alan C. Spivey. 
 Chem.Commun., 2012, 48, 991-993. DOI: 10.1039/C1CC16220A 
 
2. Bioorthogonal Chemistry for Pre-targeted Therapy and Imaging – Progress and 
Prospects  
 Laurence Carroll, Helen L. Evans, Eric O. Aboagye and Alan C. Spivey. 
 Org. Biomol. Chem., 2013, 11, 5772-5781. DOI: 10.1039/c3ob40897c 
 
3. Bioorthogonal chemistry for 68Ga radiolabelling of DOTA-containing 
compounds  
Helen L. Evans, Laurence Carroll, Eric O. Aboagye and Alan C. Spivey 
J. Labell. Compd. Radiopharm., 2013, early view article. DOI: 10.1002/jlcr.3153 
Presentations 
The 20th International Symposium on Radiopharmaceutical Sciences (2013), Jeju, 
South Korea: Poster entitled “Bioorthogonal chemistry as a pre-targeting tool for Positron 
Emission Tomography (PET) imaging.” 
The Department of Surgery & Cancer Research Student Skills Afternoon (2013): Poster 
entitled "Copper-free ‘click’ chemistry as a promising tool for PET imaging."  
The 3rd Annual Cancer Research UK & EPSRC Cancer Imaging Conference (2012): 
Oral presentation entitled "Copper-free ‘click’ chemistry as a potential tool for PET imaging." 
CRUK PhD Symposium (2012): Oral presentation entitled "Copper-free ‘click’ chemistry - a 
promising tool for pre-targeted PET imaging” 
CRUK King's College London & Imperial College London Chemistry Symposium 
(2011): Oral presentation entitled "Copper-free ‘click’ chemistry - a promising tool for pre-
targeted PET imaging” 
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Appendix 1 – Example Radio-HPLC Traces 
HPLC traces of SPAAC reactions between [18F]FEA and cyclooctynes  
Cyclooctyne: OCT2 
 
 
  
[18F]FEA 
[18F]49 
[18F]FEA 
‘Cold’ Reference Compound (49): 
 
Conditions: 40°C, H2O, 15 min 
(gradient A) 
 
Conditions: 90°C, MeCN, 15 min 
(gradient A) 
(gradient A) 
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Cyclooctyne:  OCT4 
 
 
 
 
 
 
 
 
 
[18F]50 
[18F]FEA 
‘Cold’ Reference Compound (50): 
 
Conditions: 90°C, MeCN, 15 min 
(gradient A) 
 
Appendices 
 
283 
 
Cyclooctyne: TMDIBO1 
 
 
 
[18F]FEA 
[18F]51 
[18F]FEA 
[18F]51 
‘Cold’ Reference Compound (51) 
 
Conditions: 40°C, H2O, 15 min 
(gradient A) 
 
Conditions: 40°C, H2O, 60 min 
(gradient A) 
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[18F]FEA 
[18F]51 
[18F]FEA 
[18F]51 
Conditions: 40°C, MeCN, 15 min 
(gradient A) 
 
Conditions: 90°C, MeCN, 15 min 
(gradient A) 
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Cyclooctyne: TMDIBO2 
 
 
 
 
[18F]FEA 
[18F]FEA 
[18F]52 
‘Cold’ Reference Compound (52) 
 
Conditions: 40°C, MeCN, 15 min 
(gradient A) 
 
Conditions: 90°C, MeCN, 15 min 
(gradient A) 
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Cyclooctyne: DIFO3 
 
 
 
[18F]53 
[18F]FEA 
[18F]53 
‘Cold’ Reference Compound (53) 
 
Conditions: 40°C, H2O, 15 min 
(gradient A) 
 
Conditions: 40°C, H2O, 60 min 
(gradient A) 
 
[18F]FEA 
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[18F]53 
[18F]FEA 
[18F]FEA 
[18F]53 
Conditions: 90°C, H2O, 60 min 
(gradient A) 
 
Conditions: 40°C, MeCN, 15 min 
(gradient A) 
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[18F]53 
Conditions: 90°C, MeCN, 15 min 
(gradient A) 
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Example HPLC traces of the reaction between [68Ga]DOTA-Az and DIBAC2 
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[68Ga]DOTA-Az 
[68Ga]76 
[68Ga]76 
Conditions: 50°C, MeCN, 15 min 
(gradient B) 
 
Conditions: 90°C, MeCN, 15 min 
(gradient B) 
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Example HPLC traces of 68Ga-labeled IeDDA reactions 
Alkene: ethyl vinyl ether (93) 
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[68Ga]DOTA-Tz 
Conditions: 40°C, H2O, 10 min 
(gradient B)  
 
Conditions: 90°C, H2O, 10 min 
(gradient B) 
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Alkene: 5-Norbornene-2-carboxylic acid (91)  
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Conditions: 40°C, H2O, 10 min 
(gradient B) 
 
Conditions: 40°C, H2O, 20 min 
(gradient B) 
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Alkene: (1S,4S)-N-(3-Fluorophenyl)bicyclo[2.2.1]hept-5-ene-2-carboxamide (exo) (100) 
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Conditions: 40°C, H2O, 10 min 
(gradient B) 
 
Conditions: 40°C, H2O, 20 min 
(gradient B) 
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Alkene: (1S,4S)-N-(4-Fluorophenyl)bicyclo[2.2.1]hept-5-ene-2-carboxamide (endo) 
(101) 
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Conditions: 40°C, H2O, 10 min 
(gradient C) 
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Alkene: (1S,4S)-N-(4-Fluorophenyl)bicyclo[2.2.1]hept-5-ene-2-carboxamide (exo) (102) 
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Example HPLC traces of 68Ga-labelled antibody (C225) reactions  
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Batch 1, 37°C, PBS, immediate 
injection (gradient D) 
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Conditions:  
Batch 1, 37°C, PBS, 20 min 
(gradient D) 
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(gradient D) 
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Appendix 2 – MALDI MS of C225 antibodies 
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Appendix 3 – Key NMR spectra 
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Appendix 4- Data for the Kinetics Studies  
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Raw Data for the Rate Calculation  
 
 
 
  
n = 1 
 
Times (sec) Ratio (63 : 64) Conversion (%) % [benzyl zide] [benzyl azide] (M) 1/[benzyl azide] 
900 2 : 0.05 2.4 97.6 0.0099 101.0 
1800 2 : 0.12 5.7 94.3 0.0096 104.5 
3600 2 : 0.20 9.0 91.0 0.0092 108.3 
7200 2 : 0.31 13.4 86.6 0.0088 113.8 
10800 2 : 0.43 17.7 82.3 0.0083 119.7 
14400 2 : 0.54 21.3 78.7 0.0080 125.2 
18000 2 : 0.68 25.4 74.6 0.0076 132.1 
21600 2 : 0.79 28.3 71.7 0.0073 137.5 
25200 2 : 0.95 32.2 67.8 0.0069 145.4 
28800 2 : 1.06 34.6 65.4 0.0066 150.7 
57600 2 : 2.29 53.4 46.6 0.0047 211.5 
 
n = 2 
 
Times (sec) Ratio (63 : 64) Conversion (%) % [benzyl zide] [benzyl azide] (M) 1/[benzyl azide] 
900 2 : 0.07 3.4 96.6 0.0098 102.0 
1800 2 : 0.13 6.1 93.9 0.0095 105.0 
3600 2 : 0.15 7.0 93.0 0.0094 105.9 
7200 2 : 0.27 11.9 88.1 0.0089 111.9 
10800 2 : 0.34 14.5 85.5 0.0087 115.3 
14400 2 : 0.43 17.7 82.3 0.0084 119.7 
18000 2 : 0.52 20.6 79.4 0.0081 124.1 
21600 2 : 0.64 24.2 75.8 0.0078 130.0 
25200 2 : 0.72 26.5 73.5 0.0075 134.1 
28800 2 : 0.80 28.6 71.4 0.0072 138.0 
57600 2 : 1.53 43.3 56.7 0.0057 173.8 
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Raw Data for the Rate Calculation  
 
Average Data based on 3 experiments: 
 
 
  
 
Times (sec) Ratio (63 : 65) Conversion (%) % [benzyl azide] [benzyl azide] (M) 1/[benzyl azide] 
180 2 : 4.46 69.0 31.0 0.0031 318.3 
360 2 : 5.47 73.2 26.8 0.0027 368.1 
600 2 : 6.59 76.7 23.3 0.0024 423.3 
780 2 : 7.38 78.7 21.3 0.0022 462.2 
960 2 : 7.73 79.4 20.6 0.0021 479.5 
1200 2 : 8.57 81.1 18.9 0.0019 520.9 
1380 2 : 9.42 82.5 17.5 0.0018 562.7 
1560 2 : 9.82 83.1 16.9 0.0017 582.5 
1740 2 : 10.47 84.0 16.0 0.0016 614.5 
1980 2 : 10.92 84.5 15.5 0.0016 636.7 
2160 2 : 11.41 85.1 14.9 0.0015 660.8 
2340 2 : 12.19 85.9 14.1 0.0014 699.2 
2580 2 : 13.16 86.8 13.2 0.0013 747.0 
2760 2 : 13.58 87.2 12.8 0.0013 767.7 
2940 2 : 14.40 87.8 12.2 0.0012 808.1 
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Evaluating the Concentration Dependence upon Rate of Reaction 
 
Raw Data for the Reaction between DIBAC2 and Azide 66 (at 15 min) 
 
Initial [DIBAC2] (M) 1/[DIBAC2] 
Conversion (%) Average 
Conversion (%) SDEV n = 1 n = 2 n = 3 n = 4 
2.418555155 0.41347 31.49 34.31 33.15 41.36 35.1 4.34 
1.209277578 0.82694 18.43 22.88 20.14 27.88 22.3 4.13 
0.604638789 1.65388 22.29 10.97 14.85 32.22 12.9 9.36 
0.302319394 3.30776 11.12 4.19 14.04 16.44 11.4 5.30 
 
 
Raw Data for the Reaction between Tz3 and Norbornene 91 (at 0, 5, 10, 30 and 60 min) 
  
 
Average data based on 3 experiments: 
 
 
 
Initial [Tz3] (M)  
Average Conversion (%) 
0 min 5 min 10 min 30 min 60 min 
0.002484596 0 82.61 92.50 95.45 98.89 
0.00024846 0 80.62 89.06 98.53 98.76 
2.4846E-05 0 71.71 90.20 92.92 95.20 
2.4846E-06 0 49.66 80.34 89.31 96.31 
